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Abstract 
In the presented thesis, a workflow for analysis of the extracellular proteome, or “secretome”, of 
primary human hepatocytes by a shotgun proteomics approach was developed. The secretome 
analysis on hepatocytes is of special interest for the pharmaceutical industry as well as medical 
services because secreted proteins could serve as biomarkers for drug-induced hepatotoxicity. The 
avoidance of fetal calf serum, a common supplement used for in vitro cell culture was shown to be a 
prerequisite for efficient secretome analysis because supplemented proteins severely hamper the 
identification of secreted proteins using mass-spectrometry (MS). The removal of high abundant 
proteins from the sample by immunodepletion, a common strategy for proteomic analysis of human 
plasma, was shown to increase the number of identified proteins to almost two-fold the number of 
identifications obtained without prior immunodepletion, paving the way for in-depth analysis of the 
secretome. A prefractionation step at the level of proteins and the combination of different MS-
types and ionization methods tremendously enhanced the identifications but at the cost of analysis 
time as well as the fraction of secreted proteins. The elaborated workflow without prior 
prefractionation was applied to a standard monolayer culture and a promising in vitro cultivation 
technique in a 3-dimensional bioreactor mimicking the microenvironment of a real liver. With 109 
and 160 proteins identified in monolayer and bioreactor cultures, respectively, the number of 
proteins likely to be secreted by hepatocytes into the extracellular space was much higher than 
described in the current literature. Furthermore, proteome analysis on extracellular proteins in the 
applied culture conditions confirmed the tissue-like behavior of primary hepatocytes in the three-
dimensional cultivation. Differentially expressed proteins in the bioreactor culture after application 
of the reference drug diclofenac were detected by label-free quantification and most of the detected 
differences could be traced back to the underlying mechanism of toxicity proposed for this drug. In 
summary, the presented work provides a basis for further in-depth analysis of the primary human 
hepatocytes secretome for in vitro drug-testing and demonstrates the valuable contributions of 
proteomics to toxicological research. 
Zusammenfassung 
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Zusammenfassung 
In der vorliegenden Arbeit wurde eine experimentelle Strategie zur Analyse des extrazellulären 
Proteoms („Sekretom“) von primären humanen Hepatozyten mittels „shotgun“ proteomics 
entwickelt. Die Analyse des Sekretoms von Hepatozyten ist von besonderer Bedeutung für die 
pharmazeutische Industrie sowie das Gesundheitswesen, da sekretierte Proteine als Biomarker für 
arzneimittelinduzierte Lebertoxizität verwendet werden können. Es wurde gezeigt, dass die 
Vermeidung von foetalem Kälberserum, einem gewöhnlich in der in vitro Zellkultur verwendeten 
Zusatz, eine Grundvorraussetzung für die effiziente Analyse der sekretierten Proteine darstellt, da die 
zugesetzten Proteine erheblich die Identifizierung sekretierter Proteine mittels Massenspektrometrie 
erschweren. Desweiteren erhöhte die Entfernung hoch abundanter Proteine aus den Proben mit 
Hilfe einer Immunodepletion, wie sie oft in der Proteomanalyse von menschlichem Serum 
Verwendung findet, die Anzahl an identifizierten Proteinen fast um das Doppelte und ebnete damit 
den Weg für eine detailliertere Analyse des Sekretoms. Weiterhin konnte gezeigt werden, dass eine 
Vorfraktionierung der Proteine sowie die Kombination verschiedener Massenspektrometertypen bzw. 
Ionisationsmethoden die Anzahl an Identifizierungen deutlich steigert, allerdings auf Kosten der 
benötigten Analysezeit und des Anteils an sekretierten Proteinen. Die erarbeitete analytische 
Strategie ohne vorherige Fraktionierung wurde sowohl auf Standardkultivierungen in 
Zellkulturflaschen, als auch auf eine vielversprechende Bioreaktortechnik angewendet, wobei 
letztere die dreidimensionale Umgebung in einer echten Leber nachahmt. 109 bzw. 160 sekretierte 
Proteine konnten in Standard- bzw. Bioreaktokulturen identifiziert werden, wesentlich mehr als es 
derzeitig in der Literatur für primäre humane Hepatozyten beschrieben wird. Desweiteren bestätigte 
die Analyse des extrazellulären Proteoms in den verwendeten Kultivierungstechniken das 
gewebeähnliche Verhalten der primären Leberzellen in der dreidimensionalen Bioreaktorkultur. 
Differentiell exprimierte Proteine in mit der Referenzsubstanz Diclofenac behandelten 
Bioreaktorkulturen wurden mittels labelfreier Quantifizierung bestimmt und konnten auf die 
zugrundeliegenden Toxizitätsmechanismen zurückgeführt werden, die für dieses Medikament 
bekannt sind. Zusammenfassend legt die vorliegende Arbeit den Grundstein für weitere umfassende 
Analysen des Sekretoms von Leberzellen für in vitro Wirkstofftests und veranschaulicht den 
wertvollen Beitrag der Proteomik für die toxikologische Forschung. 
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Abbreviations 
µg microgram 
µg/µl microgram per microliter 
µl microliter 
µm micrometer 
2D two-dimensional 
2D-DIGE two-dimensional differntial gel electrophoresis 
2-DE two dimensional gel electrophoresis 
3D three-dimensional 
ABC ammonium bicarbonate (NH4HCO3) 
ACN Acetonitril 
AST Asparte-aminotransferase 
CHCA -cyano-4-hydroxy-cinnamonic acid 
DTT Dithiothreitol 
EC50 effective concentration 50 
ELISA enzyme-linked immunosorbent assay  
ESI electrospray ionisation 
ETD electron transfer dissociation 
FA firmic acid 
FDR false discovery rate 
HPLC high performance liquid chromatography 
IEF isoelectric focussing 
INFγ interferon gamma 
IPG immobilized pH gradient 
LC liquid chromatography 
LC-MALDI liquid chromatography coupled to MALDI mass spectrometry 
LC-MS liquid chromatography coupled to mass-spectrometry 
LDH Lactate-dehydrogenase 
m/z  mass to charge ratio 
mA milliampère 
MALDI matrix-assisted laser desorption ionisation 
mg milligram 
min minute 
ml millilitre 
mM millimol/liter 
MS mass spectrometry or mass sectrometer 
MS/MS tandem mass spectrometry (of peptide fragments) 
MWCO molecular-weight cut-off 
ng nanogram 
NIH National Institute of Health 
nl nanoliter 
nm nanometer 
PAGE polyacrylamide gelelectrophoresis 
PFF peptide fragment fingerprint 
PHH primary human hepatocytes 
PMF peptide mass fingerprint 
PTM post translational modification 
QTOF quadrupole time of flight 
RP reversed phase 
 
Abbreviations 
|4 
 
RT room temperature, retention time 
SDS sodium dodecylsulfate 
TFA trifluoroacetic acid 
TOF time of flight 
UV ultraviolet 
V volt 
VEGF vascular endothelial growth factor 
 
 
 
Standard abbreviations for proteinogenic amino acids: 
name 3-letter code 1-letter code name 3-letter code 1-letter code 
Alanine Ala A Leucine Leu L 
Arginine Arg R Lysine Lys K 
Asparagine Asn N Methionine Met M 
Aspartic acid Asp D Phenylalanine Phe F 
Cysteine Cys C Proline Pro P 
Glutamic acid Glu D Serine Ser S 
Glutamine Gln Q Threonine Thr T 
Glycine Gly G Tryptophan Trp W 
Histidine His H Tyrosine Tyr Y 
Isoleucine Ile I Valine Val V 
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1. Introduction 
1.1 Human hepatic culture-systems for in-vitro evaluation of hepatic toxicity 
Pharmaceutical drug-development is a long and expensive process. From about 10.000 compounds 
entering the pipeline as possible drug candidates, only 1 approved drug exits after more than 10 
years of preclinical and clinical phases. The total costs for development of one new drug are in excess 
of 800 million US$, with half of the costs arising already at the preclinical level during extensive in 
vitro testing of new compounds [DiMasi et al., 2003]. Unexpected toxicity is the main reason why 
newly developed drug candidates fail to enter clinical phases and for the withdrawal of already 
approved drugs from the market. The latter is mainly due to the use of animal models during 
preclinical drug testing which are obviously not always transferable to humans [Olson et al., 1998; 
Hartung, 2009]. Playing a central role in intermediary metabolism and detoxification of xenobiotics, 
the liver is one of the first sites where adverse drug effects partly take place. These adverse effects 
can result in severe liver injury featuring intracellular accumulation of lipids (i.e. steatosis) or bile (i.e. 
cholestasis), but also cytotoxic effects leading to necrosis or apoptosis [van Summeren et al., 2012]. 
Sometimes, a drug causes toxic effects only in few patients while most others are treated 
successfully without negative consequences. This is called idiosyncratic toxicity and the underlying 
mechanisms are still elusive but polymorphisms of enzymes for hepatic drug metabolism as well as 
immunological processes were claimed to play an essential role [Boelsterli, 2003; Amacher, 2012]. 
Even though this kind of toxicity is rarely observed, very often prescribed drugs such as diclofenac 
provoke a concerning number of cases of severe liver failure [Aithal, 2004]. Drug-induced 
hepatotoxicity is often not observed until a prolonged application of a drug, thus requiring predictive 
and humanized in vitro liver models suitable for long-term toxicity studies as early as possible during 
drug development. Many in vitro studies aiming at the characterization of drug-induced 
hepatotoxicity use cell lines derived from hepatic tumors like HepG2, (e.g. [Thome-Kromer et al., 
2003; Lewis et al., 2010; Van Summeren et al., 2011]). While such human cell lines can easily be 
cultivated for longer periods, they show significantly reduced expression of many genes involved in 
drug metabolism. Consequently, they are not recommended as a reliable model system to estimate 
adverse drug reactions occurring in vivo [Jaeschke et al., 2011]. Primary human hepatocytes (PHH) 
are considered as “gold standard” for in vitro toxicological studies because they allow detection of 
human-specific toxicity and exhibit in vivo like gene expression profiles in regard to drug metabolism. 
They are isolated either from human liver grafts not suitable for transplantation or from liver 
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resections after clinical surgeries. However, primary human hepatocytes dedifferentiate within 
several days in two-dimensional (2D) monolayer culture and lose drug metabolizing functions which 
prevents their use in long-term repeated dose experiments. 2D culture systems are widely used for in 
vitro cultivation of many different cell types but are simplified and create a rather artificial 
environment. In vivo, cells are growing in tissues and need this three-dimensional (3D) environment 
not only to survive but also to build-up more physiologically relevant structures in vitro [Cukierman 
et al., 2001; Pampaloni et al., 2007; Mazzoleni et al., 2009]. One method can be considered as an 
intermediate step between 2D- and 3D-cultivation, the so-called “collagen-sandwich” culture. It 
avoids dedifferentiation by overlaying seeded primary hepatocytes with a second layer of collagen in 
addition to the collagen precoating of culture dishes as it is performed in standard monolayer 
cultures (see Fig. 1.1.). The sandwich technique ensures viability and functionality of primary 
hepatocytes for up to 10 days under serum-free conditions by partially providing three-dimensional 
stimuli to the liver cells [Godoy et al., 2009; Tuschl et al., 2009]. 
 
Figure 1.1. Common techniques for in vitro cultivation of primary human hepatocytes. The most commonly 
applied cultivation technique is the monolayer cultivation (top) where cells are seeded directly into a culture 
dish precoated with collagen. A modified form of this technique is the collagen sandwich (middle) in which cells 
are covered with an additional layer of collagen to increase survival and performance of the primary cells. In 
both techniques, the cells are covered with cultivation medium. In a perfused hollow-fiber bioreactor like the 
one used in this thesis (bottom), cells are maintained within a network of medium and gas capillaries which 
provides sufficient mass transfer for the cultivation of primary cells and allows three-dimensional organization 
of the cells in a tissue-like manner. White arrows indicate medium flux while grey arrows indicate exchange of 
nutrients and waste products. 
culture flask bottom
culture flask bottom
= hepatocytes
monolayer
collagen sandwich
3D-bioreactor
medium capillary
gas capillary
culture medium
medium capillary
collagen
culture medium
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Advances in the field of three dimensional cultivation techniques led to the development of perfused 
hollow-fiber bioreactors in which hepatocytes are cultivated in between a network of membrane 
capillaries (see Fig. 1.1). The capillaries serve as scaffold for cell adhesion and assure nutrient and 
oxygen supply but also elimination of waste products in the bioreactor which is essential for 
cultivation of larger tissue masses [Mazzoleni et al., 2009]. The bioreactor system used in this thesis 
was originally developed for extracorporeal liver support at the Charité in Berlin [Sauer et al., 2002]. 
Histological studies revealed that isolated primary hepatocytes reconstitute liver-like structures like 
bile canaliculi and can be cultivated for almost a month in this bioreactor [Gerlach et al., 2003a; 
Gerlach et al., 2003b; Zeilinger et al., 2004; Schmelzer et al., 2009]. Being perfectly suited for human 
relevant in vitro toxicological studies but requiring a large number of primary cells, the bioreactor 
was downscaled to laboratory sizes [Zeilinger et al., 2011]. In these bioreactors, PHH were 
successfully cultivated for three weeks and in-depth physiological characterization showed that liver 
specific functions were maintained over the whole cultivation time [Mueller et al., 2011b]. Proteomic 
analysis of human hepatocytes in this bioreactor is promising not only for the detection and 
prediction of toxic drug effects but also for general understanding of cellular processes involved in 
tissue reconstruction. In general, systems biological characterization in toxicology by the “-omics” 
technologies like (epi-)genomics, transcriptomics, proteomics and metabolomics holds great 
potential for the comprehensive understanding of perturbation of biological systems due to drug 
administration and will, on the long term, lead to predictive models for use in drug development 
[Bandara and Kennedy, 2002; Collins et al., 2007]. 
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1.2 Proteomics 
The term PROTEOME was introduced by the Australian scientist Marc Wilkins in the mid 90`s on a 
symposium on two-dimensional gelelectrophoresis (2-DE) as the “PROTEin complement of a 
genOME”. Thereof, the term proteomics emerged which, as an equivalent to genomics, aims at the 
analysis and characterization of all proteins in a proteome [Wasinger et al., 1995; Wilkins et al., 1996]. 
A proteome is defined as the entire set of proteins expressed by an organism, tissue or cell under 
specific conditions at a specific time [Lottspeich, 1999]. It is estimated that the 25.000 protein-
encoding genes in the human genome are translated into up to half a million different proteins if 
alternative splicing and the plethora of post-translational modifications of expressed proteins is 
taken into account [Anderson and Anderson, 2002]. In contrast to the rather static genome, the 
proteome is highly dynamic both in its qualitative and quantitative composition. The proteome 
composition is influenced by endo- and exogenous stimuli to a cell and ultimately defines its 
phenotype, thus being a promising and valuable tool for many different areas of life sciences 
including toxicology [Bandara and Kennedy, 2002; Collins et al., 2007; Gao et al., 2009]. In a modern 
proteomic experiment, proteins are analyzed by mass spectrometry (MS) after digestion of proteins 
into peptides by an endoprotease (usually trypsin). The cleavage of all proteins in a given proteome 
can easily result in the generation of hundreds of thousands of these molecules. However, because 
mass spectrometers themselves cannot deal with such complex samples, a reduction of sample 
complexity is a prerequisite. This is accomplished by separation of the sample on the level of either 
intact proteins before digestion or peptides after digestion. These variants of proteomic analyses are 
often referred to as “top-down” or “bottom-up” approaches, respectively, with the latter also called 
“shotgun” proteomics in analogy to the shotgun-sequencing of genomes, in which DNA is cleaved 
into shorter fragments before sequencing. The most commonly applied top-down approach for 
sample separation is still 2-DE. For the separation on the level of peptides, i.e. bottom-up, liquid 
chromatography is the method of choice. Nowadays, a proteomic experiment does not only identify 
the proteins within a proteome, but also aims at quantification of its changes under different 
conditions like healthy versus diseased or treated versus untreated, for example. These changes 
include not only differences in expression of distinct proteins but can also be expanded to the 
analysis of possibly differing patterns of post-translational modifications (PTM) like proteolytic 
processing, phosphorylation, acetylation and glycosylation, all of them having impact on the activity 
and/or function of a protein. For the identification and quantification of proteins as well as 
characterization of their PTMs, many MS-based methods together with computational validation and 
interpretation tools have been developed and optimized during the last two decades. 
Introduction 
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1.2.1 Methods for sample separation  
The first method capable of analyzing whole proteomes was introduced in the 1970`s as the 2-DE 
[Kenrick and Margolis, 1970; Klose, 1975; O'Farrell, 1975]. In the first dimension, which is called 
isoelectric focusing (IEF), proteins are separated based on their isoelectric point, i.e. the pH at which 
their net charge equals zero. The net charge of a protein is caused by its amino and carboxy termini 
as well as the basic and acidic side chains of the amino acids the protein is composed of. Hence, the 
charge distribution of a protein is influenced by the pH of the surrounding medium. For IEF, proteins 
are loaded onto a polyacrylamid strip containing an immobilized pH gradient (IPG) and exposed to an 
electric field with the cathode placed at the basic, and the anode placed at the acidic end of the IPG-
strip. Due to this electric field, the charged proteins move towards the electrode of opposite charge 
until they reach the pH region of the strip which corresponds to their isoelectric point. Because their 
net charge becomes zero at this point, they stop migrating in the electric field. In the second 
dimension, the focused proteins are separated based on their molecular weight by polyacrylamide 
electrophoresis under denaturing conditions with the aid of sodium dodecylsulfate (SDS-PAGE). The 
anionic detergent SDS binds to a protein providing denaturation and furthermore causes a negative 
charge proportional to the proteins molecular mass (1.4 g SDS/ g protein). The IPG strip after 
focussing is therefore placed on top of a SDS polyacrylamide gel after equilibrating the strip in a 
buffer containing SDS. By application of an electric field to the gel, the negatively charged SDS-
protein complexes migrate towards the anode and are separated by their molecular weight due to 
the “molecular sieve” effect of the polyacrylamide gel. After separation, proteins can be visualized 
within the gel using Coomassie Blue, silver staining or also fluorescent dyes. Furthermore, the 
intensities of stained protein spots can serve as a measure of protein abundance for semi-
quantitative comparison of different proteomic samples. Proteins of interest can be cut off the gel 
and applied to in-gel digestion for identification using mass spectrometry [Rosenfeld et al., 1992; 
Shevchenko et al., 1996]. 
Even though 2-DE is relatively cheap and allows detection and quantification of up to 5000 spots 
within one gel [Gorg et al., 2004], it has several limitations. The technique is very labor intensive and 
includes many steps with each of them being a possible source of errors and which can hardly be 
automated. Moreover, the throughput and the reproducibility are quite low and the detection of low 
abundant proteins is hardly feasible because of the limited sensitivity of staining techniques as well 
as masking effects of high abundant proteins on the gel. Finally, 2-DE fails to cover “extreme” 
proteins with very high or very low isoelectric points or molecular weights and also membrane 
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proteins cannot be separated well due to their high hydrophobicity and usually high basicity 
[Rabilloud, 2002]. 
To overcome these limitations for proteome analysis, much effort was made to elaborate gel-free 
proteomics approaches using liquid chromatography coupled to mass spectrometry (LC-MS) 
[Aebersold and Mann, 2003; Mitulovic and Mechtler, 2006]. The advantage of these shotgun 
approaches is the separation of the proteome on the level of peptides which overcomes many 
limitations of 2-DE because peptides originating from proteins having extreme physico-chemical 
properties can be analyzed by these methods in an automated manner. But also for these techniques, 
the large differences in protein abundances within a sample, the dynamic range, still remains 
challenging. Chromatographic separation of peptides is achieved by the use of reversed-phase high-
performance liquid chromatography (RP-HPLC). In RP-HPLC, peptides are separated in respect of 
their hydrophobicity and the separation is based on hydrophobic interactions between the peptides 
and the stationary phase as well as solvophobic interactions with the mobile phase. The most 
common stationary phase used for RP-HPLC for the separation of peptides in proteomics is based on 
octadecyl carbon chain bonded silica particles (C18). The hydrophobic moieties of peptides adsorb to 
the non-polar alkyl chains in a polar solvent (i.e. water) and are eluted by an increasing concentration 
of an organic solvent (acetonitrile (ACN) or methanol) in the mobile phase. Because of their relatively 
large molecule size, peptides can interact with the stationary phase with more than one moiety 
which is called multisite adsorption [Geng and Regnier, 1984]. Hence, in order to elute a peptide 
from the column, the solvent strength has to be high enough to desorp all parts of the peptide 
interacting with the columns stationary phase. By the addition of ion-pairing reagents such as 
triflouroacetic acid (TFA) to the mobile phase, the elution process is changed in such a way that not 
only solvophobic interactions but also electrostatic interactions provide adsorption of the analyte to 
the stationary phase. The hydrophobic part of the modifier binds to the stationary phase and the 
polar moiety (i.e. carboxyl group in the case of TFA) interacts with charged groups of the peptide 
significantly enhancing retention and peak symmetry and thus the resolution of the chromatographic 
analysis [Guo et al., 1987]. However, to avoid covering of large parts of the stationary phase and thus 
decreasing solvophobic interactions, the concentration of the ion-pairing reagent in the mobile 
phase is very low (0.05-0.2 %). A notable advantage of RP-HPLC for the use in MS-based proteomics 
is the fact that it can be operated using volatile solvents (water, ACN, TFA) in the mobile phase which 
permits direct coupling of the chromatographic separation to mass spectrometry.  
Similar to 2-DE, in which two different gel-based methods were combined, also two-dimensional 
chromatographic set-ups have been developed to deal with the high complexity of proteomic 
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samples. For example, the combination of strong-cation exchange (SCX) chromatography and RP-
HPLC or the combination of RP-HPLC at high pH (10) and low pH (2) have been successfully employed 
for the analysis of complex samples [Washburn et al., 2001; Wolters et al., 2001; Delmotte et al., 
2007]. Furthermore, combinations of both gel-based and gel-free approaches like SDS-PAGE and RP-
HPLC can be used (GeLC-MS) and can significantly enhance the performance of a proteomic analysis 
regarding protein identifications and sequence coverage [Brewis and Brennan, 2010].  
1.2.2 Mass spectrometry for the analysis of peptides 
A mass spectrometer is a device to determine the mass-to-charge ratio (m/z) of an analyte of interest. 
In general, it consists of an ion source, a mass analyzer and a detector. First, the analytes are ionized 
in the ion source, separated by their m/z in the mass analyzer and separated ions are detected to 
obtain a mass spectrum, i.e. a plot of the analytes m/z against their abundance (intensity).  
Furthermore, in the case of tandem mass spectrometry (MS/MS), specific ions are selected for 
fragmentation (precursor ions) and the m/z of the resulting fragments (fragment ions) is determined. 
The fragmentation pattern of peptides can be used to determine the underlying amino acid 
sequence. In the mass spectrometers used in this thesis, the precursors are fragmented by collision 
with gas molecules (air, He or N2), which is called collision induced dissociation (CID). Indeed, this is 
the most commonly applied technique for fragmentation of peptides besides electron transfer 
dissociation (ETD), which was introduced in 2004 [Syka et al., 2004].  
Because proteins and peptides are non-volatile substances and are labile under high temperature, 
the invention of “soft” ionization techniques in the late 80`s, namely matrix-assisted laser desorption 
ionization (MALDI) and electrospray ionization (ESI), was essential for the use of MS in the analysis of 
biomolecules like proteins and peptides but also oligosaccharides and nucleic acids [Karas and 
Hillenkamp, 1988; Tanaka et al., 1988; Fenn et al., 1989]. The importance of these techniques for the 
scientific community becomes obvious by the fact that Koichi Tanaka and John Fenn received the 
2002 Novel price in chemistry for their research on these novel ionization techniques. The principles 
of MALDI- and ESI-MS are depicted schematically in Figure 1.2 and are explained in the following. 
Prior to MALDI-MS, the sample is mixed with a matrix and this mixture is deposited on a stainless 
steel plate (target). The solvents evaporate resulting in co-crystallization of the matrix molecules and 
the analytes. The matrix is added at a high molar excess compared to the analyte, generally between 
1:10,000 -1:100,000. This ensures gentle ionization and reduces aggregate formation of the analytes. 
The target is then brought into the high vacuum of a mass spectrometer and irradiated with a pulsed 
laser beam (usually in the UV). The mechanism leading to ionization of analytes is still not fully 
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understood but it can be divided into three general stages : i) excitation of the matrix molecules by 
the laser photons, ii) desorption of matrix and sample molecules into the gas phase and iii) ionization 
of the molecules leading to the generation of presumably singly charged ions as depicted in Fig. 1.2a 
[Karas et al., 2000; Knochenmuss and Zenobi, 2003]. 
 
Figure 1.2. Schematic illustration of the two “soft” ionization techniques for MS analysis of proteins and 
peptides used in proteomics, namely MALDI (a) and ESI (b). Note that for both techniques, the operation in 
positive ion mode is shown as it is the most used in proteomics but it has to be noted that also negative ions 
can be generated by these ionization techniques. 
Very recently, the Karas group proved with the aid of deuterated matrix molecules, that both gas 
phase protonation as well as survival of precharged analytes from solution (lucky survivors) is 
responsible for ionization of sample molecules during MALDI. The preference for one of these 
processes is depending on the analytes properties and the choice of the matrix [Jaskolla and Karas, 
2011]. Because of the pulsed nature of the MALDI ionization process, this ion source is usually 
coupled to a time-of-flight (TOF) analyzer. In a TOF analyzer, ions are accelerated by an electric field 
and transferred into a field free flight tube. Because the ions are accelerated with the same kinetic 
energy in the source, they reach different velocities depending on their mass to charge ratio. 
Consequently, the time they need to pass the flight tube is depending on their mass to charge ratio 
and can be used to determine their molecular weight. Early TOF analyzers had only moderate mass 
resolution, which was significantly enhanced by the implementation of the reflector technology and 
the delayed extraction technique, both correcting for kinetic energy dispersion of molecules of the 
same mass and thus improving the resolution and mass accuracy [De Hoffmann and Stroobant, 2008]. 
In order to allow MS/MS measurements with such a mass spectrometer, TOF/TOF instruments were 
developed [Medzihradszky et al., 2000]. In a TOF/TOF instrument (like the Applied Biosystems 4800 
used in this thesis), the flight path is divided into two sections by a CID chamber (see Fig. 1.3). In MS 
mode, this chamber is evacuated and ionized peptides fly through the drifting tube until they reach 
+
+
+
+
+
+
+
+
+
+
+
+
+
+
H
+
Proton 
transfer
Mass analyzer
-+
Laser 
irradiation
Matrix molecule
Analyte molecule
+
+
+
+
+
+ +
+
+
++
+
++
+
+
+
+ +
++++
++ ++
++
+ +
++
++++
++
++
++
++++++++
+
+++ + +
++
++
++
+
++ ++++
++
+
++
++
+
+ ++++
++
+
+
++
+
++
+
++ ++++
+
+
+
++++
++
+
+
+
+
+
+
+
+
+
+
+
+
++
+
+
+
+
+
+
+
+
++
Mass 
analyzer
-
-
-
-
+
+
+
++
++
+
+
+
+
+
+
++
+
+
+
++
+
+
-
-
-
-
-+
Taylor cone
Metal capillary tip
HPLC
a b
Introduction 
|13 
 
the detector to obtain a mass spectrum of all peptides in the analyzed spot. In MS/MS mode, the CID 
chamber is charged with an inert collision gas. The precursor meant for fragmentation is isolated by 
the timed ion selector (TIS), which consists of two ion gates in series. The first gate deflects low mass 
ions until the selected precursor reaches the gate and is turned off to let pass the precursor ion. 
Afterwards, the second gate is switched on and deflects ions with a higher molecular weight than the 
precursor. After fragmentation of the precursor in the CID chamber, the resulting fragment ions are 
accelerated again and separated in the second TOF analyzer to obtain the MS/MS spectrum. 
 
Figure 1.3. Schematic illustration of off-line LC-MALDI coupling as performed in this thesis. The effluent from 
the HPLC outlet is mixed automatically with matrix and fractions are collected as spots on a MALDI-target (left). 
Subsequently, the collected fractions are analyzed in a MALDI-TOF/TOF-MS (right). 
MALDI-MS has to be coupled off-line to liquid chromatography because the peptides eluting from 
the HPLC have to be mixed with matrix and the solvents have to evaporate to allow the formation of 
crystals prior to analysis by MS (see Fig. 1.3). Commercially available fractionation devices which are 
capable of continuous matrix addition and automatic spot deposition have been developed. This 
permits automation of the process and enhances the reproducibility of sample preparation for 
hyphenation of liquid chromatography (LC) to MALDI-MS (LC-MALDI). For acquisition of MS/MS 
spectra during LC-MALDI, all fractions are first measured in MS mode to obtain an ion chromatogram 
for each mass. Precursors for fragmentation are then selected on the apex of their chromatographic 
peak, i.e. the spot in which the highest intensity of the precursor mass was detected. 
While the MALDI ionization takes place in high vacuum, ESI is performed under atmospheric pressure. 
During ESI, the analytes pass through a small capillary tube in a volatile solvent (for example the RP-
HPLCs mobile phase) and a strong voltage is applied between the capillary tip and a counter 
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electrode. This electric field leads to accumulation of charges at the liquid surface and to 
deformation of the growing droplet at the capillary tip which is resulting in a so-called “Taylor cone” 
(see Fig. 1.2 b) and the onset of the spray. Small, highly charged droplets break from this cone and 
subsequently break into smaller droplets because of occurring Coulomb explosions. After complete 
evaporation of solvent by the additional help of heated curtain gas (normally N2), the analytes are 
released as desolvated, charged molecules. The formation of ions in ESI is a result of accumulating 
charges in the shrinking droplets of the spray which are retained by the desolvated molecules and 
electrochemical processes occurring at the probe tip [De Hoffmann and Stroobant, 2008]. In contrast 
to MALDI, ESI generates not only singly charged but also multiply charged ions. The ions generated at 
atmospheric pressure during ESI have to be transferred into the high vacuum of the mass analyzer. 
This is accomplished by differential pumping at the beginning of the MS progressively decreasing the 
pressure in several succeeding compartments. These compartments are separated from each other 
by hyperbolic metal plates with very small orifices, so called skimmers. The orifices are wide enough 
to allow introduction of as many ions as possible into the mass analyzer but, at the same time, have 
to be small enough to maintain the vacuum in the mass analyzer. Among the ESI-based mass 
spectrometers, the most often used for proteomic analyses are the ion trap and the hybrid 
quadropole time-of-flight (QTOF) instruments.  
The QTOF is a hybrid instrument in which a quaduropole analyzer is coupled to a TOF analyzer (see 
Fig. 1.4 b). A quadropole analyzer consists of four parallel metal rods. Each opposing pair of rods is 
connected electrically and to each pair, a radio frequency (RF) voltage is applied and superimposed 
by a direct current voltage. This electric field influences the trajectories of axially entering ions and 
can be used to selectively filter ions based on their m/z by varying the ratios of applied voltages (i.e. 
RF to direct current). Only ions of a specific m/z exhibit stable trajectories at a given ratio and can 
pass the quadropole while the trajectories of other ions become instable and they hit the rods where 
they discharge. If the quadropole is operated in RF-only mode, i.e. no direct current voltage is 
applied, it can be used as an ion guide. In a QTOF, such a quadrupole is now coupled to a TOF with 
the two analyzers being separated by a collision cell. In MS mode, the quadrupole is operating in RF-
only mode and transmitted ions are analyzed in the subsequent TOF after orthogonal acceleration 
using a “pusher”. In MS/MS mode, the precursor is selected in the quadrupole, subsequently 
fragmented in the collision cell and the fragments are analyzed in the TOF. Modern high resolution 
QTOF instruments like the Bruker MaXis used in this thesis have very high mass accuracies in the low 
(1-5) ppm range.  
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An ion trap consists of three electrodes: one cylindrical ring electrode and two hyperbolic end-cap 
electrodes. Ions generated in the source are focused by RF-only octapoles (principally a quadrupole 
with eight rods) and enter and leave the trap through small holes in the two end cap electrodes (see 
Fig. 1.4 a). The trapping mechanism is generally based on the same principles as in a quadrupole. The 
ions are kept on stable trajectories within the trap by application of a 3-dimensional quadrupolar 
field to the electrodes and can be consecutively ejected according to their m/z by ramping of the RF 
frequency. To enhance the trapping of ions, an inert damping gas (usually helium) is present at low 
pressures in the trap. By collisions of trapped ions with helium atoms, the kinetic energy of the ions is 
decreased and they are focused in the center of the trap. For the generation of MS/MS spectra, all 
ions except the precursor are ejected. Thereafter, the frequency of the RF-voltage at the end cap 
electrodes is increased resulting in excitation of the trapped ions. Consequently, strong collisions 
with the helium atoms lead to fragmentation of the isolated precursors. The fragments are then 
ejected according to their m/z and detected. While the ion trap mass analyzers are quite inexpensive, 
sensitive and robust instruments, a disadvantage is their low mass accuracy (80-100 ppm).  
 
Figure 1.4. Schematic illustration of ion trap (a) and qudrupole time-of flight (QTOF) mass spectrometers. Both 
analyzers are equipped with an ESI source. The way of the ion beam during mass analysis is indicated by the 
red lines. 
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1.2.3 Protein identification from mass spectrometric data 
The large-scale identification of proteins and peptides using MS data became possible by the 
availability of whole genome sequences of a variety of organisms since the 1990`s. The first method 
to derive protein identities from mass spectra using sequence databases was the peptide mass 
fingerprint (PMF) proposed in 1993 simultaneously by different groups [Mann et al., 1993; Pappin et 
al., 1993; Yates et al., 1993]. In this method, peptide masses obtained from MS measurements after 
enzymatic digestion of proteins are compared to theoretical masses of an in silico digest of protein 
sequences (or translated gene sequences) available in a database. The masses are then matched to a 
specific protein according to a mathematical scoring scheme like the MOWSE score (MOlecular 
Weight Search) [Pappin et al., 1993]. However, this method requires high purity of the protein to be 
identified because already when two proteins are digested together, the resulting mass spectrum 
can hardly be matched unambiguously to a protein fingerprint from the in silico digest. Hence, PMF is 
restricted to the identification of proteins separated by 2-DE, for example. One year after the 
introduction of the PMF method, another method was introduced that matched the masses of 
MS/MS spectra to the sequence databases and which was called peptide fragment fingerprint (PFF) 
[Eng et al., 1994; Blueggel et al., 2004]. The advantage of PFF is the additional information on 
underlying amino acid sequences which is deduced from the fragment ion pattern. During CID, a 
peptide is fragmented preferably at its peptide bonds resulting in N-terminal (b-ions) and C-terminal 
fragments (y-ions). Also other fragmentations can occur as it is shown in Figure 1.5 a, but b- and y-
ions are the fragments most likely observed after fragmentation via CID.  
 
Figure 1.5. Nomenclature of peptide fragments as proposed by Roepstorff and Biemann [Roepstorff and 
Fohlman, 1984; Biemann, 1988] (a). MS/MS spectrum of the peptide AEFAEVSK after fragmentation via CID in a 
MALDI-TOF/TOF-MS (b). 
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A peptide can be fragmented at every peptide bond which results in a spectrum where each peak 
represents a different peptide fragment. The mass differences between the peaks can now be used 
to determine the amino acid sequence, because the masses of amino acids are known (see Fig.1.5b). 
Many algorithms have been developed to interpret MS/MS spectra of fragmented peptides, because 
the manual interpretation requires high expertise and becomes impractical for the application to 
large-scale proteomics analyses, in which several thousand peptides are analyzed at once. SEQUEST 
was the first being commercialized using the algorithm developed by Eng et al. in 1994 and which 
cross correlates the empirical with the theoretical data. Another widely used algorithm is Mascot, 
which was introduced in 1999 [Perkins et al., 1999] and which uses a probability based scoring 
scheme. It calculates the probability that the observed match is a random event and calculates an 
“ion score” from this probability. The ion score is calculated as -10*log10(P), where “P” is the 
probability of a random match. For example, a score of 200 is equivalent to a probability of 10-20 that 
the match happened by chance. The higher the ion score, the lower the probability of a random 
match. In order to identify significant matches, Mascot provides a second score which incorporates 
the number of applicants into score calculation. This “identity score” is calculated as -10*log10(p/no. 
of matches), where “p” is the probability threshold defined by the user (normally 5%) and “no. of 
matches” is the number of different precursor masses that matched to the spectrum. Thus, only 
peptides with an ion score above the identity score, i.e. when ion score minus identity score is above 
0, can be considered as being confidently identified. However, for all of the algorithms used for 
MS/MS spectra interpretation, there is a level of uncertainty regarding the correct assignments of 
experimental spectra to the theoretical data. The estimation and control of this false discovery rate 
(FDR) in such approaches can be achieved by the use of “target-decoy” database searches [Elias and 
Gygi, 2007]. The principle of this technique consists in the implementation of decoy-sequences into 
the sequence database to be searched (“target” database). The decoy sequences are generated by 
reversing or randomizing the correct sequences. If a spectrum can be matched to a sequence of the 
decoy entries, it can be considered as a false positive identification. The score threshold for accepting 
identifications can now be adjusted until the number of decoy matches is at a tolerable level, usually 
around 1 %. Furthermore, algorithms have been introduced which calculate the possibility that the 
peptide and protein assignments are true, namely PeptideProphetTM and ProteinProphetTM [Keller et 
al., 2002; Nesvizhskii et al., 2003]. They use Bayesian statistics to calculate the probability of true 
positives from the score distributions in the underlying data set and subsequently assign the 
confidently identified peptides to the most probable protein (see Fig. 1.6.). Software solutions are 
available implementing all of the aforementioned techniques and/or algorithms providing a simple 
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and user friendly interface for validation of database search results such as Scaffold, for example 
[Searle, 2010].    
 
Figure 1.6. Typical score distribution obtained after a target-decoy database search using Mascot. Red bars 
indicate the number of correct assignments of spectra to a peptide sequence, blue bars indicate incorrect 
assignments, both as a function of the “ion minus identity score”. The red and blue lines indicate score 
distributions as calculated by PeptideProphet
TM
. The dashed line indicates the minimum ion-identity score 
above which PeptideProphet
TM
 has calculated a 95% probability of a correct peptide spectrum match. 
1.2.4 Quantification in Proteomics  
As mentioned previously, one of the most important goals of proteomics is the determination of 
quantitative changes in protein expression in response to a specific perturbation [Ong and Mann, 
2005]. The development of methods enabling accurate quantification of proteins in complex samples 
using mass spectrometry is one of the most challenging and rapidly growing areas in proteomics 
[Elliott et al., 2009]. Most quantitative proteomics methods developed so far provide relative 
quantification, i.e. the up- or down-regulation of a protein compared to a control sample. In contrast, 
absolute quantification aims at providing absolute concentration values of a distinct protein in a 
sample. Actually, this absolute quantification is also achieved by relative quantification, but to an 
internal standard for which the absolute concentration is known.  
In gel-based workflows, relative quantification is performed at the level of intact proteins by 
comparing spot intensities between gels. However, this approach requires high reproducibility of the 
gels to be compared and the quantification is limited by the low linearity range of staining techniques 
like Coomassie Blue in regard to the protein amount in the spot. The development of 2D 
fluorescence differential gel electrophoresis (2D-DIGE) significantly enhanced the performance of 
gel-based quantification because the compared samples are run together on the same gel, 
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eliminating potential gel-to-gel variation [Alban et al., 2003]. However, it suffers from already 
mentioned restrictions imposed by the 2-DE approach like limited dynamic range and difficulties in 
handling proteins with extreme properties [Zhu et al., 2010]. Furthermore, biases can be introduced 
because a spot can contain more than one protein.  
Most techniques for quantification in shotgun proteomics techniques rely on the incorporation of 
stable heavy isotopes into the analyzed peptides. Because labeled peptides have identical chemical 
and physical properties as their natural counterparts except in mass, there is no difference in their 
behavior during applied separation techniques but they can be separated in the subsequent analysis 
by MS. Compared samples from which one (or more) have been labeled are mixed prior to analysis 
and by comparing the ion intensities or peak areas of the labeled and the unlabeled species after MS, 
the differences in abundance can be determined. A variety of labeling approaches have been 
developed like TMT [Thompson et al., 2003], iTRAQ [Ross et al., 2004], ICAT [Gygi et al., 1999] or 
SILAC [Ong et al., 2002]. A special quantification technique using isotope labeled peptides is the 
selected reaction monitoring (SRM) also called multiple reaction monitoring (MRM) if several 
proteins are quantified at once. This targeted quantification approach uses the ability of triple-
quadrupole mass analyzers to isolate a precursor ion as well as a specific fragment ion after CID by 
using three quadrupoles in series. In the first quadrupole, the precursor is selected and is then 
fragmented in the second quadrupole which serves as collision cell. After fragmentation, the third 
quadrupole isolates a fragment ion, which is specific for a peptide of interest if combined with the 
precursor mass. The specific combination of precursor and fragment ion masses is called a 
“transition”. If this transition is derived from a peptide which is found only in one protein 
(proteotypic peptide), this technique is highly specific. Quantification is achieved by spiking the 
sample with this proteotypic peptide as an isotope labeled variant and comparing the intensities of 
the fragment ions. Because the concentration of the spiked peptide is known, the absolute 
concentration of a protein can be determined [Lange et al., 2008]. The limitations of labeling-based 
approaches include the increased time and complexity of sample preparation, the high costs of the 
reagents as well as the possibility of incomplete labeling of analyzed samples [Zhu et al., 2010]. 
Therefore, label-free methods are gaining more and more attention by the proteomic community 
[Elliott et al., 2009; Neilson et al., 2011].  
Label-free quantification is generally based on two categories of measurements. The first is the 
intensity of chromatographic peak heights or peak areas, which has been shown to correlate with the 
abundance of the corresponding protein [Chelius and Bondarenko, 2002]. The second way of label-
free quantification is based on the number of sequenced peptides of a distinct protein during MS/MS 
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acquisition. The more abundant a protein within a sample, the more likely is the identification of 
peptides derived from this protein during MS-analysis. This manifests itself in the achieved sequence 
coverage of a protein, i.e. the part of the amino acid sequence being covered by the identified 
peptides. Furthermore, protein abundance can be deduced from the total number of identified 
peptides (peptide hits) or from the total number of identified spectra (spectrum counts) with the 
latter also including redundant spectra of the same peptide. By using standard proteins spiked in a 
complex sample at different ratios, Liu et al. compared the correlation of protein abundance to 
sequence coverage, peptide hits as well as spectrum counts [Liu et al., 2004]. They found a perfectly 
linear relationship between spectrum counts and protein abundance. The sequence coverage 
exhibited no or weak correlation to the spiked-in protein amount whereas the peptide hits showed 
good but not linear correlation. The latter was successfully applied to the determination of changes 
in protein expression in yeast after cultivation on different carbon sources as well as for the 
detection of protein biomarkers for inflammation in human urine [Pang et al., 2002; Gao et al., 2003]. 
Moreover, the peptide hit approach was able to identify biomarkers for idiosyncratic toxicity using 
primary hepatocytes which was confirmed by western blotting [Gao et al., 2004]. 
1.3 The Secretome as a valuable source of biomarkers 
According to the National Institute of Health (NIH), a biomarker is "a characteristic that is objectively 
measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention" [2001]. A biomarker should be easily 
accessible during clinical surveillance and in this regard, the easiest way would be a simple blood 
sampling from the patient. Since the liver secretes many proteins directly into the blood-stream of 
the human organism, proteins found to be differentially secreted upon drug-application in an in vitro 
culture of primary human hepatocytes are likely to be present in plasma of patients. The main 
advantage of analyzing secreted proteins in the conditioned medium of cell cultures rather than in 
the human plasma itself for biomarker discovery is the decreased complexity of the conditioned 
medium regarding protein number and dynamic range. Moreover, the cells can be cultivated in a 
well controlled system minimizing biases due to different origins and histories of clinical samples. 
Thus, the biomarker discovery process is significantly facilitated [Dowling and Clynes, 2011]. In this 
thesis, the secretome is defined as the totality of proteins found in the conditioned medium of 
cultivated human hepatocytes as a result of active secretion but not leakage from cells due to 
damaged plasma membranes. The active secretion of proteins by a cell can be achieved by a variety 
of pathways. To enter the classical secretory pathway, proteins must contain a signal sequence to 
enter the endoplasmic reticulum and are secreted after travelling through the Golgi apparatus [Klee 
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and Sosa, 2007]. For secretion by unconventional or non-classical pathways, proteins do not require 
a signal sequence and are released by a variety of mechanisms, including efflux through plasma 
membrane transporters, shedding from the plasma membrane or exocytosis of secretory lysosomes 
and exosomes [Nickel, 2010].  
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1.4 The aim of the BMBF-project “HEPATOX” 
The presented work was done within the german research project “3D-in vitro model for hepatic 
drug-toxicity” or “HEPATOX” funded by the Federal Ministry of Education and Research (BMBF). 
The project aimed at the prediction of drug-induced toxicity using a novel 3D-cultivation technique 
and in-depth characterization of this culture to establish read-out parameters specific for hepatic 
drug toxicity. The project is based on the hypothesis that long-term maintenance of liver specific 
functions of human hepatocytes can be achieved by cultivation of primary human hepatocytes in a 
complex 3D perfusion culture device that closely reflects the microenvironment of hepatocytes in 
real liver tissue. 
The consortium consisted of three academic and two industrial partners, each representing a 
subproject: 
1. Pharmacelsus GmbH, Saarbrücken (Coordinator) 
2. Charité Bioreactor Group, Charité University Medicine, Berlin 
3. Traumatology, Technical University Munich, München 
4. Technical Biochemistry, Saarland University, Saarbrücken 
5. Elexopharm GmbH, Saarbrücken 
The specific aim of the subproject No. 4 at the Department of Biochemical Engineering was the 
“Systems biotechnological characterization of the physiology of hepatic cell cultivation in 3D 
bioreactors” using state of the art systems biology approaches, namely metabolomics and 
proteomics. 
The subproject aimed at providing metabolomics and proteomics data for the detailed analysis of 
long-term bioreactor performance and for detecting potential toxic effects after application of 
reference drugs. This detailed analysis should reveal biomarker candidates for the prediction of early 
drug toxicity.  
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1.5 Goal and outline of this thesis 
The goal of this thesis was the identification of protein biomarker candidates for drug-induced liver 
toxicity in the secretome of primary human hepatocytes cultivated in a 3D-bioreactor by proteomics 
techniques. 
To achieve this goal, the following steps had to be elaborated:  
1) Long-term functional cultivation of primary liver cells for efficient secretome analysis  
2) Optimization of sample preparation for in-depth characterization of the secretome 
3) Setup of a nano-scale high-pressure liquid-chromatography system coupled to an automatic 
spotting device allowing analysis of the hepatocytes secretome via LC-MALDI 
4) Comparison of the secretome in monolayer and bioreactor culture 
5) Detect differences in the secretome upon drug-exposure 
 
First, the serum-free cultivation had to be established for standard monolayer cultures to allow set-
up and optimization of secretome analysis by LC-MALDI while establishing the serum-free cultivation 
of primary human hepatocytes in the 3D-bioreactor. The established workflow should be applied to 
bioreactor samples containing proteins secreted by primary hepatocytes and the differences upon 
exposure to a reference drug (diclofenac) should be detected to identify proteins related to 
diclofenac induced toxicity events.  
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2. Chemicals 
All used chemicals were purchased at the highest purity/reagent grade available. 
Ammonium peroxodisulfate, bromophenol blue sodium salt, formaldehyde, iodoacetamide, CHCA (α-
cyano-4-hydroxycinnamic acid; MALDI matrix), [Glu1]-fibrinopeptide B human (for internal 
calibration), EZblue gel staining reagent was obtained from Sigma-Aldrich (Steinheim, Germany). 
Tris-(hydroxymethyl)-aminomethane, sodium dodecyl sulfate (SDS), acrylamide solution 
Rotiphorese® Gel 30 were purchased from Carl Roth GmbH (Karlsruhe, Germany). 
Glycerol, ethanol, acetic acid, methanol (for synthesis), silver nitrate (for analysis) and sodium 
thiosulfate pentahydrate were obtained from Chemical Storage Facility of the University of Saarland.  
Dithiotreitol (DTT) was purchased from MBI Fermentas (St. Leon-Rot, Germany). 
ß-Mercaptoethanol, Trifluoroacetic acid (TFA) and Temed (N,N,N´,N´-tetramethylethylendiamine) 
was purchased from Fluka (Steinheim, Germany). 
Sequencing grade modified trypsin was obtained from Promega (Madison, WI, USA). 
 
Deionized water (18 MΩ) for preparation of buffers was prepared using a Purelab Ultra Genetic 
system (ELGA, Griesheim; Germany), while HPLC grade water and acetonitrile (Chromasolv plus) for 
preparing solvents for chromatography were purchased from Sigma-Aldrich. 
 
All other materials and instruments used in this work are reported in the respective methods section.  
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3. Material and Methods 
3.1 Isolation of primary human hepatocytes 
The isolation of primary human hepatocytes (PHH) was performed by Dr. Daniel Knobeloch at Charité 
Virchow clinic, Berlin.  
Resected liver tissues from patients with primary and secondary tumors were used. Tissue was 
collected according to the institutional guidelines and with the patient’s written consent. 
Hepatocytes were isolated using a two-step collagenase P (from Clostridium histolyticum) perfusion 
technique, followed by a Percoll density gradient centrifugation [Nussler et al., 2009]. The purity and 
viability was determined under light microscopy using trypan blue exclusion. 
PHH for bioreactor inocculation were shipped as suspension in Cold Storage Solution (Hepacult, 
Regensburg) directly after isolation according to the protocol provided by the company. For 
monolayer cultures, PHH were seeded after isolation on rat tail collagen coated dishes (BD Falcon) in 
Williams medium E, supplemented with penicillin/streptomycin (100 U/ml, 100 µg/ml), HEPES (15 
mM), fetal calf serum (10%), insulin (1 mM), sodium pyruvate (1mM) and fortecortin (0.8 µg/ml). The 
cells were incubated in a humidified incubator with 95 % air and 5 % CO2 at 37 °C. 24 hours after 
seeding, cells were shipped under standardized operating procedures. Rat tail collagen was prepared 
according to the protocol of Rajan et al. [Rajan et al., 2006]. 
3.2 Monolayer cell culture 
Human primary hepatocytes (department of surgery, Charité-Universitätsmedizin, Virchow-Klinikum, 
Berlin, Germany) were obtained in 6-well plates at a density of 1x106 cells per well and the medium 
was changed at the day of arrival to Heparmed medium containing 1% ITG supplement (0.8 mg/l 
insulin, 5mg/l transferrin and 3 µg/l glucagon; both Biochrome AG, Berlin, Germany), with 10 % FCS 
(PAA, Cölbe, Germany) and penicillin/streptomycin. After 24h, the medium was removed and the 
cells were washed four times with Heparmed medium (2ml) without FCS and cultured for 4 days with 
daily medium exchange. The medium of three wells was removed, pooled and a protease inhibitor 
cocktail (Complete; Roche Diagnostics, Mannheim, Germany) was added as a 25 x stock solution to 
avoid unspecific proteolysis. The collected medium containing the secreted proteins and metabolites 
from primary human hepatocytes is in the henceforth referred to “conditioned medium”, while 
“unconditioned medium” means fresh medium. 
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3.3 Bioreactor cultivation 
The 3D bioreactor (Stem Cell Systems GmbH, Berlin, Germany) used in this work consisted of three 
interwoven hollow-fiber capillary bundles integrated into a polyurethane housing resulting in four 
different compartments. Two bundles of hydrophilic polyethersulphone membranes with a pore size 
of 0.5 mm (Membrana, Wuppertal, Germany) were used for medium supply. The third bundle is 
made of hydrophobic multilaminate hollow-fiber membranes (MHF; Mitsubishi, Tokyo, Japan) for gas 
supply. However, for the bioreactor cultivations performed in our lab, the oxygen-supply was 
achieved by a different strategy (see Fig. 3.1 a). The medium was oxygenated using a self-developed 
gassing-unit consisting of a thin air-permeable silicone tubing (i.d. 1.47 mm, wall thickness 0.5 mm; 
Helix Medical, Carpinteria, USA) placed before the bioreactor. Thus, the medium was saturated with 
oxygen by diffusion of air through this tubing. The hollow-fibers originally thought for gas-supply 
were filled with sterile water. Additionally, 5% CO2 was adjusted using this gassing system. The 
bundles for medium supply were connected to a tubing system which was equipped with two oxygen 
sensors (PreSens, Regensburg, Germany), one in front of the bioreactor and one behind to calculate 
oxygen-uptake rates for on-line monitoring of cell-viability [Mueller et al., 2011b]. The bioreactor 
polyurethane housing was equipped with separate access ports for each individual capillary bundle 
and one additional port to inoculate the cells into the extracapillary compartment. The bioreactor 
and the connected tubing system were placed into a specifically developed, heatable perfusion 
system (Stem Cell Systems, Berlin; see Fig. 3.1 d) providing two peristaltic pumps, one for medium-
recirculation (7 ml per minute) and the other for the supply of fresh medium (1.5 ml per hour). 
Furthermore, the perfusion system allowed proportional regulation of air and CO2 in the gas mixture 
for gassing via built-in rotameters. The cell compartment of the “jelly-fish”-bioreactor used for 
cultivation in our lab (see Fig. 3.1 b) had a volume of 2 ml and was inoculated with 1x108 cells while 
the “two-layer”-bioreactor used for the serum-free cultivation at Charité, Berlin (see Fig. 3.1 d) had a 
cell-compartment size of 0.5 ml and was inoculated with 2x107 cells. 
The continuous supply with fresh-medium resulted in an overpressure in the system, thus provoking 
an efflux of conditioned medium. This efflux was collected in a refrigerator in a flask containing 
protease inhibitors for the analysis of the extracellular proteome. 
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Figure 3.1. The bioreactor system used in this work. Scheme of the bioreactor with tubing system, pumps, 
oxygen sensors (O2 IN, O2 OUT) and the gassing-unit (a). Picture of the “jelly fish” bioreactor used for cultivations 
at the Saarland University (b), of the perfusion system for bioreactor operation (c) and of the “two-layer” 
bioreactor used for serum-free cultivation at Charité, Berlin (d, courtesy of Charité, Berlin).  
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3.4 Physiological characterisation of the hepatocyte cultures 
To characterize the monolayer cultivation of primary human hepatocytes, supernatants of the 
cultures were analyzed for several parameters i.e. metabolism (via sugar uptake/release and lactate 
production), viability (via enzyme release) and protein production of the cells. The methods used to 
achieve this goal are explained in this section and the results are reported in section 4.2. 
3.4.1 Determination of albumin concentrations 
Albumin concentration in the culture supernatant was determined via an enzyme-linked 
immunosorbent assay (ELISA) kit, containing all required buffers and reagents (Albuwell II; Exocell, 
Philadelphia, PA), according to the manufacturer´s instructions in 96-well plates. In brief, samples 
(100 µl) were incubated for about 30 minutes at room temperature (RT) with 100 µl of CONJUGATE 
in the precoated 96-well plate supplied with the kit. For color development, 100 µl of COLOR 
DEVELOPER was added and incubated for about 10 minutes at RT. Afterwards, color development 
was stopped with 100 µl COLOR STOPPER and absorbance at 450 nm was determined using a 
microplate reader (iEMS Reader MF; Labsystems, Helsinki, Finnland). Albumin concentration was 
calculated using a standard of human serumalbumin derived with the kit and measured 
simultaneously as a 1:2 dilution series. Both standard and samples were determined as duplicates. 
For calculation of production rates, the value obtained for the blank (medium) was subtracted and 
rates were calculated by normalizing the values to the total volume of the supernatant and dividing 
the resulting values by the number of seeded cells (one million per well of a 6-well plate). 
For calculation of daily production rates from bioreactor effluent samples, the following formula 
provided by the charitè was used: 
(CE (tx) – CE (tx-1)) * VE (tx) + ((CE (tx) + CE (tx-1))/2 - CM) * VR 
with CE being the analytes concentration in the effluent samples at the day of sampling (tx) and the 
day before (tx-1); VE being the total volume of effluent; CM being the medium (blank) value and VR 
being the total recirculation volume of the bioreactor. 
3.4.2 Determination of LDH activity 
The specific activity of Lactate-Dehydrogenase (LDH) in the culture supernatant was determined 
using a colorimetric enzymatic assay kit (Cytotoxicity Detection Kit; Roche). LDH released in the 
supernatant oxidizes lactate to pyruvate with the formation of NADH+H+. A catalyst (diaphorase) 
then uses this NADH+H+ to reduce a tetrazolium salt (INT) to the corresponding formazan whose 
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amount can be determined photometrically. In brief, 100 µl of sample was mixed with 100 µl 
reaction mix (containing lactate, NAD+ and diaphorase) in a 96-well plate and incubated for 30 
minutes at RT under light-protection. Absorbance was determined at 492 nm using a microplate 
reader (iEMS Reader MF). For normalization, a dilution series of a standard serum (NobiCal-MULTI; 
HITADO, Möhnesee-Delecke) was measured simultaneously. Release rates were calculated by 
normalizing the values to the total volume of the supernatant and dividing this value by the number 
of seeded cells (one million per well of a 6-well plate). Release was calculated after subtracting the 
activity determined in the unconditioned cultivation medium. 
3.4.3 Determination of AST activity 
The activity of liver-specific aspartate aminotransferase (AST) in the culture supernatant was 
determined using a kinetic UV assay kit (Hitado, Möhnesee-Delecke, Germany). L-Aspartate and 2-
Oxoglutarate are converted to L-Glutamate and Oxalocetate by Transamination through AST. In a 
second reaction, the produced Oxalocetate is oxidized to L-Malat by the enzyme Malat-
Dehydrogenase under formation of NAD+ from NADH+H+. The decrease in NAD+ can be determined 
photometrically at a wavelength of 340 nm and is proportional to the amount of AST in the sample. 
20 µl of sample were mixed with the reaction mixture (5 parts R1 and 1 part R2), that was warmed to 
37° C and the extinction was determined at 340 nm in a microplate reader (iEMS reader MF) after 1 
minute and after 10 minutes. To calculate the activity of AST, a dilution series of a standard serum 
(NobiCal-MULTI; Hitado, Möhnesee-Delecke) was measured simultaneously. Release rates were 
calculated by normalizing the values to the total volume of the supernatant and dividing this value by 
the number of seeded cells (one million per well of a 6-well plate) after subtracting the activity of 
AST determined in the unconditioned medium. 
3.4.4 Determination of glucose, galactose, sorbitol and lactate concentrations 
D-glucose, D-galactose, D-sorbitol and L-lactate concentrations in the samples were determined 
using enzymatic assay kits (all from R-Biopharm, Darmstadt, Germany) after manufacturer`s 
instructions as described below. Release/production rates were calculated by normalizing the values 
to the total volume of the supernatant and dividing this value by the number of seeded cells (one 
million per well of a 6-well plate) after subtracting the concentration of the respective metabolite 
determined in the unconditioned medium. 
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3.4.4.1 D-Glucose 
The assay is based on the conversion of D-glucose to gluconate-6-phosphate by hexokinase and 
glucose-6-phosphatedehydrogenase with the formation of equimolar NADPH. Absorbance of NADPH 
is measured at 340 nm using an Ultrospec 2000 UV/Vis spectrophotometer (Amersham Pharmacia 
Biotech, Buckinghamshire, UK) photometer. Samples were diluted 1:10 with distilled water. 500 µl of 
solution 1 of the kit was pipetted into cuvettes. 50 µl of diluted sample and 950 µl of distilled water 
were added and mixed. Absorbance at 340 nm (A1) was measured after 3 minutes. Reaction was 
started by adding 10 µl of suspension containing enzymes. After 15 min incubation at room 
temperature absorbance was again measured at 340 nm (A2). Blank values with all reagents except 
culture samples were taken at every measurement. Differences between A2 and A1 were 
determined. Absorbance difference of blank sample was substracted from absorbance differences of 
samples. D-glucose concentrations were calculated using a formula given by the manufacturer.  
3.4.4.2 D-Galactose 
The assay is based on the conversion of galactose to galactonic acid by galactose dehydrogenase with 
the formation of equimolar NADH. Absorbance of NADH is measured at 340 nm using an Ultrospec 
2000 UV/Vis spectrophotometer (Amersham Pharmacia Biotech, Buckinghamshire, UK) photometer. 
The kit consists of solution 1 and solution 2. Samples were diluted 1:10 with distilled water. 100 µl of 
solution 1 was pipetted into plastic cuvettes. 50 µl of diluted sample was added, mixed and 
incubated for 20 min at room temperature. 500 µl of solution 2 and 975 µl distilled water were 
added. After 3 min, absorbance at 340 nm (A1) was measured. Reaction was started by adding 25 µl 
of enzyme suspension. After 20 min incubation at room temperature absorbance was again 
measured at 340 nm (A2). Blank values with all reagents except culture samples were taken at every 
measurement. Differences between A2 and A1 were determined. Absorbance difference of blank 
was substracted from absorbance differences of samples. D-galactose concentrations were 
calculated using a formula given in the manual. 
3.4.4.3 D-Sorbitol 
This colorimetric assay is based on the conversion of D-sorbitol to fructose by sorbitol 
dehydrogenase with the formation of equimolar NADH. Because equilibrium lies on the side of 
sorbitol, NADH is removed in a subsequent reaction, whereas formazan is formed. The absorption of 
formazan is measured at its maximum at 492 nm using an Ultrospec 2000 UV/Vis spectrophotometer 
(Amersham Pharmacia Biotech, Buckinghamshire, UK) photometer. Samples were diluted in 1:10 
ratio with distilled water. 300 µl of solution 1, 100 µl of solution 2 and 3 respectively and 50 µl of 
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diluted samples were pipetted into plastic cuvettes. 950 µl distilled water was added and after 2 min 
absorbance (A1) at 492 nm was measured. Reaction was started by adding 25 µl of enzyme 
suspension. After 30 min incubation absorbance was again measured at 492 nm (A2). Blank values 
with all reagents except culture samples were taken at every measurement. Differences between A2 
and A1 were determined. Absorbance difference of blank was substracted from absorbance 
differences of samples. D-sorbitol concentrations were calculated using formula provided with the kit. 
3.4.4.4 L-Lactate 
The assay is based on the conversion of L-lactate to L-alanine via pyruvate with formation of 
equimolar NADH. Absorbance of NADH is measured at 340 nm. Samples were diluted in 1:10 ratio 
with distilled water. 500 µl of solution 1, 100 µl solution 2 and 10 µl suspension 3 were pipetted into 
plastic cuvettes. 50 µl of diluted sample and 450 µl distilled water were added and mixed. After 5 
min, absorbance at 340 nm (A1) was measured using an Ultrospec 2000 UV/Vis spectrophotometer 
(Amersham Pharmacia Biotech, Buckinghamshire, UK) photometer. Reaction was started by adding 
10 µl of enzyme suspension. After 30 min incubation absorbance was again measured at 340 nm (A2). 
Blank values with all reagents except culture samples were taken. Differences between A2 and A1 
were determined. Absorbance difference of blank was substracted from absorbance differences of 
samples. Again, L-lactate concentrations were calculated using the formula supplied with the kit. 
3.4.5 Determination of urea concentration (HPLC) 
The concentration of urea in the conditioned medium of primary human hepatocytes was 
determined using an HPLC-method [Clark et al., 2007]. In this method, the urea present in the culture 
supernatant is converted to N-9H-xanthen-9-ylurea by derivatisation with xanthydrol (9H-xanthen-9-
ol). After chromatographic separation on a Agilent 1100 equipped with a C18-column (Eclipse XBD 
RP-18 column (150 mm × 4.6 mm ID, 5 µm); Agilent Technologies, Weinheim), the derivative was 
detected using a fluorescence detector (λex = 213 nm; λem = 308 nm) and quantified using a urea 
standard curve measured in the same way. Production rates were calculated by normalizing the 
values to the total volume of the supernatant and dividing this value by the number of seeded cells 
(one million per well of a 6-well plate). 
3.5 Protein extraction from collected culture supernatants 
The collected medium from the cultivations was centrifuged once (3000 x g at 4° C) to pellet dead 
cells and cell-debris. At this timepoint, protease inhibitors (complete, Roche, Mannheim, Germany) 
were added and an aliquot of 1 ml was removed for determination of physiological parameters as 
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depicted in section 3.4. The remainder was filtered through a 0.44 µm regenerated cellulose filter 
(VWR) to remove small debris. 4 ml of conditioned medium (corresponding to 2 million seeded cells 
in monolayer culture) was concentrated 20-fold using an ultrafiltration device with a molecular-
weight cut-off of 10 kDa (Vivaspin4, Sartorius) for 30 minutes at 10000 x g at 4°C. Retenuates (50 -
100 µl) were rebuffered to an appropriate binding buffer for immunodepletion (see 3.6) by filling up 
the ultrafiltration device with the respective buffer and centrifugation as described before. This step 
was performed twice resulting in 99.9 % buffer-exchange. For the bioreactor samples, the volume of 
samples was between 6 and 8 ml, depending on the available material. For these samples, the first 
centrifugation step was performed twice after filling-up the device with the rest of the sample. After 
concentration, the protein content was estimated using a Bradford-based protein assay (Bio-Rad 
Protein Assay, Bio-Rad, München, Germany) [Bradford, 1976]  and production rates were calculated 
by normalizing the values to the total volume of collected supernatant and dividing this value by the 
number of seeded cells (one million cells per well of a 6-well plate containing 2 ml of medium). For 
calculation of protein production rates from bioreactor samples, the same formula as for calculation 
of albumin production rates was used (see section 3.4.1).  
3.6 Immunodepletion for the removal of high-abundant proteins 
For specific depletion of high abundant proteins (albumin, transferrin, haptoglobin, antitrypsin), an 
antibody-based spin cartridge (Hu-6 Multiple Affinity Removal Spin Cartridge; Agilent, Böblingen) was 
used. Samples were rebuffered into binding buffer (“buffer A”) by ultrafiltration as described in 3.5. 
The sample was loaded onto the column and spun at 100 x g for 1.5 minutes. 400 µl of buffer A were 
added and spun for 2.5 minutes. This step was conducted twice resulting in 1 ml of depleted sample. 
The bound fraction was eluted by pushing 2 ml of elution buffer (“buffer B”) through the cartridge 
and re-equilibrated for the next sample with 4 ml of buffer A using a Luer-Lock syringe.  Flow-through 
as well as bound fraction were rebuffered by ultrafiltration into 25 mM NH4HCO3 buffer and analyzed 
directly by SDS-PAGE or, alternatively, by LC-MALDI following in-solution digest of proteins using 
trypsin as endoprotease. 
3.7 Gel electrophoresis (SDS-PAGE) 
Before in-gel tryptic digestion, proteins were separated using one-dimensional discontinuous Tris-
Glycine SDS-PAGE (sodium-dodecyl polyacrylamide gel-electrophoresis) under denaturing conditions 
[Laemmli, 1970]. Samples were denatured and reduced for 5 min at 95°C in 1x sample buffer (4 % 
SDS, 10 % Glycerol, 5 % ß-Mercaptoethanol, 0.02 % bromphenol blue in 125 mM Tris) and 
electrophoretic separation was performed at constant current (25mA per gel) on a 12.5 % separation 
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gel after focusing at 15 mA per gel on a 4 % stacking gel for 15 min (see table 3.1). For molecular 
weight estimation, 6 µl of prestained protein standard (Precision Plus Protein Standard Dual Color; 
Bio-Rad) was run simultaneously. Electrophoresis was stopped as the bromphenol blue front just run 
out of the gel. After electrophoresis, gels were stained either by colloidal Coomassie Blue (G-250) 
staining or by silver-ammonium staining (see section 3.8). 
Table 3.1. Solutions for casting of SDS-PAGE gels 
Separation gel (12.5%) Stacking gel (4%) 
dH2O 3.2 ml dH2O 3.05 ml 
1.5 M Tris pH 8.8 2.5 ml 0.5 M Tris pH 6.8 1.5 ml 
10 % SDS 100 µl 10 % SDS 50 µl 
30 % acrylamide/bisacrylamide 4.1ml 30 % acrylamide/bisacrylamide 0.65 ml 
TEMED 5 µl TEMED 5 µl 
10 % APS 50 µl 10 % APS 50 µl 
 
3.8 Gel-staining 
3.8.1 Colloidal Coomassie Blue staining 
For colloidal Coomassie Blue staining of SDS-gels, a colloidal Coomassie-based (Coomassie Brilliant 
Blue G-250) staining solution (EZblue Gel Staining Reagent, Sigma-Aldrich, Steinheim) was used. After 
electrophoresis, gels were washed three times with water (10 minutes each) and incubated for 45 
minutes to 1 hour in 20 ml EZblue reagent. Afterwards, gels were washed three to four times (or 
overnight) with water before scanning to minimize backround staining. 
3.8.2 Silver-ammonium staining (MS-compatible) 
For silver staining of SDS-gels, an silver-ammonium staining compatible with mass-spectrometry was 
used [Chevallet et al., 2006]. Gels (containing 0.5% sodium thiosulfate as sensitivity enhancer) were 
impregnated 45 minutes in silver-ammonia solution (7 ml 1 M NaOH, 7.5 ml 5 M NH4OH and 12 ml 1 
M AgNO3 add 500 ml with water) and developed in acidic developer (350 µM citric acid and 0.1% 
formalin in water) for about 10 minutes for visualization of protein bands while keeping backround 
staining as low as possible. Staining was stopped with 0.5% ethanolamine, 2% acetic acid in water for 
1h at room temperature. For in-gel digest, excised gel-slices were washed twice with water and 
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destained with 15 mM potassium ferricyanide and 50 mM sodium thiosulfate in water for 5-10 min 
at room temperature (RT) prior to reduction and alkylation as described in the following. 
3.9 In-gel digest 
After staining of SDS-gels, bands were excised using a clean scalpel and transferred into a 0.5 ml 
Eppendorf tube. Slices were washed with 100 µl water and with 100 µl 50% acetonitrile (ACN; 2 x 5 
min each; 37°C). Disulfide-bonds were reduced using 50 µl of 10 mM dithiothreitol (DTT; 1h, 60°C) 
and after washing with 100 µl of water, Carbamidomethylation of free cysteins was conducted with 
50 µl of 55 mM iodoacetamid (IAA) for 1h at RT under light protection. Gel-slices were destained 
completely by washing with 100 µl 50 % ACN in water several times until the gel-slices were 
completely destained (for Coomassie staining; for silver-stained gels, the gel-slices were destained 
prior to the described protocol here; see section 3.8.2). The destained gel-bands were dehydrated 
with 100µl of pure ACN, 10µl of sequencing-grade modified trypsin (Promega; 12.5 ng/µl in 25 mM 
ABC) was added and incubated at room temperature until trypsin solution was soaked completely 
into the gel-slices. Remaining trypsin solution around the gel-slices was removed and the slices were 
covered with 25 mM ABC buffer followed by incubation overnight at 37°C for digestion. Trypsin-
proteolysis was stopped by adding 10 % TFA to a final concentration of 0.2 %, mixed 1:1 with matrix 
(CHCA, 5 mg/ml in 70 % ACN + 0.1 % TFA) and immediately spotted onto a MALDI-target (384well 
Opti-TOF, Applied Biosystems). 
For the analysis of whole gel lanes for the evaluation of prefractionation on different LC-MS 
platforms, 40 µg of sample was separated on a 12 % polyacrylamid gel and lanes were cut in 24 2x2 
mm slices using a special device for gel-excision (gel-company, Tübingen). Slices were reduced and 
alkylated on an automated liquid handling device (MassPREP Station; Waters, Milford, MA) as 
described in [Weiss et al., 2009]. In brief, gel pieces were washed three-times with 50 % ACN in 25 
mM ABC. Cysteine residues were reduced with 10 mM DTT at 57 °C for 30 minutes and alkylated in 
55 mM IAA at room temperature for 20 minutes. After dehydration with ACN, proteins were digested 
in gel with 10 μL of 12.5 ng/μL sequencing-grade modified trypsin (Promega, Madison, WI) in 25 mM 
ABC overnight at 37 °C. Tryptic peptides were extracted firstly with 60 % ACN in 0.1 % formic acid (for 
ESI-MS) or with 60 % ACN in 1 % TFA (for MALDI-MS). Then, a second extraction step with 100 % ACN 
was performed. For extractions, samples were vigorously shaken for 1 hour on an orbital shaker at 
1200 rpm at room temperature. After extraction, supernatants were pooled, the volume was 
reduced to 5 µl in a speed-vac and the resulting sample was analysed by nanoLC-MS/MS (nanoliquid 
chromatography coupled to tandem mass spectrometry). The procedure was performed identically 
in triplicate to allow comparison of the three different LC-MS platforms. 
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3.10 In-solution digest 
Proteins were thermally denatured for 15 minutes at 90 °C and disulfide bonds were reduced using 5 
mM DTT for 30 minutes at 60 °C. Carbamidomethylation of free cysteins was performed in 15 mM 
IAA for 45 minutes at RT under light protection. Digestion was performed overnight with sequencing 
grade-modified trypsin (Promega, Madison, WI, USA) applying a trypsin to protein ratio of 1:50. After 
proteolysis the trypsin was inactivated by addition of TFA (final concentration 0.1%) and another 
ultrafiltration step (Amicon 0.5, 10 kDa MWCO, Millipore) was performed to remove the trypsin and 
remaining undigested proteins. The filtrate was evaporated to dryness in a speed-vac (Jouan RC 
10.22, Saint-Nazaire, France) and resuspended in 2 % ACN + 0.05 % TFA for LC-MALDI analysis. 
For the analyses performed together with the LSMBO (University of Strasbourg), the denaturation 
was performed at 95°C for 10 minutes in 25 mM ABC containing 1 % sodium desoxycholic acid (DOC) 
as a detergent maximizing denaturation as well as digestion of the polypeptide chains. Reduction, 
alkylation and proteolysis were performed as described above. Afterwards, the DOC was removed by 
adding TFA (or FA for the ESI-sample) to a final concentration of 0.2 %. Under these (acidic) 
conditions, the DOC precipitated and was removed by centrifugation for 5 minutes at 14.000 x g. The 
supernatant was then used for LC-MS analysis after ultrafiltration as described above. 
3.11 Liquid-chromatography and fraction collection 
The HPLC system used in this study was a biocompatible version of an Ultimate 3000 nano LC system 
consisting of a solvent degassing unit (SRD-3600), a dual low-pressure gradient pump (DGP-3600MB), 
a column oven with integrated 1:1000 splitting cassette (FLM-3100), a variable wavelength detector 
with a 3 nl z-shaped flow-cell (VWD-3400) and a thermostated autosampler (WPS-3000T/TB; all from 
Dionex, Sunnyvale, CA). Peptides were separated on a C18 column (PepMap, 75 µm i.d., 15 cm, 3 µm, 
100 Å) at a flow rate of 300 nl/min (after splitting) in combination with a C18 precolumn (PepMap100, 
300 µm i.d., 5 mm, 5 µm, 100 Å) at a flow rate of 30 µl/min. Eluent A consisted of 0.05 % TFA in 
water and eluent B was 90 % acetonitrile in water containing 0.04 % TFA. The UV-chromatogram was 
recorded at a wavelength of 214 nm. After loading the samples onto the precolumn and desalting for 
5 minutes with 0.1 % TFA in water at 30 µl per minute, the precolumn was switched into the gradient 
flow and peptides were eluted employing a gradient from 10 % (fast rise from 5 % to 10 % in one 
minute) to 45 % Eluent B in 90 minutes (liquid digests). For the separation of peptides originating 
from in-gel digests, the employed gradient was 15 % to 55 % in 30 minutes. The column was then 
washed for 5 minutes with 95 % Eluent B and re-equilibrated for 15 minutes to 5 % Eluent B for the 
next analysis.  
Material and Methods 
| 36  
 
Fraction collection during chromatography was performed with a Probot microfraction collector 
(Dionex). The MALDI matrix used was α-Cyano-4-hydroxycinnamic acid (CHCA; Fluka Chemistry AG, 
Buchs, Switzerland) and was continuously added to the effluent at a flow rate of 1.2 µl per minute at 
a concentration of 3 mg/ml in 70% ACN containing 0.1 % TFA. A signal was sent to the Probot at 
minute 13 of the LC run to start fractionation. Fractions were collected every 12 sec for 90 minutes 
generating 450 spots per run. Fractions were spotted directly on a blank Opti-TOF LC/MALDI plate 
(Applied Biosystems, Darmstadt, Germany) using a 50 x 32 geometry (1600 spots per plate). 
3.12 MALDI mass-spectrometry 
MS and MS/MS analysis was performed on an Applied Biosystems 4800 MALDI TOF/TOF analyzer 
(Applied Biosystems, Darmstadt, Germany). Before each MALDI measurement and also before each 
MS run, the analyzer was externally calibrated using the 4700 Proteomics Analyzer Calibration 
Mixture (4700 proteomics analyzer mass standards kit, Applied Biosystems) resulting in a mass 
accuracy of 50 ppm. Furthermore, Glu1-Fibrinopeptide B (1570.677 m/z) was added to the matrix 
used for LC-MALDI at a concentration of 25 nM for internal calibration of each MS spectrum to 
improve the average mass accuracy to 15 ppm. If internal calibration failed due to presence of high 
intensities of sample peptides leading to peak suppression of Glu1-Fibrinopeptide B, the default 
calibration was used (i.e. 50 ppm). 
MS-data was generated in positive reflector-mode in a mass range of 700-4000 m/z with 50 shots per 
subspectrum accumulating 1000 shots in total. An exclusion list was written to avoid fragmentation 
of the internal calibrant as well as common Matrix-ions. Laser frequency used was 200 Hz (at 355nm; 
Nd/YAG-laser) and laser intensity was adjusted individually (normally between 3100 and 3500). 
However, for the comparative analyses of bioreactor samples, the laser intensity was fixed at 3400 
for all measurements. A maximum of 15 precursor ions per fraction were automatically selected by 
the software (4000 series explorer software, version 3.5.1, Applied Biosystems) for MS/MS-analysis. 
For the comparison of MALDI- and ESI-MS, the 6 most intense precursors were analysed by MS/MS 
both for the liquid and the in-gel digests. Criteria for a peak to be selected as a precursor were: 
minimum signal-to-noise ratio 35; precursor mass tolerance between spots 100 ppm; minimum 
chromatogram peak width of two fractions (i.e. spots). For acquisition of MS/MS spectra, 100 shots 
were fired per subspectrum with 3000 shots in total or after reaching a signal-to-noise ratio of 35 for 
at least 10 peaks in the MS/MS spectrum. Peptides were fragmented by 1kV collisions via CID (air as 
collision gas). External calibration was performed using fragments of Glu1-Fibrinopeptide from the 
4700 proteomics analyzer mass standards kit (Applied Biosystems) prior to each MS/MS run.  
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3.13 Analyses performed at LSMBO, CNRS; University of Strasbourg 
3.13.1 Analyses using an ion trap instrument 
NanoLC-MS/MS analyses were performed using an Agilent 1100 series nanoLC-Chip/MS system 
(Agilent Technologies, Palo Alto, USA) coupled to an amaZon ion trap (BrukerDaltonics, Bremen, 
Germany). The system was fully controlled by HyStar 3.2 (BrukerDaltonics). The chip contained a 
Zorbax 300SB-C18 column (43 mm×75 µm, 5 µm particle size) and a Zorbax 300SB-C18 enrichment 
column (40 nl, 5 µm particle size). The solvent system consisted of 2 % acetonitrile, 0.1 % formic acid 
in water (Eluent A) and 2 % water, 0.1 % formic acid in acetonitrile (Eluent B). 
3 µl of each sample were loaded onto the enrichment column at a flow rate set to 3.75 µl per minute 
with eluent A. Elution was performed at a flow rate of 300 nl per minute with a 8–40 % linear 
gradient (eluent B) in 30 minutes (in gel) or 45 minutes (liquid digest), followed by a 4 minute 
washing step at 70 % of eluent B before reconditioning the column at 8 % of eluent B. 
MS spectra were acquired with the following settings: source temperature was set to 135°C while 
cone gas flow was at 3 liter per minute. The nanoelectrospray voltage was optimized to −1850 V. The 
MS spectra were acquired in the positive ion mode on the mass range 250 to 1500 m/z using the 
standard enhanced resolution at a scan rate of 8.1 m/z per second. The ion charge control was fixed 
at 200,000 with a maximum accumulation time of 200 milliseconds. For tandem MS experiments, the 
system was operated with automatic switching between MS and MS/MS modes. The 6 most 
abundant peptides were selected on each MS spectrum for further isolation and fragmentation with 
a preference for doubly charged ions (absolute threshold of 5000, relative threshold 5 %). The 
MS/MS spectra were acquired in the mass range from 100 to 2000 m/z. The ion charge control was 
fixed at 300000 and 2 scans were averaged to obtain a MS/MS spectrum. Ions were excluded after 
acquisition of one MS/MS spectrum and the exclusion was released after 0.3 minutes. The smart 
parameters setting option was used for the selected precursor ions.  
3.13.2 Analyses using a quadropole-time of flight (Q-TOF) instrument 
NanoLC-MS/MS were performed using a nanoACQUITY Ultra-Performance-LC system (Waters, 
Milford, MA, USA) coupled to a MaXis 4G Q-TOF mass spectrometer (BrukerDaltonics, Bremen, 
Germany). The system was fully controlled by HyStar 3.2 (BrukerDaltonics). The UPLC system was 
equipped with a Symmetry C18 precolumn (20 х 0.18 mm, 5 µm particle size, Waters, Milford, USA) 
and an ACQUITY UPLC® BEH130 C18 column (75 µm × 200 mm, 1.7 µm particle size, Waters). The 
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solvent system consisted of 0.1 % formic acid in water (eluent A) and 0.1 % formic acid in ACN 
(eluent B). 
3 µL of each sample were trapped during 1 min at 15 µl per minute with 99 % of A and 1 % of B. 
Elution was performed at 60 °C at a flow rate of 450 nl per minute, using a 6-35 % gradient of B for 
21 minutes (in gel) or a 6-43.5 % gradient of B for 35 minutes (liquid sample) followed by a fast rise 
to 90 % of B and back to 1 % B. 
The MaXis was operating in positive mode, with following settings: source temperature was set to 
150°C while dry gas flow was at 4 liter per minute. The nanoelectrospray voltage was optimized to 
−5000 V. Mass calibration of the TOF was achieved using Tuning Mix (Agilent) in the mass range of 
322-2722 m/z. Online correction of this calibration was performed with methylstearate ([M+H]+ 
299.2945 m/z) and hexakis(2,2,3,3,-tetrafluoropropoxy)phosphazine ([M+H]+ 922.0098 m/z) as the 
lock-mass.  
For tandem MS experiments, the system was operated with automatic switching between MS and 
MS/MS modes in the range of 50-2200 m/z (MS acquisition time of 0.68 s, MS/MS acquisition time 
between 0.68 (intensity > 26000) and 4.76 s (intensity <1000). The 4 (in gel) or 5 (liquid digest) most 
abundant peptides (absolute intensity threshold of 1000), preferably doubly, triply and quadruply 
charged ions, were selected from each MS spectrum for further isolation and CID fragmentation 
using argon as collision gas. Ions were excluded after acquisition of one MS/MS spectrum and the 
exclusion was released after 0.6 (in gel) or 0.8 minutes (liquid digest), respectively. 
3.14 Database search for protein identification 
The peak-lists were searched against a SwissProt-derived (January 2011) combined target-decoy 
database (containing 20254 target sequences plus the same number of reversed decoy sequences) of 
human proteins including common contaminants (human keratins and porcine trypsin). It was 
generated using the database generation toolbox from the laboratory of bio-organic mass-
spectrometry of the University of Strasbourg (https://msda.u-strasbg.fr/index.php). Peak lists were 
sent to a local Mascot server (version 2.1, Matrix science, London, England) using the GPS explorer 
software (version 3.6, Applied Biosystems, Darmstadt, Germany) for the measurements on the 
MALDI instrument. Mascot generic files (.mgf) generated during analyses performed on the ESI 
instruments in Strasbourg were sent to the same server using Mascot deamon (version 2.0). No 
differences in identifications were observed when using these two different approaches for 
submission of peak-lists using a test dataset. Search parameters applied were: one missed cleavage 
Material and Methods 
| 39  
 
by trypsin. Variable modifications allowed were oxidation of Methionine (+16 Da) and 
carbamidomethylation of Cysteine (+57 Da).  
Mass accuracy settings for the different instruments were as follows: 
MALDI:  50 ppm for precursor ions, 0.3 Da for the fragment ions 
Ion-trap:  0.25 Da for precursor as well as for fragment ions 
QTOF:  5 ppm for precursor ions, 0.02 Da for fragment ions 
3.15 Reprocessing of Mascot search results 
After database search, the Mascot result files (.dat) were imported into Scaffold 3 software 
(Proteome Software Inc.) and the identified proteins were filtered both at the 1- and 2-peptide level 
by adjusting the Mascot “delta score” (ion minus identity score). For proteins identified by 2 peptides 
and more, the delta score had to be > 0, which means that the ion score had to be above the 
minimum identity threshold at 95% probability. For identifications with one peptide only, the 
filtering was more stringent (normally delta score > 5) thus minimizing false positives by only 
accepting high quality MS/MS spectra. All identifications above the (lower) threshold for the 2-
peptide level (i.e. delta score > 0) were exported from Scaffold. Subsequently, all identifications with 
only one peptide and with scores below the more stringent threshold were removed in Excel. Using 
this approach together with a combined target-decoy database search [Elias and Gygi, 2007], the 
false discovery rate (FDR) could be controlled and was kept below 2 % (about 1 decoy hit in 100 
identifications) for all measurements. However, for the comparison of different donors and for the 
immunodepletion experiment, the FDR was reduced to 0 % which means that no decoy-hit was 
tolerated in the final protein list. 
3.16 Annotation of identified proteins 
For functional annotation enrichment analysis of identified proteins, the Database for Annotation, 
Visualization and Integrated Discovery (DAVID, version 6.7; http://david.abcc.ncifcrf.gov/) was used 
[Huang da et al., 2009a; Huang da et al., 2009b]. Proteins were examined for the enrichment of 
annotations in the Panther database [Thomas et al., 2003; Mi and Thomas, 2009] compared to the 
whole list of proteins known for Homo sapiens as the backround list. The information about the 
presence of a signal peptide required for secretion via classical secretion pathways was also 
extracted from Uniprot using DAVID. The subcellular location of identified proteins was retrieved 
from Uniprot (http://www.uniprot.org/) [2009]. 
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3.17 Prediction of non-classically secreted proteins 
To predict if identified proteins were secreted via non-classical secretion pathways, proteins not 
annotated to have a signal peptide in DAVID were processed using the web-based software 
SecretomeP (version 2.0). The algorithm underlying the prediction has been explained in detail in 
[Bendtsen et al., 2004] but generally relies on the common properties secreted proteins are thought 
to share based on their amino acid sequence. All proteins with a NN-score above 0.5 were accepted 
as possibly secreted as proposed in the online manual. 
SecretomeP is available under: http://www.cbs.dtu.dk/services/SecretomeP/ 
3.18 Quantification by peptide hit counting 
Differentially expressed proteins were identified by the number of peptides leading to identification 
of a specific protein. This was done by the help of Scaffold, which applies a statistical test (one-way 
ANOVA in this case) to detect significant differences in the number of peptides assigned to a protein 
between groups (i.e. 2 treated and 1 untreated group) compared to the differences observed within 
a group (i.e. three replicates). The ANOVA test delivers a p-value and in this study, only proteins with 
a p-value < 0.05 were accepted as differentially expressed. Prior to the ANOVA test, peptide hits in 
each sample were normalized to the total amount of peptide hits in each sample by averaging the 
peptide counts across all groups, and then multiplying the peptide counts in each sample or group by 
the average divided by the individual sample or group sum. For example:  
Two samples: A and B  
Each biosample has three proteins: One, Two and Three  
Protein One has 12 peptides in sample A and 8 peptides in sample B  
Protein Two has 6 peptides in sample A and 3 peptides in sample B  
Protein Three has 4 peptides in sample A and 3 peptides in sample B  
Scaffold would normalize as follows:  
Sample A has 22 peptides, sample B has 14 peptides, the average of both is 18  
Scaffold would multiply all of the protein peptide counts in sample A by (18/22), and all of the 
peptide counts in sample B by (18/14).  
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3.19 Principal component analysis (PCA) 
Principal component analysis to detect and visualize significant changes in protein expression by 
peptide counts was performed using Matlab software (version R2006a, The MathWorks). Normalized 
peptide counts were auto-scaled for PCA by dividing the peptide counts of one protein by the 
standard deviation of all peptide counts for that protein in all replicates of all groups. PCA is a type of 
multivariate statistics reducing the dimensions within a dataset to a set of independent and 
orthogonal variables, the “principal components”. The number of principal components is less or 
equal to the original number of variables in the underlying dataset, with the first component 
explaining most of the variance explaining the differences in the dataset. 
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4. Results 
4.1 Establishment of an analytical strategy for hepatocyte secretome analysis 
4.1.1 Optimizing the cultivation for efficient secretome analysis 
Before sample collection for secretome analysis, the FCS-supplemented medium had to be removed 
and replaced by serum-free medium. This was done because the supplemented proteins mask the 
proteins secreted by cultured hepatocytes. The removal of FCS in standard monolayer cultures could 
be achieved fairly simple by washing the cells with serum-free medium. However, the removal of 
serum proteins from the bioreactor used in this project turned out to be not that easy, which is 
reported below. 
4.1.1.1 FCS-free monolayer cultivation 
The number of wash-cycles required to minimize the amount of FCS in the cell culture flasks was 
determined. Since PHH were delivered in FCS-supplemented medium and maintained in medium 
containing 10 % FCS for about 24h before any experiment in order to recover from “transport stress”, 
they had to be washed several times with serum-free medium. Thus, proteins originating from FCS 
were withdrawn.  
After 24h of equilibration, primary human hepatocytes (PHH) were washed four times with serum-
free medium. The cells were cultivated for 96h (4 days) in serum-free medium without medium 
exchange. The medium of washing steps and supernatants from the cultivation was concentrated by 
ultrafiltration and subjected to SDS-PAGE (see Figure 4.1). As shown in Figure 4.1 a and c, the protein 
concentration decreased rapidly within 2 washing steps and was further diminished by a third wash 
to a protein concentration already present in fresh medium (HM0). Obviously, four wash-cycles were 
sufficient to minimize the amount of proteins from FCS leaving human transferrin (supplemented in 
the medium) as the only proteinaceous material detected by coomassie blue staining in the 
supernatant and thus allowing secretome analysis of primary human hepatocytes in monolayer 
culture. 
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Figure 4.1. SDS-PAGE of wash-cycles (a) and supernatants (b) of PHH in conventional 2D-culture for removal of 
proteins originating from fetal calf serum (FCS). Cells cultivated in Heparmed +10% FCS (HM10) were washed 
four times (W1-W4) with serum-free medium (HM0) and cultivated for 96h in HM0. Supernatants were 
concentrated by ultrafiltration (10.000 MWCO) and 7.5µl (a) or 10µl (b) were subjected to SDS-PAGE. Total 
protein content in the concentrated samples (c) as determined via Bradford-assay. Error bars indicate standard 
deviation of triplicate measurements (n=3). 
4.1.1.2 FCS-free bioreactor cultivation 
Several runs of “jelly-fish”-bioreactors were performed using FCS-supplemented medium for 
inoculation of cell-suspension and initial cultivation to ensure best survival of the primary 
hepatocytes. At day 9, the cultivation medium was replaced by serum-free medium to allow analysis 
of secreted proteins. The cultivation medium was concentrated by ultrafiltration and after 
determining the protein concentration, the concentrated samples were subjected to SDS-PAGE. 
In Figure 4.2 a, the total protein concentration of bioreactor samples during a cultivation employing 
FCS is depicted. It is obvious that the protein concentration at the first days was entirely dominated 
by the supplemented FCS (2.2 µg/µl). It has to be mentioned, that the amount of FCS in the medium 
was already lowered from 10 % to 2.5 % at this time. After switching to serum-free conditions on day 
9, the protein concentration decreased rapidly to 1.8 µg/µl at day 10 and to 0.27 µg/µl at day 11. 
Afterwards, the protein concentration further decreased and was estimated to 0.18 µg/µl at day 12, 
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0.14 µg/µl at day 13 and 0.11 µg/µl at day 14. During the final phase of cultivation (day 15 to 19), the 
protein concentration remained at 0.06 µg/µl. The elevated value at day 16 is most probably 
attributable to the fact that only little effluent was produced at day 16 and a high concentration of 
Protease Inhibitors was present in the sample. The Protease Inhibitors were filled into the collection 
bottles prior to collection as 25-fold stock solution to prevent unspecific proteolysis and may have 
affected the Bradford assay. 
The absence of proteins in the sample of day 16 was confirmed by SDS-PAGE carried out with the 
concentrated samples (see Fig. 4.2 b). The electrophoresis of samples from day 3 to 11 proves the 
domination of proteins by bovine albumin accounting for more than 60 % of total protein in serum. 
Albumin has a molecular weight of about 67 kDa and there was a very intense band visible in the 
region of the gel where proteins of this size should migrate. This band predominated until the FCS 
was withdrawn from the culture at day 9. At day 10, the concentration of FCS was still quite high, 
even though there was already a decrease in the intensity for mostly all of the bands. After day 11, 
only three bands could be detected by coomassie staining. These proteins were, as confirmed by 
MALDI-TOF/TOF analysis of in-gel digests at day 13 and 17 from the top to the bottom: human 
transferrin (supplemented in the medium), bovine albumin and human liver carboxylesterase. By 
applying a more sensitive method for detection, namely silver-ammonium staining (see Fig. 4.2 b, 
small picture), many more bands could be detected in the samples from day 13 to 19, but the 
intensity of the bands is decreasing constantly. This decrease is most probably due to a long-lasting 
wash-out of proteins from FCS still residing in the bioreactor circuit. 
LC-MALDI analysis of samples before (day 2) and after (day 14) withdrawing of FCS strengthened this 
assumption and showed that it is hardly possible to identify human proteins upon FCS addition 
because the bovine proteins remain in the bioreactor for many days (see Table 4.1). 
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Figure 4.2. Wash-out of FCS from a 3D bioreactor containing primary human hepatocytes. Inoculation and 
cultivation until day 9 was performed in medium containing 2.5 % FCS. At day 9, the medium was changed for 
serum-free cultivation. Daily samples (effluent) were concentrated by ultrafiltration and protein concentration 
was determined via Bradford-assay (a). SDS-PAGE of the same samples starting at day 3 (b). Shown are gels 
stained with Coomassie Blue and silver-ammonium (small picture). 1 µl of concentrated sample was loaded 
from day 3 to 11, while 10 µl were loaded from day 13 to 19.   
On day 2, 16 human proteins could be identified and the supplemented human transferrin was 
identified by only 2 peptides, while bovine transferrin was identified by 16 peptides as one of 13 
bovine proteins identified in the sample. Only 3 peptides of human albumin where identified in 
contrast to 20 peptides that were found for the bovine albumin. Since human transferrin is present 
as a supplement in the cultivation medium and was identified consistently with more than 35 
peptides in monolayer cultures, this strongly underlines masking of human proteins by their bovine 
equivalents. On day 14, the situation was slightly better but still unsatisfactory. Human transferrin 
was identified with 41 unique peptides and also human albumin was identified by 9 peptides, but 
bovine transferrin and albumin were still identified with 23 and 22 peptides, respectively. This 
implies, again, that the FCS leaves the bioreactor very slowly, especially the bovine albumin as the 
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predominant protein in fetal calf serum because many more peptides were assigned to the bovine 
proteins.  
Table 4.1. LC-MALDI analysis of bioreactor samples before (day 2) and after (day 14) withdrawal of FCS. 
Number of unique peptides leading to the identification of human or bovine transferrin and albumin in the 
culture medium of 3D cultures of PHH as well as the total number of identified proteins. 
 day 2 day 14 
 human bovine human bovine 
transferrin 2 16 41 22 
albumin 3 20 9 23 
identified proteins 16 13 6 11 
 
Therefore, completely serum-free bioreactor cultivation was needed and it has been shown by the 
scientists who developed the 3D-bioreactor used in this study, that it is possible to inoculate primary 
hepatocytes and run the bioreactor under serum-free conditions without influencing the 
performance of the hepatocytes (Kathrin Zeilinger, personal communication). Indeed, it has been 
shown that cells cultivated in a serum-free environment were not inferior to hepatocytes cultivated 
in medium supplemented with bovine serum regarding viability and maintenance of liver-specific 
functions like expression of cytochrome P450 enzymes.  
Finally, samples from serum-free bioreactor cultivations were available for the analysis of 
extracellular proteins from 3D-bioreactor cultures of primary human hepatocytes. The results are 
reported in section 4.4. 
 
4.1.2 Removal of high-abundant proteins by immunodepletion 
The SDS-PAGE of proteins collected in the supernatant of FCS-free cultivated hepatocytes (see Figure 
4.1 b), especially in the lanes where supernatants after 24h and 48h are shown,  indicates that there 
are few bands showing very high intensities compared to the intensities of the many other bands 
detected by staining with Coomassie blue. These few proteins emerge in high concentrations, while 
most other proteins are present at much lower concentrations in the sample. The difference in 
concentrations of studied analytes in biological samples often spans several orders of magnitude. In 
order to reduce the dynamic range within the samples, albumin, transferrin, haptoglobin and 
antitrypsin, four proteins that are present at high concentrations in the culture supernatant were 
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removed by immunodepletion. For this purpose, a commercially available antibody-based spin-
cartridge was used, originally designed for the proteomic analysis of human serum. Because 
hepatocytes produce many of the proteins present in human serum, this technique could also be 
applied to the analysis of the hepatocyte secretome. The procedure is quite fast with approximately 
20 minutes needed for the depletion of one sample including re-equilibration of the spin cartridge. 
The efficiency of the method is demonstrated by the fact that none of the four depleted proteins 
mentioned above was identified by LC-MALDI after depletion. Additionally, while in the undepleted 
sample 58 proteins were identified with 2 or more peptides (116 in total), the number of identified 
proteins in the depleted sample increased to 201, with 118 of them identified by 2 peptides or more 
(see figure 4.3 b). By applying a filtering approach to control the false discovery rate (FDR; see 3.14 
for detailed description), the number of identifications increased from 74 to 134 proteins after 
immunodepletion. 17 proteins were identified in the bound fraction including the proteins targeted 
for depletion. On the other hand, eight of the proteins identified before depletion could not be found 
after depletion, additionally to the four highly-abundant proteins mentioned above. These eight 
proteins were: GSH-S-transferase, Cofilin-1, kinesin-like protein KIF15, isocitrate dehydrogenase, 
heat shock protein 60, galectin-1, complement factor H, and nucleotide diphosphate kinase B.  
 
Figure 4.3. Immunodepletion of culture supernatants of primary human hepatocytes for the removal of high-
abundant proteins. a, SDS-PAGE (coomassie staining) of undepleted and depleted samples of primary human 
hepatocytes in conventional 2D-culture as well as proteins depleted by the immunoaffinity column (bound 
fraction; TRFE=transferrin, ALB=albumin, A1AT=alpha-1-antitrypsin, HPT=haptoglobin). Cells were cultivated in 
serum-free medium for 96h; b, number of proteins identified with one or at least two peptides before (bD) and 
after depletion (aD) as well as in the bound fraction (bF), shown are results before and after applying a target-
decoy search strategy and subsequent stringent filtering resulting in a false discovery rate (FDR) of 0%.  
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4.1.3 Gradient optimization for liquid-chromatographic separation of peptides 
For the separation of tryptic peptides, the employed solvent gradient had to be determined. For this 
purpose, a commercially available mixture of peptides from tryptic digest of six standard proteins 
(bovine serum albumin, transferrin and cytochrome C; beta-galactosidase from E. coli; chicken 
lysozyme and alcohol dehydrogenase from Yeast) was separated applying different solvent 
compositions at the beginning and the end of the gradient. Solvent A was water containing 0.05 % 
TFA and solvent B consisted of 90 % ACN in water containing 0.04 % TFA. For the separation of the 
protein mixture standard, the gradient had a length of 60 minutes, starting at minute 5, the 
timepoint when the precolumn was switched into the flow of the separation column. After the 
gradient, the column was washed with 95 % of solvent B for 5 minutes and reconditioned to 5 % 
solvent B for 15 minutes. First, the endpoint of the gradient was determined at which all of the 
peptides had eluted from the column. Then, this endpoint was fixed and the starting values for 
solvent B were varied to spread the separation window as far as possible regarding retention time. A 
summary of the optimization is shown as the recorded UV-chromatograms in Figure 4.4. 
The separation in reversed-phase HPLC is based on hydrophobicity of the analytes, i.e peptides in this 
special case. The more hydrophobic a peptide is, the later it elutes from the column if a gradient with 
increasing amount of organic solvent is used over time. At a certain percentage of organic solvent, all 
of the peptides should have eluted from the column. The determination of this percentage was the 
aim of the first step of optimization as shown in Figure 4.4 a. While the starting point was kept fixed 
at 5 % solvent B, the endpoint of the gradient was changed from 30 % B to 65 % B. In between, it was 
gradually increased by 5 %, but only the most informative elution profiles are given in Figure 4.4a.  
When the gradient reached 35 % B (Fig. 4.4a, black chromatogram), there were many peptides not 
yet eluted from the column resulting in a big peak after 72 minutes. This is the time when analytes 
eluted during the wash of the column (starting at minute 65.1) reach the detector and is called the 
“dwell-time” (In this case the system has a dwell-time of 6.5 minutes). If the percentage of solvent B 
is increased to 40 % B (Fig. 4.4a, red chromatogram), there is still a quite large peak eluting at minute 
72, indicating that there are still peptides not eluting from the column by going up to 40 % of solvent 
B. Finally, when the gradient is further increased to 45 % B (Fig. 4.4a, blue chromatogram), there is 
only a small peak appearing at minute 72, showing that nearly all of the peptides are eluted from the 
column using this endpoint (45 % solvent B, corresponding to about 40.5 % ACN). 
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Figure 4.4. Optimization of solvent gradients for liquid-chromatographic separation of tryptic peptides. For 
optimization, a standard containing a mixture of peptides from a digest of six standard proteins (bovine serum 
albumin, transferrin and cytochrome C; beta-galactosidase from E. coli; chicken lysozyme and alcohol 
dehydrogenase from Yeast) was used. Shown are UV-chromatograms recorded at a wavelength of 214 nm for 
determination of the optimal solvent composition during separation, i.e. endpoint (a) and starting point (b) of 
the gradient. The gradient started after 5 minutes and the length was 60 minutes. Legends indicate the 
percentage of solvent B (90% ACN, 0.04 % TFA) employed during the gradient. 
Increasing the percentage of solvent B at the end of the gradient resulted in a decrease of the wash 
peak and a shift of the whole chromatogram to earlier retention times. Further increase of the 
endpoint (55 %, 60% and 65%, data not shown) did not led to a decrease of this peak but to a shift of 
the whole elution profile towards earlier retention times what was not desirable. The peptides 
should elute over the whole time of the gradient to maximize separation. 
After determining the minimum amount of solvent B needed for the elution of peptides, the starting 
composition of the gradient was optimized. Therefore, the endpoint was kept fixed at 45 % solvent B 
and the starting value was gradually increased from 5 % to 15 % solvent B (see Fig. 4.4b). As it 
becomes obvious from the blue chromatogram in Figure 4.4b, only few peptides eluted before 
minute 25 if the gradient started at 5 % solvent B and the latest peaks are observed until minute 70 
of the chromatogram. By increasing the starting point of the gradient to 10 % B, the elution of the 
first peaks could be relocated to minute 16 to 17 of the chromatogram, but peaks detected at the 
end of the chromatogram eluted earlier, namely until minute 65. When the starting point was 
further increased to 15 % solvent B, there was no more shifting of the elution profile to earlier 
retention times but the early peaks eluted more condensed as with 10 % B as starting composition. 
Furthermore, the biggest part of the more hydrophobic peptides eluted until minute 60, which was 
not desired as mentioned above. 
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Finally, the optimal gradient for the separation of tryptic peptides was determined as 10 to 45 % 
solvent B, which corresponds to a percentage of ACN of 9 to 40.5 %. This gradient was used to 
separate secretome samples, but the time of separation was extended to 90 minutes taking into 
account the increased complexity of real samples after liquid digestion of proteins present in the 
conditioned medium from primary human hepatocytes. 
4.2 Physiological characterization 
The conditioned media of primary human hepatocytes were analyzed in order to investigate the 
performance of the primary cells regarding survival, liver specific functions and protein production 
during cultivation. The standard monolayer culture should serve as a control for the secretome 
analysis of samples from the bioreactor. Because intracellular contaminants could be released by cell 
death disturbing the analysis of truly secreted proteins, it was tested how much intracellular 
enzymes were released into the culture medium as an indicator for viability or cell-death, 
respectively. Additionally, the common anti-inflammatory drug Diclofenac was applied at two 
different concentrations as a model drug to study drug-induced hepatotoxicity. 
4.2.1 Characterisation of monolayer cultures 
Primary human hepatocytes were maintained for four days in monolayer culture and exposed to two 
concentrations of the anti-inflammatory drug diclofenac (6.4 µM and 100 µM). Physiological 
parameters like carbohydrate consumption and glucose or lactate production were determined to 
monitor the general energy metabolism of the cells. Furthermore, the release of LDH and AST was 
analyzed as a parameter reflecting cell viability or cell death, respectively. Albumin as well as urea 
production rates were determined as hepatocyte-specific parameters. Finally, protein production 
was calculated from the estimated protein concentrations in concentrated culture supernatants. At 
first, all rates were calculated as rates per day per million seeded cells. All values except the rates 
illustrating the carbohydrate metabolism were additionally normalized to enzyme release and total 
protein production with both having been normalized to production and release per day per million 
seeded cells. Thus, cell-death occurring during cultivation was taken into account for indirect, a priori 
estimation of contamination of the secretome by intracellular proteins. In the special case of urea 
production, normalization was achieved by division by the sorbitol uptake rate which has been 
shown to be a reliable parameter of hepatocyte viability [Gerlach et al., 2010]. 
Figure 4.5 illustrates the carbohydrate consumption and lactate production during standard 
monolayer cultivation of primary human hepatocytes. 
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Figure 4.5. Carbohydrate metabolism in primary human hepatocytes during monolayer cultivation under 
diclofenac exposure. Galactose (a) and sorbitol (b) uptake, glucose release (c) and lactate production (d) are 
normalized to daily production (or uptake) per million seeded cells. Error bars indicating standard deviation of 
duplicate measurements (n=2). 
For the untreated control, both galactose and sorbitol uptake (see Fig. 4.5 a, b; black bars) as well as 
glucose release (see Fig. 4.5 c; black bars) remained stable for the first 48h of cultivation with an 
uptake of about 2.5 µmol and 2.75 µmol sorbitol after 24h and 48h, respectively, and an uptake of 
about 3.25 µmol galactose as well as a release of glucose of about 2 µmol. After 72h, the 
consumption rates decreased (2.25 µmol galactose, 2.5 µmol sorbitol) as it was the case for the 
glucose release (0.5 µmol). About 0.75 µmol sorbitol and galactose were taken up and 0.5 µmol 
glucose was released after 96h. Lactate production increased from 4.5 µmol after 24h to about 6.5 
µmol after 48h. After 72h, the untreated cells produced 6.25 µmol and after 96h the lactate 
production decreased to 2.5 µmol. The group exposed to the lower diclofenac concentration (6.4 
µM, see Fig. 4.5, dashed bars) took up 2.7 µmol galactose and 3.2 µmol sorbitol, both after 24h as 
well as after 48h. After 72h the consumption of galactose decreased to 2.3 µmol and that of sorbitol 
to 2.7 µmol and further to 0.75 µmol for galactose and 1.0 µmol per million seeded cells for sorbitol 
after 96h. Glucose release was determined as 1.2 µmol after one day in culture, then increased to 1.6 
µmol after 48h and afterwards decreased to 0.75 µmol of released glucose after 72h and 96h. Under 
these conditions (6.4 µM diclofenac), lactate production (see Fig. 4.5 d; dashed bars) increased from 
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5.25 µmol after 24h to about 6.1 µmol after 48h as well as 72h and decreased to 2.5 µmol lactate per 
million seeded cells after 96h.  The cells exposed to higher concentrations of diclofenac (100 µM, see 
Fig. 4.5 a, b; grey bars) consumed 3 µmol galactose as well as 4 µmol sorbitol after 24h after which 
the daily carbohydrate uptake decreased to 2.1 µmol galactose and 2.9 µmol sorbitol after 48h. After 
72h the galactose and sorbitol uptake decreased to 1.3 and 2.0 µmol galactose and sorbitol, 
respectively, and further decreased to 0.65 µmol galactose and 0.7 µmol sorbitol after 96h. The cells 
released 5 µmol glucose after 24h and 3 µmol after 48h when exposed to high concentrations of 
diclofenac (see Fig. 4.5 c, grey bars) while after 72h and 96h, 0.1 µmol glucose was released per day 
per million seeded cells. Daily lactate production decreased steadily from 4.8 µmol after 24h to 4.3 
µmol, 1.5 µmol  and 0.2 µmol lactate after 48h, 72h or 96h, respectively, when 100 µM diclofenac 
were applied (see Fig. 4.5 d; grey bars). 
In order to assess cell death occurring during cultivation, the activity of intracellular enzymes was 
determined in the supernatant, namely the activity of Lactate dehydrogenase (LDH) and Aspartate-
aminotransferase (AST). LDH is an enzyme involved in central carbon metabolism while AST is specific 
for hepatocytes as an enzyme involved in amino-acid metabolism. Both enzymes are indicators of cell 
lysis or cell death because they are localized intracellularly and are released if the cell membrane is 
disrupted, thus indicating dying cells. Figure 4.6 shows the determined activities of LDH and AST in 
the culture supernatants of standard monolayer cultures. The release of AST per day per million cells 
is shown in Figure 4.6 a. The control group (see Fig. 4.6 a, black bars) showed increasing AST release 
from 24h to 72h (45, 62 and 130 mU, respectively) which was then decreasing after 96h to 80 mU. 
The group exposed to 6.4 µM diclofenac (see Fig. 4.6 a, dashed bars) showed almost the same 
distribution with slightly less release after 24h and 72h (30 and 105 mU) and comparable releases 
after 48h and 96h (70 and 80 mU). The group exposed to the highest concentration of 100 µM 
diclofenac (Fig. 4.6 a, grey bars) released much more AST during the first two days of cultivation (100 
and 112 mU) but released less AST after 72h and 96h (90 and 60 mU, respectively). Most likely, this 
was due to the already reduced number of cells at this time of exposure. 
When the release of AST per day per million seeded cells was normalized to the total protein content 
in the supernatant, the profile was changing in time as shown in Figure 4.6 b. For all of the three 
groups, the release is increasing for the time points examined with the maximum release appearing 
after 96h. The control group releases more AST per protein as the group exposed to 6.4 µM 
diclofenac after 24h (1.25 mU versus 0.5 mU) but afterwards, the release of the two groups is 
comparably increasing from 1.25 mU AST per µg protein after 24h to 2.25 mU per µg protein after 
96h. The cells that underwent treatment with 100 µM diclofenac, showed an increased AST release 
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for all 4 timepoints compared to the other two groups reaching from 1.75 mU per µg protein after 
24h to almost 4.5 mU after 96h following a plateau of AST that was released after 48h and 72h (2.0 
mU). 
 
Figure 4.6. Release of intracellular enzymes (LDH, AST) by primary human hepatocytes during monolayer 
cultivation upon diclofenac exposure. The release is given as milliunits (mU) per million seeded cells (a, c) as 
well as milliunits per µg of total protein in the supernatant (b, d). Error bars indicate standard deviations of 
triplicate measurements (n=3). 
The release of LDH per day by one million cells seeded in standard monolayer culture is shown in 
Figure 4.6 c. The untreated cells released 2 mU LDH after 24h as well as after 48h. The release is then 
increasing to 8 mU after 72h and to 16 mU after 96h. The group treated with 6.4 µM diclofenac is 
releasing as much LDH after 24h as after 72h but releases more LDH after 48h (4.5 mU) and less LDH 
after 96h (10 mU) compared to the control. For the cells treated with 100 µM diclofenac, the amount 
of enzyme released into the culture supernatant is equivalent to 13 mU for the first two days (24h 
and 48h, respectively) after which the release is slightly decreasing to 11 mU LDH per day per million 
seeded cells after 72h and is then increasing to 15 mU after 96h. 
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After normalizing the release of LDH to the total amount of protein released by one million cells per 
day, the cells that were either untreated or treated with 6.4 µM diclofenac showed almost identical 
profiles of LDH release (see Fig. 4.6 d; black and dashed bars). They released about 0.06 mU LDH per 
µg protein after 24h and 48h and 0.1 mU after 72h. After 96h the control group released 0.5 mU LDH 
while the group treated with 6.4 µM diclofenac released 0.35 mU only. For all of the time points, the 
cells treated with 100 µM diclofenac released more LDH as the other two groups when the release 
was normalized to the total protein amount in the supernatant (see Fig. 4.6 d; grey bars). From 24h 
to 72h, they released about 2.25 mU LDH per day and after 96h, the release increased to 1.1 mU. 
Two of the main functions of hepatocytes exhibited in vivo are the production of serum proteins and 
the detoxification of ammonia. Ammonia is produced during protein turnover in the human body and 
is converted into urea by hepatocytes. This urea is then excreted through the renal system. The 
formation of albumin and urea should still be carried out in an in vitro system that should mimic the 
in vivo situation. To evaluate for how long this is applicable using monolayer culture conditions like 
the ones in this thesis, albumin and urea production was determined. Albumin concentration was 
measured using an ELISA and urea concentration was determined by HPLC as described in the 
methods section (see 3.4). 
The production of albumin and urea is summarized in Figure 4.7. The albumin production per million 
seeded cells after 24h was about 4 to 4.5 µg for all of the three groups (see Fig. 4.7 a). For the 
untreated cells (black bars), the production remained at 4 µg after 48h, increased to 5.5 µg after 72h 
and decreased again to 2.5 µg after 96h. The cells treated with 6.4 µM diclofenac (dashed bars) 
produced 6.5, 7 and 2.5 µg after 48h, 72h and 96h, respectively. The albumin production per million 
cells for the group treated with 100 µM diclofenac (grey bars) was decreasing constantly with 3, 2 
and 0.5 µg per day after 48h, 72h and 96h, respectively. 
The albumin production was normalized to the total amount of protein in the supernatant and is 
reprted as the percentage of total protein as shown in Figure 4.7. The fraction of albumin in the 
supernatant of the control group (see Fig. 4.7 b, black bars) decreased from 11 % to 8 % from 24h to 
48h and remained at 7 % after 72h and 8 % after 96h. The cells under 6.4 µM diclofenac-exposure 
(dashed bars) produced slightly more albumin after 48h (11 %) than after 24h (9 %). Thereafter, the 
fraction of albumin was 10 % after 72h and decreased to 8 % after 96h. The group under treatment 
with 100 µM diclofenac (grey bars) showed decreasing albumin production over time with 8 % after 
24h, 5 % after 48h, 4 % after 72h and only 3 % albumin after 96h of cultivation in serum-free 
medium. 
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Figure 4.7. Albumin and urea production by primary human hepatocytes in standard monolayer culture under 
diclofenac exposure. The production is given as production per million seeded cells (a,c) as well as production 
per µg of total protein for albumin (b) and production per consumed sorbitol for urea (d). Error bars in a and b 
indicate standard deviations of duplicate measurements (n=2). For determination of urea concentrations using 
HPLC, samples were injected once.  
Urea production per million seeded cells (shown in Fig. 4.7 c) for the untreated group (black bars) 
was 1.8 µmol after 24h and 48h, increased to 2.26 µmol after 72h and decreased again to 1.5 µmol 
after 96h. When the cells were treated with 6.4 µM diclofenac (Fig. 4.7 c; dashed bars) the urea 
production increased from 1.6 µmol after 24h over 1.9 µmol after 48h to 2.3 µmol after 72h and 
decreased to a value of 1.5 µmol after 96h. 2.0 µmol production of urea was determined after 24h 
treatment with 100 µM diclofenac (Fig. 4.7 c, grey bars) whereby production increased to 2.7 µmol 
after 48h. The production then decreased to 2.1 µmol and 1.5 µmol after 72h and 96h. The urea 
production normalized to the amount of consumed sorbitol (Figure 4.7 d) increased steadily for all 
three groups. The control (Fig. 4.7 d, black bars) showed values of 0.56, 0.57, 0.95 and 1.85 µmol 
urea per µmol sorbitol during cultivation, while the cells treated with 6.4 µM diclofenac (Fig. 4.7 d, 
dashed bars) delivered values of 0.5, 0.64, 0.89 and 1.57 µmol after 24h, 48h, 72h and 96h, 
respectively. The production of urea by the cells that underwent treatment with 100 µM diclofenac 
(Fig. 4.7 d, grey bars) exhibited values of 0.51 µmol after 24h, 0.94 µmol after 48h as well as 1.1 µmol 
after 72h and 2.0 µmol urea per µmol sorbitol after 96h. 
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As this thesis is dedicated to the analysis of secreted proteins by primary human hepatocytes, the 
first step of analyzing the proteins in the supernatant was to determine how much protein is found in 
the culture medium. Therefore, the culture supernatants were concentrated 20-fold as described in 
materials and methods and protein concentration was estimated using a Bradford-based colorimetric 
assay. The results of these measurements after normalization to the number of initially seeded cells 
and furthermore to the release of intracellular enzymes are depicted in Figure 4.8. The normalization 
to the amount of released LDH should provide estimates of contamination of secreted proteins by 
leaked intracellular proteins which would distort the secretome analysis. 
The protein production  per million seeded cells (see Fig. 4.8 a) increased for the control group (black 
bars) from 37 µg after 24h to 50 µg after 48h and further increased to 78 µg after 72h. After 96h, 
only 35 µg were produced. The cells treated with 6.4 µM diclofenac (see Fig. 4.8 a, dashed bars) 
produced 49, 60 and 74 µg after 24h, 48h or 72h, respectively. The production then decreased to 33 
µg of protein per million seeded cells. The protein production for the group exposed to 100 µM 
diclofenac (see Fig. 4.8 a, grey bars) decreased steadily from 58 µg after 24h, over 55 µg after 48h 
and 50 µg after 72h. Also here, the production fell rapidly to a value of only 14 µg after 96h of 
cultivation under serum-free conditions. 
The values after normalization of the protein production to the activity of LDH in the supernatant are 
shown in Figure 4.8 b. When the protein production was normalized to the activity of LDH in the 
culture supernatant, the group exposed to 100 µM diclofenac (see Fig. 4.8 b, grey bars) produced 4.5 
µg of protein after 24h, 48h as well as 72h. However, after 96h, only 1 µg protein was produced per 
mU LDH. The cells that remained untreated (see Fig. 4.8 b, black bars) for the whole cultivation 
period produced 16 µg protein after 24h, 20.5 µg after 48h, 9.1 µg after 72h and 2 µg after 96h per 
mU LDH in the culture supernatant of one million cells. In the supernatant of cells treated with 6.4 
µM diclofenac (see Fig. 4.8 b, dashed bars), 20.7 µg protein was produced per mU LDH after 24h and 
13 µg were detected after 48h. Meanwhile, 9 µg of protein was found after 72h and 3 µg after 96h of 
serum-free cultivation. 
Obviously, cells cultivated in standard monolayer culture perform very well during the first two days 
of culture in regard to central metabolism and liver-specific functions like albumin and urea 
production as well as protein production. Afterwards, cells start to die as it is visible from the 
increasing release of intracellular enzymes (AST and LDH) as well as decreasing consumption of 
carbohydrates and decreasing production of protein. As it was mentioned above, accompanied with 
the release of LDH and AST, there is also an increased release of other intracellular proteins 
“contaminating” the actual secretome. The protein production normalized to the LDH activity in the 
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supernatant can be interpreted as the fraction of “non-contaminated” protein and decreased after 
72h to only half of the value obtained after 24h and 48h. Among the contaminants from the 
intracellular compartements is the protein Arginase I, an enzyme of the urea cycle which converts 
arginin to ornithin and urea [Peters et al., 2008]. The release of this enzyme in the supernatant is 
most probably the reason for the increased urea production after 72h. Moreover, the treatment with 
diclofenac induced visible changes in the general cultivation profiles of the primary human 
hepatocytes. While the application of a subtoxic concentration (6.4 µM) seemed to have no or only 
little effect on the cells, the application of a more toxic concentration (100 µM) near the EC50 value of 
diclofenac led to an impairment of all of the analyzed parameters, most probably due to a high 
number of cells dying when applying such a high concentration of the drug. 
 
Figure 4.8. Protein production/release by primary human hepatocytes in standard monolayer culture under 
diclofenac exposure. Every 24h, the cultivation medium was changed and protein content was estimated in the 
20-fold concentrated supernatants via Bradford-assay. The production is given as production per day per 
million seeded cells (a) as well as production per day per million seeded cells normalized to the activity of LDH 
(b) in the supernatant. Error bars indicate standard deviations of triplicate measurements (n=3). 
According to these findings, it was decided to use samples from 24h or 48h to characterize the 
secretome of primary human hepatocytes cultivated in standard monolayer culture. However, later 
time points were used to establish the immunodepletion procedure (see section 4.1.2) and to 
evaluate the impact of prefractionation and instrumentation on identified proteins (see section 4.5). 
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4.2.2 Characterization of 3D-bioreactor cultures 
The serum-free bioreactor cultivation of primary human hepatocytes described in this paragraph was 
performed by Stefan Hoffmann at the Brandenburg Center for Regenerative Therapies, Division of 
Experimental Surgery at the Charité clinic in Berlin. A publication of the detailed results is in 
preparation but with the emphasis on metabolism of diclofenac in this miniaturized cultivation 
device for use in pharmacological studies (Hoffmann et al., in preparation). Bioreactors with a cell 
compartment volume of 0.5 ml (“two-layer”) were run in Berlin under serum-free conditions for ten 
days. From day 3 to day 10, diclofenac was applied at two different concentrations (6.4 µM and 100 
µM) plus an untreated control using three bioreactors filled with isolated liver cells from the same 
donor. A scheme of the experiment is shown in Figure 4.9. A suspension containing a total of 20 
million cells (78 % viability) was inoculated. Daily samples from the effluent during treatment (day 4 
to day 10) were supplemented with protease-inhibitors and sent to our laboratory. 
 
 
Figure 4.9. Scheme illustrating the time course of a bioreactor cultivation of primary human hepatocytes with 
application of the anti-inflammatory drug diclofenac performed at Charité, Berlin. The experiment lasted 10 
days with the drug applied from day 3 to day 10, after which the bioreactor cultures were terminated. Cell 
suspension was inoculated at day 0. Both at day 3 and day 10, so-called “CYP-assays” were conducted to verify 
the metabolic capacity of the culture. Samples from day 4 to day 10 were sent to our laboratory and analysed 
as described in the text. 
Protein concentrations were determined via Bradford assay after concentrating the samples 20-fold 
by ultrafiltration. These values were divided by the applied concentration factor (i.e. 20) to obtain 
the original concentrations in the bioreactor samples which are shown in Figure 4.10, a. The protein 
concentration in the bioreactor of the untreated control (Fig. 4.10 a; black bars) increased from 5.4 
ng/µl at day 4 to 39.7 ng/µl at day 7, with 10.5 and 29.0 ng/µl at day 5 and 6, respectively. At day 8, 
the protein concentration was 37.8 ng/µl after which it increased to 95.7 ng/µl at day 9 and 
decreased again to 34.6 ng/µl at day 10. In the bioreactor treated with 6.4 µM diclofenac (Fig. 4.10a; 
dashed bars), no protein could be detected at day 4. At day 5, the concentration measured was 16.1 
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ng/µl, at day 6, the concentration increased to 62.3 ng/µl and at day 7 the protein content increased 
further to 75.3 µg/µl. Afterwards the protein concentration decreased again to 49.4 ng/µl at day 8 
and to 40.6 ng/µl at day 9. In the sample of day 10 of this bioreactor, a protein concentration of 82.2 
ng/µl was determined. The protein concentration in the bioreactor treated with 100 µM diclofenac 
(Fig. 4.10a; grey bars) increased from a non-detectable level at day 4 to 5.4 ng/µl at day 5, 19.8 ng/µl 
at day 6 and to 32.3 ng/µl at day 7. Thereafter, the concentration did not change much with 28.1 
ng/µl at day 8 and 42.4 ng/µl determined at day 9. The protein concentration determined in the 
sample before termination of the experiment (day 10) was 34.6 ng/µl.  
The profile for the calculated protein production normalized to one million inoculated cells is shown 
in Figure 4.10 b. The protein production per day per million inoculated cells for the control bioreactor 
(see Fig. 4.10 b, black bars) increased from 2 µg at day 4 over 8 µg at day 5 to 21 µg at day 6, and 
further increased to 26 µg of produced protein at day 7. After slightly decreasing to 23 µg at day 8, 
the protein production in the control bioreactor increased to 65 µg at day 9 after which it decreased 
again to 11 µg of protein per million cells. In the bioreactor treated with 6.4 µM diclofenac (see Fig. 
4.10 b, dashed bars), no protein production could be detected at day 4 but at day 5, 13 µg of protein 
was produced and the production further increased to 53 µg at day 6. Thereafter, the production 
decreased to 48 µg, 25 µg and 23 µg of protein at days 7, 8 and 9, respectively. On the last day of 
cultivation (day 10), 59 µg of protein was produced per day per million inoculated cells. If the cells in 
the bioreactor were cultivated in the presence of 100 µM diclofenac (see Fig. 4.10 b, grey bars), the 
production increased from non-detectable levels at day 4 to 25 µg at day 7, with 4 and 17 µg of 
protein produced at days 5 and 6, respectively. At day 8, the production decreased to 18 µg, at day 9 
the protein production was 29 µg and at day 10, 22 µg of protein was produced per day. 
Albumin concentrations in the bioreactor samples were determined before concentration via ELISA 
and the determined values were calculated as production rates per day per million inoculated cells 
(see Figure 4.10 c). The determined albumin concentration in the cultivation medium of the control 
bioreactor (see Fig. 4.10 c, black bars) increased during the first four days from 0.25 µg per day per 
million inoculated cells at day 4 to 2.6 µg at day 7, with 0.5 and 2.2 µg of albumin produced at days 5 
and 6, respectively. At day 8, the albumin production was determined as 2.1 µg, then increased to 
3.6 µg at day 9 and decreased to 1.2 µg of albumin produced at the last day of the experiment (day 
10). One million cells in the bioreactor treated with 6.4 µM diclofenac (see Fig. 4.10 c, dashed bars) 
produced 0.25 µg albumin per day at day 4, after which the production increased to 1.1 µg at day 5, 
3.5 µg at day 6 and 3.8 µg at day 7. At day 8, 1.6 µg of albumin was produced per day, at day 9, 2.2 
µg and at day 10, 2.3 µg of albumin was produced per day per million inoculated cells in this 
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bioreactor. 100 µM diclofenac were applied in the third bioreactor (see Fig. 4.10 c, grey bars) and 
here, the albumin production was determined as 0.22, 0.28, 1.48, 3.2 µg of albumin produced at days 
4, 5, 6 and 7, respectively. 1.6, 2.5 and 1.9 µg of albumin were produced per day per million 
inoculated cells at days 8, 9 and 10. 
 
 
Figure 4.10. Protein and albumin production by primary human hepatocytes during 3D-bioreactor cultivation 
upon diclofenac exposure as determined via Bradford assay or ELISA, respectively. a) protein concentration in 
the conditioned culture medium. b) calculated protein production per million seeded cells. c) albumin 
production per million seeded cells. d) albumin production as percentage of total protein production as 
depicted in b. Error bars indicate standard deviations of multiple measurements (n>2). 
As for the monolayer cultures, the albumin production rates were normalized to that of total protein 
released into the culture medium as depicted in Figure 4.10 a. The fraction of albumin in the 
supernatant of the untreated control (see Fig. 4.10 d, black bars) was 12 % at day 4 and decreased to 
7 % at day 5. At days 6 and 7, the percentage of albumin increased again to 10 % of total protein 
while at days 8, 9 and 10, 9 %, 6 % and 10 % of total protein was albumin. For the cells in the 
bioreactor where 6.4 µM diclofenac was applied (see Fig. 4.10 d, dashed bars) the percentage 
increased from non-detectable levels at day 4 to 9 % at day 5. Afterwards, the calculated fraction of 
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albumin was 7 % (day 6), 8 % (day 7) and 6 % (day 8) of total protein in the bioreactor circuit.  While 
9 % of total protein was albumin was at day 9, 4 % of total protein in the culture medium from this 
bioreactor was determined to be albumin. The bioreactor receiving treatment with 100 µM 
diclofenac (see Fig. 4.10 d, grey bars) also showed non-detectable levels of albumin production if the 
values were normalized to the total protein amount released into the bioreactor. Thereafter, the 
production increased to 6 % at day 5 and further increased to 9 % at day 6. At day 7, 10 % of total 
protein was albumin in this bioreactor, while over the last three days of culture (days 8, 9 and 10) the 
fraction of proteins contained in the conditioned medium being albumin was determined as 9 %. 
It has to be mentioned that for all of the three bioreactors, so-called “CYP-assays” were performed at 
days 3 and 10. During such a CYP-assay, specific substrates for the most important cytochrome P450 
isoenzymes are injected into the bioreactor and the production of phase I metabolites of these 
substrates are measured by LC-MS [Zeilinger et al., 2011]. After finishing this assay at day 3, the 
bioreactor was extensively purged with fresh medium to remove the applied substances (i.e. drugs) 
from the system. Hence, the protein as well as albumin concentration at day 4 was very low for all of 
the three bioreactors. 
According to these results, the cultures were divided into two distinct phases. The first phase (phase 
I) from day 4 to day 6 of the bioreactor cultivation showed increasing protein concentration while 
the second phase (phase II) from day 7 to 10 was defined because of a more stable protein 
concentration in the culture-medium. Samples belonging to the same phase were pooled and 
analyzed by LC-MALDI after immunodepletion. The results of these experiments are reported in 
section 4.4. 
4.3 Proteins identified in monolayer culture 
The supernatant of a monolayer culture of primary human hepatocytes after 48h of serum-free 
cultivation (without medium change) was analyzed to get a reference set of proteins for later 
analysis of bioreactor samples. To eliminate inter-individual differences, the cells were obtained from 
the same liver resection (i.e. the same donor) as the ones used for inoculation of the bioreactor. 
After immunodepletion and tryptic digest, 3 µg of the resulting peptide mixture was analyzed in 
triplicate by LC-MALDI. In Figure 4.11 the separation and subsequent mass-spectrometric analysis is 
illustrated as a recorded UV-chromatogram and the resulting base-peak chromatogram for the first 
run. The intensity in the UV (see Fig. 4.11 a) did not necessarily correlate with the intensity in the 
base peak chromatogram of the MALDI analysis (see Fig. 4.11 b). During separation by nanoHPLC, the 
chromatogram recorded at a wavelength of 214 nm showed two high peaks having intensities of 14 
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mAU at minutes 22 and 47, respectively. The rest of the chromatogram showed intensities around 10 
mAU with a strong increase from minute 17 and a decrease starting at minute 40, reaching the 
“base-line” of about 2 mAU at minute 70.  
In contrast, the intensity in the mass spectrometer was quite constant over the whole base peak 
chromatogram with intensities between 40.000 and 50.000 counts. Noteworthy, some peaks 
exhibiting only very low absorptions in the UV showed much higher intensities in the mass-
spectrometer. For example, for the peak at minute 67, the absorption in the UV is only 2 mAU, while 
the intensity in the base-peak chromatogram is 45.000, which is comparable to other peaks having 
much higher intensities in the UV-chromatogram. This illustrates the important problem of ion-
suppression during ionization of peptides, especially during phases where many peptides co-elute 
from the column into one fraction (i.e. spot) as it is the case from minute 20 to 40.  
 
Figure 4.11. LC-MALDI analysis of a tryptic digest of the extracellular proteome of primary human hepatocytes 
in standard monolayer culture after 48h of serum-free cultivation. The UV-chromatogram (a) was recorded at a 
wavelength of 214 nm, the dashed line indicates the employed gradient (percentage of solvent B) during 
separation by nano-scale HPLC. Resulting base-peak chromatogram (b) of the subsequent analysis of spotted 
fractions by MALDI-TOF-MS. 
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As mentioned above, the analysis was performed in triplicates and in each run, 10 precursors were 
selected for fragmentation in each fraction. However, the runs should rather be called “pseudo-
replicates” because during the first run, the MS/MS acquisition started with the strongest precursor, 
while the weakest precursors in each fraction were fragmented first during runs 2 and 3 to maximize 
good-quality spectra of low abundance peptides. This resulted in at most 20 fragmented peptides per 
fraction. The data from each run was subjected to a database search using Mascot and the results 
were filtered in Scaffold to control the FDR. One decoy hit was allowed for proteins identified with 
one peptide and more and the FDR was estimated by doubling the number of decoy hits and dividing 
this by the total number of hits (target + decoy hits) at a given score threshold [Elias and Gygi, 2007]. 
The estimated FDR in each run was kept at comparable levels (1.8 % for run 1 and 2.0 % for run 2 and 
3) and afterwards, the overlap in identifications was examined (see Fig. 4.12). Almost 60 % (59.8) of 
the identified proteins were identified in all three runs. Another 16.7 % were identified in at least 
two runs, with 7.6 % identified in run 1 and run 2, 0.8 % identified in run 1 and run 3 and 8.3 % of all 
proteins were identified both in run 2 and run 3. 
 
Figure 4.12. Overlap in identified proteins after LC-MALDI analysis of the same sample performed in triplicate. 
For all runs, 10 peptides were selected in each fraction for MS/MS analysis. In run 1, peptides having the 
strongest signals were fragmented first while in runs 2 and 3, the precursors showing the weakest intensites in 
the MS-scan of each fraction were fragmented. The numbers in the Venn diagram are given as percentage of 
126 proteins identified in total. 
Thus, 76.5 % of the proteins identified in total were identified in at least two runs. The remainder 
(23.5 %) was only found in one run of the “pseudo-triplicate” analysis. 5.3 % were identified only in 
run 1, 12.6 % were identified only in run 2 and 6.1 % could only be found in run 3.   
a
59.8
Run 1 Run 2
Run 3
5.3
0.8
7.6
12.1
8.3
6.1
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For the final protein list, the results of all three runs were merged while importing the mascot result 
files into Scaffold software. Thus, 126 proteins were identified after database search of acquired 
MS/MS-spectra in a concatenated target-decoy database. The estimated false identifications in the 
list of identified proteins were calculated as 2 false positives in 127 total identifications which 
correspond to a FDR of 1.6 %. The average sequence coverage achieved was calculated as 10.5 % and 
the fraction of proteins identified by one peptide was 35.7 %. The complete list of identified proteins 
can be found in the Appendix. 
For identified proteins, the subcellular location was extracted from the UniprotKB database 
(http://www.uniprot.org) and the results of the annotation are depicted in Figure 4.12. More than 
two-thirds (63.5 %) of identified proteins were annotated as secreted. 5.6 % were membrane 
proteins and for 3.2 % of identified proteins, no information about the localization was found in the 
database.  
 
Figure 4.13. Distribution of subcellular locations of the identified proteins as described in the UniProt database. 
126 proteins were identified in total by LC-MALDI-MS/MS analysis of a tryptic digest of the extracellular 
proteome of primary human hepatocytes in standard monolayer culture after 48h of serum-free cultivation.  
ER = endoplasmic reticulum 
The remaining proteins were apparently released from intracellular parts, namely cytoplasm (8.7 %), 
endoplasmic reticulum (4.8 %), the Golgi apparatus (0.8 %), from lysosomes (3.2 %), from 
mitochondria (5.6 %) or from the cell nucleus (4.8 %). This indicates a significant predominance of 
secreted proteins in the supernatant, even though contaminant proteins from also intracellular origin 
were identified.  
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To get an overview of the biological processes the identified proteins are involved in, the list of 
proteins was annotated via DAVID [Huang da et al., 2009a; Huang da et al., 2009b]. This online tool 
calculates overrepresented ontologies in the uploaded dataset compared to a so-called “background-
list”. The background list used for the analysis of identified proteins discussed here was the whole list 
of proteins known for homo sapiens. The EASE-score (p-value) for enrichment was set to default as 
used by DAVID (i.e. 0.1). 14 terms were found to be significantly enriched among the 133 proteins 
indentified and are shown in table 4.2 
Table 4.2. Over-represented biological processes of identified proteins in the supernatant of a monolayer 
culture of primary human hepatocytes after 48h of serum-free cultivation. Annotation was extracted from the 
Panther database via DAVID. Listed are the total number of proteins (count) annotated to a term (panther ID in 
brakets), the percentage (%) of involved proteins compared to total identifications as well as corresponding p-
values as a measurement for statistical relevance of enrichment in the underlying dataset. Note that proteins 
can be annotated to more than one process. 
Biological process Count % p-value 
Proteolysis (BP00071) 35 27.8 1.2E-13 
Immunity and defense (BP00148) 40 31.7 8.6E-13 
Blood clotting (BP00176) 12 9.5 3.5E-10 
Lipid and fatty acid transport (BP00028) 11 8.7 1.2E-07 
Growth factor homeostasis (BP00270) 4 3.2 2.5E-05 
Blood circulation and gas exchange (BP00209) 7 5.6 9,4E-05 
Extracellular matrix protein-mediated signaling (BP00275) 6 4.8 2.1E-04 
Protein metabolism and modification (BP00060) 40 31.7 7.7E-04 
MHCI-mediated immunity (BP00150) 3 2.4 1.0E-02 
Homeostasis (BP00267) 6 4.8 2.9E-02 
Lipid, fatty acid and steroid metabolism (BP00019) 13 10.3 2.8E-02 
Vitamin/cofactor transport (BP00088) 3 2.4 4.7E-02 
Transport (BP00141) 18 14.3 4.8E-02 
Coenzyme and prosthetic group metabolism (BP00081) 5 4.0 5.4E-02 
not annotated/enriched 33 24.8  
 
The most enriched terms were “Proteolysis” including proteases as well as protease inhibitors with 
35 proteins and “Immunity and defense” (40 proteins) comprising complement factors but also 
proteins like coagulation factors. These classes of proteins also belonged to “blood clotting”, the 
process being enriched at the third place if ordered by p-values (12 proteins). Furthermore, a 
significant enrichment was found for proteins related to “lipid and fatty acid metabolism and 
transport” with 11 and 13 proteins, respectively. The most prominent protein class to be mentioned 
here is the family of Apolipoproteins. 4 isoforms of the insulin-like growth factor binding protein 
were found (“growth factor homeostasis”), 7 proteins were annotated as part of “Bloodcirculation 
and gas exchange” and 6 proteins belonged to “Extracellular matrix protein-mediated signaling”.  40 
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proteins were annotated to “Protein metabolism and modification” and 3 proteins were part of the 
major histocompatibility complex 1 (“MHCI-mediated immunity”) whereas 6 proteins were 
attributed to “Homeostasis”. 3 or 18 proteins, respectively, were annotated to “Vitamin/cofactor 
transport” or “transport” and 5 proteins were members of the “Coenzyme and prosthetic group 
metabolism”. The process of “Detoxification” was represented by 3 proteins, while the “Amino acid 
metabolism” was enriched with 5 proteins annotated to this term. Finally, 2 proteins were members 
of “Protein disulfide-isomerase reaction” and 33 proteins were not annotated or did not belong to a 
significantly enriched term. 
4.4 Proteins identified in 3D-bioreactor cultures 
As mentioned in section 4.2.2, the samples of the bioreactor experiment were divided into two 
phases based on protein concentration in the conditioned medium. Phase I was defined as the time 
from day 4 to day 6, in which protein concentration was increasing, while in phase II, the samples 
from day 7 to day 10 were combined because of a more stable protein concentration in the 
conditioned medium. The pooled samples from both phases of the bioreactor not being treated with 
diclofenac (control) were immunodepleted and analyzed in triplicate by LC-MALDI. The mascot 
results from three replicate runs were merged as mentioned in the previous section. 
In the first phase of the bioreactor from day 4 to day 6, 133 proteins were identified in total with a 
FDR of 1.49 %. The average sequence coverage was 10.8 % and the percentage of proteins identified 
with one peptide was 23.3 %. For the second phase from day 7 to day 10, the number of identified 
proteins was 250. The calculated FDR was 0.8 % and the average sequence coverage was the same as 
for the first phase (10.8 %). 38.3 % of identifications were based on one assigned peptide. The 
complete lists of identified proteins can be found in the Appendix. 
As for the monolayer cultures, information about the subcellular location of the identified proteins 
was obtained from Uniprot database (see Fig. 4.12). In the sample of phase I, 40.6 % of the 133 
proteins identified were annotated as secreted, 3 % were proteins of the cell membrane and 6.8 % of 
all identifications were not annotated in the uniprot database. 24.8 % of identifications were 
annotated as cytoplasmic proteins, 6 % belonged to the endoplasmic reticulum (ER) and 4.5 % were 
lysosomal proteins. 11.3 % were of mitochondrial origin and 3 % of all proteins were from the 
nucleus. From the 250 proteins identified during the second phase of the bioreactor cultivation, 
almost one third (31.6 %) were secreted proteins and another 31.2 % were cytoplasmic proteins. 
5.9 % of total identifications were proteins of the cell membrane and 5.5 % were apparently released 
from the ER. One protein of the golgi-apparatus was found (0.4 %) and about 4.4 % of identifications 
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were proteins from lysosomes. Furthermore, another 4.4 % of the identifications were annotated to 
be located in the mitochondrion and 5.1 % are known to be located in the cell nucleus. 
 
Figure 4.12. Distribution of subcellular locations of identified proteins in the culture medium of primary human 
hepatocytes cultured in a 3D-bioreactor under serum-free conditions. Pooled samples from days 4 to 6 (Phase 
I) and days 7 to 10 (Phase II) were analyzed. The total number of identified proteins was 133 (Phase I) and 250 
(Phase II), respectively. Subcellular location is reported as described in the UniProt database. ER = endoplasmic 
reticulum 
According to DAVID, the significantly enriched biological processes of the 133 identified proteins 
during phase I of the bioreactor culture (see Table 4.3) were “Immunity and defense” (41 proteins), 
“Amino acid metabolism” (15 proteins), “Carbohydrate metabolism” (21 proteins), “Proteolysis” (26 
proteins) and “Coenzyme and prosthetic group metabolism” (9 proteins). Moreover, “Blood clotting” 
and “Lipid and fatty acid transport” (6 proteins each), “Vitamin metabolism” (4 proteins), “Fatty acid 
beta-oxidation” (3 proteins), “Detoxification” (4 proteins) and “Tricarboxylic acid pathway” (3 
proteins) were represented by a significant number of proteins. Finally, “Protein metabolism and 
modification” (36 proteins), “Antioxidation and free radical removal” (3 proteins), “Vitamin/cofactor 
transport” (3 proteins) and “Growth factor homeostasis” (2 proteins) belonged to the terms showing 
significant enrichment during phase I of the bioreactor culture. 22 proteins were not annotated or 
did not belong to one of the 15 significantly enriched terms. 
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Table 4.3. Over-represented biological processes of identified proteins in the culture medium of primary 
human hepatocytes cultured in a 3D-bioreactor under serum-free conditions in the pooled samples from day 4, 
5 and 6 (phase I). Annotation was extracted from the Panther database via DAVID. The total number of 
proteins (count) annotated to a term (panther ID in brakets), the percentage (%) of involved proteins compared 
to total identifications as well as corresponding p-values as a measurement for statistical relevance of 
enrichment in the underlying dataset are listed. Note that proteins can be annotated to more than one 
process. 
Biological process Count % p-value 
Immunity and defense (BP00148) 41 30.6 6.2E-12 
Amino acid metabolism (BP00013) 15 11.2 3.5E-08 
Carbohydrate metabolism (BP00001) 21 15.7 4.1E-07 
Proteolysis (BP00071) 26 19.4 1.4E-06 
Coenzyme and prosthetic group metabolism (BP00081) 9 6.7 1.8E-04 
Blood clotting (BP00176) 6 4.5 1.8E-03 
Lipid and fatty acid transport (BP00028) 6 4.5 6.8E-03 
Vitamin metabolism (BP00083) 4 3.0 7.5E-03 
Fatty acid beta-oxidation (BP00022) 3 2.2 2.6E-02 
Detoxification (BP00180) 4 3.0 2.9E-02 
Tricarboxylic acid pathway (BP00008) 3 2.2 3.6E-02 
Protein metabolism and modification (BP00060) 36 26.9 4.3E-02 
Antioxidation and free radical removal (BP00268) 3 2.2 5.1E-02 
Vitamin/cofactor transport (BP00088) 3 2.2 5.6E-02 
Growth factor homeostasis (BP00270) 2 1.5 6.8E-02 
not enriched/annotated 22 16.4  
 
During phase II of the bioreactor cultivation, 19 processes were found to be significantly enriched, 
while 65 of the 250 identified proteins were not in the list of enriched terms. The processes found to 
be statistically over-represented were in particular (see Tab. 4.4): “Immunity and defense” (66 
proteins), “Proteolysis” (40 proteins), “Blood clotting” (11 proteins), “Carbohydrate metabolism” (27 
proteins), “Other protein targeting and localization” (6 proteins), “Amino acid metabolism” (15 
proteins), “Lipid and fatty acid transport” (11 proteins) and “Other carbon metabolism” as well as 
“Blood circulation and gas exchange” (8 proteins each). Additionally, “Coenzyme and prosthetic 
group metabolism” (9 proteins), “Other metabolism” (18 proteins), “Tricarboxylic acid pathway” (4 
proteins), “Extracellular matrix protein-mediated signaling” (5 proteins) and “Nitrogen metabolism” 
(3 proteins) represented terms enriched during the second phase.  Finally, “Protein disulfide-
isomerase reaction” (3 proteins), “Protein folding” (7 proteins), “Other carbohydrate metabolism” (4 
proteins) as well as “Lipid, fatty acid and steroid metabolism” (19 proteins) showed significant 
enrichment. 
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Table 4.4. Over-represented biological processes of identified proteins in the culture medium of primary 
human hepatocytes cultured in a 3D-bioreactor under serum-free conditions in the pooled samples from day 7 
to day 10 (phase II). Annotation was extracted from the Panther database via DAVID. Total number of proteins 
(count) annotated to a term (panther ID in brakets), the percentage (%) of involved proteins compared to total 
identifications as well as corresponding p-values as a measurement for statistical relevance of enrichment in 
the underlying dataset are listed. Note that proteins can be annotated to more than one process. 
Biological process Count % p-value 
Immunity and defense (BP00148) 66 26.5 1.5E-16 
Proteolysis (BP00071) 40 16.1 6.7E-08 
Blood clotting (BP00176) 11 4.4 3.3E-06 
Carbohydrate metabolism (BP00001) 27 10.8 3.9E-06 
Other protein targeting and localization (BP00140) 6 2.4 9.0E-06 
Amino acid metabolism (BP00013) 15 6.0 3.3E-05 
Lipid and fatty acid transport (BP00028) 11 4.4 4.9E-05 
Other carbon metabolism (BP00292) 8 3.2 3.7E-04 
Blood circulation and gas exchange (BP00209) 8 3.2 6.0E-04 
Antioxidation and free radical removal (BP00268) 5 2.0 3.7E-03 
Coenzyme and prosthetic group metabolism (BP00081) 9 3.6 6.9E-03 
Other metabolism (BP00289) 18 7.2 1.2E-02 
Tricarboxylic acid pathway (BP00008) 4 1.6 1.6E-02 
Extracellular matrix protein-mediated signaling (BP00275) 5 2.0 2.2E-02 
Nitrogen metabolism (BP00090) 3 1.2 3.6E-02 
Protein disulfide-isomerase reaction (BP00069) 3 1.2 3.6E-02 
Protein folding (BP00062) 7 2.8 6.1E-02 
Other carbohydrate metabolism (BP00012) 4 1.6 6.6E-02 
Lipid, fatty acid and steroid metabolism (BP00019) 19 7.6 8.4E-02 
not enriched/annotated 65 26.1  
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4.5 Comparison of LC-MALDI and LC-ESI with and without prior fractionation 
Parts of the sample preparation (SDS-PAGE, reduction and alkylation of gel-slices) and mass-
spectrometric analysis described in this section was performed in the laboratory of Dr. Alain van 
Dorsselaer at the Laboratory of bio-organic mass-spectrometry (LSMBO) at CNRS, University of 
Strasbourg.  
To evaluate the established LC-MALDI workflow for secretome-analysis of primary human 
hepatocytes, a sample was analyzed on two commonly used LC-ESI-MS platforms, namely a hybrid 
quadropole-time of flight (Q-TOF; MaXis, Bruker daltonics, Bremen) and an ion-trap (Amazon, also 
Bruker daltonics) mass-spectrometer following reversed-phase liquid chromatography of tryptic 
peptides (LC-MS). Furthermore, the extent prefractionation of the sample via one-dimensional 
electrophoresis prior to LC-MS analysis (GeLC-MS) enhances the identification of secreted proteins 
was evaluated. After mass spectrometric analysis of separated peptides, the resulting peak lists were 
searched against the same database using the same Mascot-version to minimize artifacts resulting 
from different protein databases and search algorithms. Furthermore, the adjacent data 
reprocessing was performed equally by the same operator (i.e. myself) to exclude deviations by 
differently interpreted search results. The injected amount of peptides was also the same, except for 
the GeLC-MS analysis, where only half of the amount was injected for LC-MALDI. However, the 
gradient for the liquid chromatography on the different instruments used was different, especially 
for the liquid digest, because it was optimized empirically on each instrument (see methods section 
for details). 
As it is shown in Figure 4.14 a, the MALDI-based workflow identified 94 proteins if the sample was 
analyzed via LC-MS after in-solution digestion. The average sequence coverage of identified proteins 
was 10.2 % and the average mascot ion-score was calculated as 50.3 (see Fig. 4.14, a; black bars). The 
Q-TOF identified 84 proteins with identified peptides covering 8.3 % of the protein sequence and 
having an average ion-score of 31.7 (see Fig. 4.14 a, white bars). The ion-trap could identify 49 
proteins with an average sequence coverage of 8.9 % and an average ion-score of the fragmented 
peptides of 30.8 (see Fig. 4.14 a, dashed bars). After merging the mascot results of the three 
instruments within Scaffold, the number of identified proteins was increased to 118 and the 
sequence coverage was 12.2 %, while the average observed ion-score was 45.2 (see Fig. 4.14 a, grey 
bars). These identifications were all based on a FDR of 0 %, i.e. that no decoy hit was tolerated while 
adjusting the score threshold for accepted identifications. This was done because the number of 
identifications was well below 100 proteins and for such small datasets, the target-decoy approach 
was shown to be inappropriate. But because the number of identified proteins was above 100 after 
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merging the results from the different instruments, the score threshold adjustment was repeated 
and adjusted to 1.6 % (i.e. one decoy hit in 127 (target + decoy hits) total identifications). This led to 
126 identified proteins with an average sequence coverage of 11.5 % and an average ion-score of 45 
(see Fig. 4.14 a, chequered bars).    
The GeLC-MS analysis was evaluated similarly (see Fig. 4.14 b). After analysis on the MALDI-MS, 540 
proteins were identified in the 24 gel-bands with an average sequence coverage of 14.9 % and an 
average ion-score of 74.1 (see Fig. 4.14 b, black bars). The ion-trap identified 538 proteins while 
these proteins were identified with an average sequence coverage of 19.2 % and an average ion-
score of 38.5 (see Fig. 4.14 b, dashed bars). When the sample was analyzed on the Q-TOF instrument, 
512 proteins were identified with a sequence coverage of 27.9 %. The average ion-score achieved 
was 35.3 (see Fig. 4.14 b, white bars). For all analyses by GeLC-MS mentioned, the FDR was below 
0.8 % (see Fig. 4.14 b, legend). After merging the results in Scaffold, the number of proteins being 
identified increased to 681 at a FDR of 0.58 % (see Fig. 4.14 b, grey bars). The identified peptides 
spanned in average 26.1 % of the amino acid sequences and were identified with an average ion-
score of 51.1. 
 
Figure 4.14. Comparison of different LC-MS platforms for the analysis of secreted proteins of primary human 
hepatocytes in 2D-culture. a) performance parameters for the analysis of a liquid digest (LC-MS); b) analysis of 
the same sample employing prefractionation by SDS-PAGE and subsequent analysis of in-gel digests of 24 
adjacent bands (GeLC-MS). Values obtained for each instrument as well as after merging the database results 
of all three instruments are shown. In the legend, the corresponding false discovery rates (FDR) are reported. 
As for previously mentioned identifications, information about the subcellular location of identified 
proteins was obtained from Uniprot database and is shown in Figure 4.15. Without prefractionation, 
49.2 % of 126 proteins identified were annotated as secreted, 3.2 % were proteins of the cell 
membrane and 5.6 % were not annotated in the uniprot database. 28.6 % of identifications were 
annotated as cytoplasmic proteins, 3.2 % belonged to the endoplasmic reticulum (ER) and 1.6 % 
were lysosomal proteins. 4.8 % were mitochondrial proteins and 4 % were proteins from the cell 
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nucleus. Out of 681 proteins identified after prefractionation by SDS-PAGE, 23.6 % were secreted 
proteins and almost 39 % were cytoplasmic proteins. 8.7 % were proteins of the cell membrane and 
3.7 % were annotated as being located to the ER. The amount of golgi-derived proteins was 1.8 % 
and about 2.9 % of identifications were proteins from lysosomes. Furthermore, 6.9 % of the 
identifications were annotated to the mitochondrion and 3.7 % are located in the cell nucleus. Finally, 
0.7 % were annotated as peroxisomal proteins and for 11.2 %, the subcellular location was unknown. 
 
 
Figure 4.15. Distribution of subcellular locations of identified proteins in the culture medium of primary human 
hepatocytes cultured in a monolayer culture after merging of results from three different MS-platforms 
without and with prefractionation of proteins using SDS-PAGE. Subcellular location is reported as described in 
the UniProt database. ER = endoplasmic reticulum 
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4.6 Effects of diclofenac on the extracellular proteome of PHH in the 
bioreactor 
Samples from phase II (day 7 to day 10) of the bioreactor cultures treated with diclofenac were 
analyzed by LC-MALDI and tested for differences in protein expression levels as a result of diclofenac-
treatment. The estimation of abundances of identified proteins was performed using Scaffold by 
means of peptide hit counting, i.e. the number of peptides that led to the identification of a protein, 
which has been found to be a rough estimate of relative abundances of proteins identified in 
complex mixtures [Pang et al., 2002; Gao et al., 2003]. Only proteins identified at or above 99 % 
confidence with at least 4 peptides identified at or above 95 % confidence were included in the 
analysis. The probabilities were calculated by Scaffold based on algorithms used in PeptideProphetTM 
[Keller et al., 2002] and ProteinProphetTM [Nesvizhskii et al., 2003]. Although these algorithms are 
more stringent than the “Mascot delta-score approach” which was employed for protein 
identification, it was used for quantification because acquired data could be converted into 
normalized peptide hits directly in Scaffold. Additionally, a one-way Analysis Of Variance (ANOVA) 
could be applied in Scaffold to detect significant differences in peptide hits. Furthermore, only high-
confident identifications were considered for quantification with differences in peptide hits 
improbably based on under-sampling of peptides. The latter is often observed in proteomic analyses 
of complex samples when proteins are identified with only few (i.e. 1-3) peptides [Old et al., 2005; 
Mueller et al., 2008]. 
20 proteins showed significant differences in assigned peptide hits among the 66 proteins identified 
with 4 peptides and more in at least one of the three bioreactor cultures as calculated by Scaffold 
(ANOVA p-vaue < 0.05). After discarding intracellular proteins not being predicted to be possibly 
secreted via non-classical pathways according to SecretomeP, 12 secreted proteins left exhibiting 
significant differences in peptide hits after application of diclofenac. The normalized peptide hits of 
these proteins are shown in Figure 4.16 and the estimated up- or down-regulation as well as 
corresponding ANOVA p-values are listed in Table 4.5. 
Four proteins showed an up-regulation upon 6.4 µM diclofenac, namely alpha-1-antitrypsin, 
fibrinogen gamma chain, histidine-rich glycoprotein and leucine-rich alpha-2-glycoprotein. One 
protein was found to be down-regulated (4-hydroxyphenylpyruvate dioxygenase) under these 
conditions.  In the group treated with 100 µM diclofenac, eight proteins were up-regulated and two 
proteins were down-regulated. The proteins with increased abundances in the sample were, in 
particular: Apolipoproteins A-I and A-IV, Fibrinogen gamma chain, inter-alpha-trypsin inhibitor heavy 
chain H2, retinol-binding protein 4, histidine-rich glycoprotein, ceruloplasmin as well as alpha-2-
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macroglobulin. The two proteins with decreased abundances upon application of 100 µM diclofenac 
were: cytoplasmic isocitrate dehydrogenase and 4-hydroxyphenylpyruvate dioxygenase. The two 
down-regulated proteins were the only proteins predicted to be possibly secreted via non-classical 
secretion pathways by SecretomeP. 
 
Figure 4.16. Analysis of proteins identified in the culture medium of primary human hepatocytes in a 3D-
bioreactor in the pooled samples from day 7 to day 10 (phase II) during application of 6.4 µM and 100 µM 
diclofenac, respectively. Peptide hits of proteins showing significant deviations in assigned peptides according 
to a one-way ANOVA test performed in Scaffold are shown. A change in hits indicates a significant change in 
the abundance of a protein in the sample. Peptide hits were normalized to the total amount of peptide hits in 
each sample by averaging the peptide counts across all groups, and then multiplying the peptide counts in each 
sample or group by the average divided by the individual sample or group sum. Error bars indicate standard 
deviations of three replicate measurements (n=3). 
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Table 4.5. Global regulation of secreted proteins identified in the culture medium of primary human 
hepatocytes in a 3D-bioreactor in the pooled samples from day 7 to day 10 (phase II) during application of 6.4 
µM and 100 µM diclofenac, respectively. all proteins showing significant deviations in peptide hits according to 
a one-way ANOVA test performed in Scaffold and contain either a signal peptide to enter the classical secretion 
pathway or are predicted to be secreted via non-classical secretion pathways according to SecretomeP are 
listed. Regarding the regulation, up-regulation of a protein is indicated by +, down-regulation is indicated by -, 
while no change is indicated by •. 
Protein name 
ANOVA 
(p-Value) Regulation 
  6.4 µM 100 µM 
Alpha-1-antitrypsin 0.000026 + • 
Isocitrate dehydrogenase [NADP] cytoplasmic  0.00018 • - 
Apolipoprotein A-IV  0.0011 • + 
Apolipoprotein A-I  0.0038 • + 
Fibrinogen gamma chain  0.0054 + + 
Inter-alpha-trypsin inhibitor heavy chain H2  0.0067 • + 
Retinol-binding protein 4  0.0067 • + 
Histidine-rich glycoprotein  0.011 + + 
4-hydroxyphenylpyruvate dioxygenase  0.020 - - 
Leucine-rich alpha-2-glycoprotein 0.023 + • 
Ceruloplasmin  0.031 • + 
Alpha-2-macroglobulin  0.038 • + 
 
To independently confirm the significance of changes in peptide hits during diclofenac exposure and 
to exclude the impact of the “pseudo-replicates”, a principal component analysis (PCA) was 
performed for the 66 identified proteins fulfilling the criteria for identification as stated above. PCA is 
an approach of multivariate statistics reducing a large number of variables present in a dataset to a 
fewer number of independent and orthogonal variables, the “principal components”, ideally 
explaining most of the variance within the dataset. As it is shown in Figure 4.17, the three replicates 
of each group formed clusters while no overlap was observed between the three groups within the 
95 % confidence interval. Furthermore, the cluster of the group treated with 6.4 µM diclofenac (see 
Fig. 4.17, circles) is closer to the control group (see Fig. 4.17, squares) than the group treated with 
100 µM (triangles) what is in concordance with the normalized peptide hits also showing larger 
differences in the group treated with 100 µM diclofenac (see Fig. 4.16). The first two principal 
components describe the biggest part of variance observed between the three groups. In this case, 
the percentage of variance described was 48 %. 
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Figure 4.17. Principal component analysis (PCA) of spectral counts of identified proteins in the conditioned 
medium from PHH during phase II (days 7 to 10) of a 3D-bioreactor culture. Proteins identified with 4 peptides 
and more were included in the analysis. Diclofenac was applied at two concentrations, 6.4 µM (dots), 100 µM 
(triangles) plus an untreated control (squares) in three bioreactors filled with hepatocytes from the same 
donor. 95 % confidence intervals are indicated as ellipses around the clusters. Shown is the PCA-plot for the 
first two principal components (PC1, PC2) explaining 48 % of total variance within the dataset. 
The contribution of the different proteins to variances in the dataset is described by the calculated 
loading-coefficients (“loadings”) in each principal component. The loadings of the first two principal 
components calculated from observed peptide counts of identified proteins are shown in Figure 4.18. 
Most of the proteins reported by Scaffold to have significantly different peptide counts as calculated 
by a one-way ANOVA test (proteins marked with an asterisk in Fig. 4.18) also show the highest 
loadings for the first principal component. The proteins having low loadings for the first component, 
however, have a high loading in the second principal component. 
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5. Discussion 
In the presented thesis, the extracellular proteome (“secretome”) of primary human hepatocytes 
was analyzed by a proteomics approach. For this purpose, an analytical strategy was elaborated 
which is depicted schematically in Figure 5.1. The workflow comprises sample preparation and LC-
MALDI analysis of tryptic peptides after ensuring efficient secretome-analysis by serum-free 
cultivation of primary human hepatocytes. 
 
Figure 5.1. Schematic illustration of the workflow for proteomic analysis of the extracellular proteome of 
primary human hepatocytes elaborated in the course of this thesis. Hepatocytes are cultivated in in vitro 
systems and collected conditioned media are first concentrated and rebuffered by ultrafiltration. High 
abundant proteins are removed by immunodepletion and the remaining proteins are either directly digested 
in-solution or in-gel after prefractionation by SDS-PAGE. Resulting peptide mixtures are separated by nano-
scale liquid-chromatography (nHPLC) and fractions are automatically mixed with matrix and spotted onto a 
MALDI-target for subsequent mass spectrometric analysis. Identified proteins after database search are 
verified and characterized using bioinformatic tools.  
The workflow was applied to standard monolayer cultures and results were compared to an 
organotypic bioreactor culture. Furthermore, the impact of drug-treatment on the secretome of 
hepatocytes cultivated in the 3D-bioreactor was examined semi-quantitatively by label-free 
quantification of identified proteins via peptide counting. On the following pages, the workflow as 
well as the obtained results will be critically discussed and compared to the current literature.  
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5.1 Serum-free cultivation 
Each proteomic analysis starts with a sample with both origin and preparation of the sample being 
crucial for meaningful results. Because artifacts introduced during sample generation and processing 
are carried through the whole analysis process, these artifacts can lead to wrong conclusions and 
interpretations made from generated data. Therefore, both steps have to be tightly controlled and 
optimized.  
The first step was to optimize the cultivation of primary human hepatocytes to allow secretome 
analysis using conditioned media. Fetal calf serum (FCS) is commonly used in mammalian cell culture 
because attachment to the surface of culture dishes and survival of cells in vitro is strongly 
dependent on such a supplement. However, it is a known obstacle in secretome analysis because 
proteins of bovine origin hamper identification of proteins secreted by the cells of interest. Even if 
the amount of supplemented serum is reduced from the commonly applied 10 % to amounts as low 
as 0.5 %, efficient secretome analysis remains extremely difficult [Dowling and Clynes, 2011]. In the 
case of hepatocytes, this obstacle is even more challenging to overcome because the proteins 
present in bovine serum closely resemble proteins secreted by hepatocytes. In vivo, the liver is the 
organ producing the major part of serum proteins such as carrier-proteins (e.g. albumin, transferrin, 
haptoglobin), protease-inhibitors (e.g. antitrypsin) or complement factors [Miller and Bale, 1954]. 
These proteins show a high degree of homology between different species. For example, human and 
bovine albumins share more than 76 % of their amino-acid sequences. Because MS-based protein 
identification relies on determination of amino-acid sequences of peptides which are subsequently 
assigned to a specific protein, this approach can hardly distinguish between human or bovine 
proteins in the supernatant of hepatocytes. An unambiguous identification is possible only if “unique” 
peptides, i.e. peptides only present in the protein of one species, are identified, which is not 
guaranteed in complex samples. Furthermore, the sequence coverage of a protein, i.e. the fraction of 
the amino acid sequence that could be identified by LC-MS is - amongst others - a function of its 
abundance in the sample. Generally speaking, the lower the concentration of a protein in a sample, 
the lower is the sequence coverage. In fact, this correlation is the basis of label-free quantification of 
proteins by peptide hit counting [Pang et al., 2002] and spectral counting [Liu et al., 2004], in which 
the number of identified peptides/spectra for a specific protein is used as an estimate of its 
abundance in the sample. Adding fetal calf serum means adding complexity, both in terms of protein 
number and protein abundance. Especially for low abundant proteins which are most likely to serve 
as biomarker candidates, the presence of serum proteins can eliminate the possibility of 
identification and quantification. As such, FCS has to be removed from cultures prior to collection of 
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conditioned medium or better completely avoided during cultivation of mammalian cells for efficient 
analysis of secreted proteins. The masking of secreted proteins by supplemented serum proteins was 
proven by LC-MALDI analysis of samples from FCS-supplemented bioreactor cultures before and after 
switching to serum free conditions. The bovine proteins remained in the bioreactor for at least 5 
days, especially the bovine albumin as the most abundant protein in bovine serum. Identifications 
were severely impaired with only low numbers of both human and bovine proteins being identified. 
The possibility of serum-free cultivation of primary hepatocytes in the bioreactor was previously not 
considered by the scientists at the Charité, because the bioreactor was predominantly used in 
morphologic and drug metabolism studies which can be performed in the presence of FCS. However, 
with beginning of the HEPATOX project and realizing the problems for proteome analysis, the 
possibility of serum-free inoculation and cultivation was tested and shown to be possible without 
reduction of culture quality. This fact points out the exceptional position of the hollow-fiber 
bioreactor among the 3D-culture systems, because no cultivation technique using standard medium 
without specific growth factors is able to keep primary hepatocytes alive for more than a few days. In 
regard to proteome analysis, conducting a FCS-free cultivation in the bioreactor was, as expected, 
very advantageous. The number of identified proteins was more than ten times higher but this is 
discussed later. Finally, ethical concerns evolving from conducting animal experiments in 
toxicological studies and other disciplines of life-science also imply the necessity for banishment of 
animal serum from in vitro cultivation. Additionally, because of large batch-to-batch variances, any 
new batch of purchased FCS has to be tested for applicability for primary hepatocytes. This is another 
reason for the need of standardized media ensuring survival of cells and replacing animal serum.  
The general physiological and biochemical parameters during serum-free monolayer cultivation were 
determined to identify the optimal timepoint for secretome collection. Both carbohydrate 
metabolism and enzyme release indicated that the cultivation of primary hepatocytes for a longer 
period than 48h resulted in a decreased carbohydrate uptake and increased release of intracellular 
enzymes. Additionally, the amount of produced protein per day was decreasing rapidly after 48h 
when it was normalized to the amount of released LDH as a measure of occurring cell death. This 
finding is in accordance with other secretome studies in hepatic, but also other cell lines in which the 
period of serum-free cultivation was not exceeding 48h to avoid contamination by intracellular 
proteins leaking from dead cells [Chevallet et al., 2007; Planque et al., 2009; Lewis et al., 2010; Van 
Summeren et al., 2011]. However, the monolayer cultures examined here exhibited liver specific 
functions over the whole cultivation time of 96 h as it was shown by a constant release of albumin 
and urea, but the values started to decrease after 72h. Other groups already showed that primary 
hepatocytes cannot be cultivated in standard monolayer cultures for a longer period (i.e. more than 
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72h) because cells start to dedifferentiate and lose their liver specific functions regardless of 
presence or absence of FCS [Tuschl and Mueller, 2006; Godoy et al., 2009; Zeilinger et al., 2011]. If 
the aim is to perform short-term toxicoproteomics studies, the limited lifespan of monolayer cultures 
is not a constraint, but when it comes to long-term studies aiming to detect biomarkers for late-
onset or chronic toxicity of a drug, other cultivation techniques must be applied. The introduction of 
the bioreactor was a big step towards the possibility of examining longer-term and chronic toxicity 
especially after recent down-scaling [Zeilinger et al., 2011]. In earlier studies, porcine hepatocytes 
were shown to maintain liver functionality for up to one month using this bioreactor technique 
[Zeilinger et al., 2004]. Also our group confirmed that bioreactor cultures of primary human 
hepatocytes maintain liver like properties for up to 2 weeks and constant oxygen consumption rates 
indicated viability even 3 weeks after inoculation with a constantly low release of intracellular 
enzymes [Mueller et al., 2011b].  During FCS-free bioreactor cultivation, constant protein and 
albumin production rates were observed.  
5.2 Sample preparation 
The proteins secreted by hepatocytes are extremely diluted in the large volume of cultivation 
medium with concentrations in the low µg/ml range requiring concentration of conditioned media 
before analysis. Furthermore, culture media contain large amount of salts interfering with most 
proteomic techniques. Different strategies have been employed for desalting and concentrating 
conditioned media from cell cultures but the most often applied techniques are ultrafiltration and 
precipitation by trichloroacetic acid (TCA), the latter being carried out with and without the help of 
carriers like sodium lauroyl sarcosinate [Chevallet et al., 2007; Skalnikova et al., 2011]. Dowell and 
co-workers found ultrafiltration to be superior to TCA-precipitation regarding sample recovery 
[Dowell et al., 2009]. More recently, it was shown that each of the concentration methods has its 
advantages, either in sample recovery (ultrafiltration) or number of identifiable proteins 
(precipitation). But they also give different information about the secretome and should therefore be 
considered as complementary approaches [Cao et al., 2011]. In this thesis, the choice was made 
towards ultrafiltration because it allowed fast concentration and rebuffering. Proteins could be 
recovered in high yields and in their native forms which was required for the immunodepletion 
procedure following the concentration/desalting step. 
Immunodepletion became a standard technique in preprocessing of human plasma and serum 
samples because it allows analysis of low abundant proteins not detectable without depletion of the 
high abundant proteins present in serum [Echan et al., 2005]. In this thesis, the application of 
immunodepletion to the analysis of the hepatocyte secretome was shown to be a valuable tool 
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reducing the range of protein concentrations in the samples. The number of identified proteins in the 
supernatant of monolayer cultures was almost doubled by depletion of four high abundant proteins, 
namely transferrin, albumin, alpha-1-antitrypsin and haptoglobin illustrating the beneficial 
contribution of this technique to secretome analysis of hepatocytes. However, as for (almost) all 
steps in proteomic sample preparation, there is a risk of losing sample material in the course of the 
depletion procedure. The observed sample loss was estimated to almost 25 % as determined via 
Bradford assay performed before and after depletion. Additionally, 50 % of total protein was 
removed as high abundant proteins reducing the amount of depleted material to be analyzed and 
thus increasing the required quantity of starting material. What should be mentioned is the fact, that 
albumin binds many molecules including small proteins and peptides. It binds so diversely, that a 
distinct term called Albuminome [Gundry et al., 2007] has emerged. The risk of removing possible 
identification candidates by the depletion of albumin is well known but for the immunodepletion 
column used during this work it has been shown that it removes the lowest number of non-targeted 
proteins compared to other depletion devices [Gundry et al., 2009; Bellei et al., 2011]. Analysis of the 
bound fraction led to identification of 13 proteins. Undesired removal of albumin-bound proteins 
could partially be overcome by using an organic solvent during ultrafiltration (e.g. 10 % Acetonitrile), 
thus reducing the non-covalent interactions. But this could also diminish the binding-efficiency to the 
depletion column and also lead to a faster degradation of the affinity resin. Therefore, and because 
the advantages outweighed the disadvantages, the depletion column was used as proposed by the 
manufacturer without any modifications. One drawback of the spin-cartridge format used in this 
work is the low throughput but a column-format is available which can be implemented in standard 
HPLC-instruments increasing the number of processed samples per time in an automated work-flow. 
Furthermore, there are columns available capable of removing up to 14 high abundant proteins from 
human plasma samples with 10 of them also being identified during this thesis in the upper third of 
identifications if ordered by identified peptides and thus by their abundance in the sample. These 
columns could be applied for immunodepletion of samples from hepatocyte cultures, further 
increasing the depth of the analysis. Only one other study was found in PubMed using 
immunodepletion for in vitro secretome analysis, in this case using HepG2 cells [Lewis et al., 2010]. 
5.3 LC-MALDI analysis 
The solvent composition used for chromatographic separation of tryptic peptides was optimized 
using a commercial peptide standard and was determined to be 9 to 40.5 % acetonitrile. When this 
gradient was applied to real samples, it became obvious that there is still room for further 
optimization. The fraction of more hydrophilic peptides was much larger in the real sample than in 
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the protein standard used for gradient optimization. When separating the standard mixture, the first 
minutes showed only few well-separated peptides (see Fig. 4.4 b, red chromatogram). In contrast, 
the chromatogram of the real sample showed many peptides from minute 20 to 40. Furthermore, 
the elution window of the real sample is not that broad towards the end of the gradient as 
determined for the digest of six standard proteins. No peptides elute after 70 minutes which 
corresponds to a percentage of acetonitrile of about 31.5 %, in contrast to the determined amount of 
40.5 % for elution of the biggest part of peptides from the six-protein standard mixture. This could be 
due to a loss of hydrophobic peptides during sample preparation, i.e. adsorption of these peptides to 
the wall of the reaction tube and/or the HPLC vial, even though special tubes were used during 
sample preparation for which protein binding is reduced to a minimum. Another reason could be 
aggregation of hydrophobic parts of the proteins during digestion protecting them from being 
thoroughly digested and consequently from being detected after the second ultrafiltration step 
designated for the removal of trypsin and uncompletely digested polypeptide chains from the 
digestion mixture. For further optimization studies, more appropriate standards should be applied 
that contain many proteins in different - but known - concentrations to simulate a complex sample 
more realistically. One such standard was recently introduced as the SC-200 proteomics standard 
mixture [Bauman et al., 2011]. It was developed at the Seattle Children`s Hospital and consists of 200 
proteins with known identities and molar concentrations derived from 6 microbial genomes, thus 
ideally suited to develop and optimize proteomic workflows for analysis of complex samples. 
Containing 200 proteins, this standard is in the same range as the number of identified proteins in 
the secretome of primary human hepatocytes described in this work. Additionally, as this standard 
consists of proteins, the optimization would start already at the sample preparation, i.e. digestion 
step which was not the case for the commercial standard that consisted of peptides after digestion. 
In this thesis, the success of digestion of real samples was confirmed by SDS-PAGE as the absence of 
distinct protein bands after over-night digestion (data not shown). 
A nano-scale HPLC was purchased and coupled to an automated fraction collection robot capable of 
automatic matrix addition and deposition of eluting fractions as spots on a blank target for LC-MALDI 
analysis. The ratio of added matrix was the same as described for the analysis of proteins from C. 
glutamicum [Lasaosa et al., 2009a; Lasaosa et al., 2009b], i.e. 4 parts of matrix (3 mg/ml CHCA) were 
mixed at a flow-rate of 1.2 µl/min with one part of sample eluting from the column at a flow rate of 
0.3 µl/min. This provided an appropriate matrix concentration on the target (i.e. 2.4 mg/ml) 
comparable to the determined optimal concentration used for manual spotting of in-gel digests. 
Additionally, when the fraction collection interval at these flow-rates was set to 12 seconds, the 
applied flow-rate and mixing-ratio provided spot volumes of about 0.3 µl per fraction, ensuring 
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homogenous co-crystallization within the spots as well as appropriate spot diameters (about 1.2 mm) 
after evaporation of solvents. Larger spot volumes obtained by increasing the fractionation intervals 
would increase the measurement time because more laser shots had to be accumulated and would 
cause a loss of separation. Smaller spot volumes would result in a loss of sensitivity by limited sample 
amounts within each fraction and a reduced number of acquirable MS/MS spectra per spot. The 
latter was also the reason for fragmenting the weakest precursors per fraction first in the second and 
third run because the amount of peptides in each fraction decreases during acquisition of several 
MS/MS spectra. The laser desorbs not only the precursor that is meant for fragmentation but rather 
all peptides contained in the spot or at least the peptides that ionize well. The selection of a specific 
mass (i.e. peptide) for fragmentation is achieved after the ion source by the timed-ion-selector (TIS) 
of the MALDI-TOF/TOF instrument. Hence, the probability of acquiring a high-quality fragment 
spectrum of a peptide present at low amounts in the spot is increased if this low-abundant peptide is 
analyzed as early as possible during MS/MS acquisitions. The choice of this strategy is supported by 
the fact that more than a quarter (26.5 %) of identified proteins in the monolayer culture could have 
been identified only in the two runs (runs 2 and 3) in which the acquisition started with the weakest 
precursor. If the acquisition started with the strongest precursor, the percentage of identifications 
unique to this run was only 5.3 %. An additional strategy to increase the number of identifications 
could be the generation of an exclusion list of all identified peptides during the first and second run 
to minimize redundant acquisition in the third run as described in [Chen et al., 2005]. Future studies 
should also optimize the matrix to analyte ratio, which is a critical parameter when performing 
MALDI as it influences the ionization efficiency of the analytes. This could be done by varying the 
injected amount and/or applied matrix concentration.  
5.4 Influence of the type of ionisation and sample prefractionation  
A sample after 96h of serum-free monolayer cultivation with and without prior prefractionation by 
SDS-PAGE was analyzed on three different MS-platforms commonly used in proteomic analyses. On 
one hand the LC-MALDI platform used in our laboratory coupling chromatographic separation off-
line to a MALDI-TOF/TOF instrument and on the other hand, two MS-platforms in which 
chromatographic separation is coupled on-line to either a linear ion-trap or a hybrid quadropole 
time-of-flight instrument (QTOF) employing electrospray-ionization (ESI). It was shown that the 
number of identified proteins was increased for both unfractionated and fractionated samples using 
the MALDI-instrument. One reason for the differences may lie in the mass accuracy of the three mass 
analyzers. The MALDI-instrument is able to achieve an average mass accuracy of about 15 ppm using 
internal calibraton of the mass spectra, the Q-TOF has an accuracy of less than 2 ppm using the lock-
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mass option and the ion-trap is only capable of an average mass-accuracy around 80 ppm. The 
number of “applicants” for determination of the identity score in mascot algorithm is accuracy-
dependent, i.e. the lower the mass accuracy, the higher the number of peptides that could match to 
a precursor mass. This results in a higher identity threshold and reduces the number of assigned 
peptides for a given ion score. One reason why the MALDI-TOF/TOF could outplay the high-mass 
accuracy of the Q-TOF probably lies in the different ways of spectra acquisition. During ESI-MS, the 
MS/MS spectra are acquired “on the fly” during elution with a specific exclusion of peptides (i.e. 
mass values) for a specific time (usually in the range of 5-15 seconds). The offline LC-MALDI approach, 
however, uses the advantage of deposition of fractions on a MALDI-target and thus “freezes” the 
separation in time. This provides the opportunity to acquire MS/MS spectra at the apex of the 
elution-peak of a precursor after a MS scan of all spotted fractions, significantly increasing the 
sensitivity. Furthermore, more time can be spent on one single MS/MS spectrum gaining intensity of 
fragment peaks and thus increasing the average score and overall identifications. The most probable 
reason, however, is the applied solvent gradient used for peptide separation. For LC-MALDI analysis, 
the slope of the solvent gradient was 0.38 % ACN per minute while during LC-ESI, the slope was 0.71 
and 0.82 % ACN per minute for the ion trap and for the Q-TOF, respectively.  
For the analysis of in-gel digests, the slopes were only slightly different (1.1-1.4 % per minute) and 
consequently, the difference in number of identified proteins between the three instruments was 
marginally. The separation by SDS-PAGE is a common approach for reduction of complexity prior to 
LC-MS [Brewis and Brennan, 2010]. In this thesis, it increased the number of identified proteins 
tremendously. More than five times the number of identifications could be achieved using the GeLC-
MS approach in contrast to the 1D-LCMS analysis of the liquid digest for all of the three platforms, 
for the ion-trap the increase is even 10-fold. Furthermore, the sequence-coverage was more than 
doubled for the two ESI-instruments, for the MALDI the increase was 1.5-fold. The average ion-score 
also increased by the reduction of sample complexity, especially for the MALDI-workflow (increase 
from 50 to 74). However, the differences in identified proteins are not as large as in the 
unfractionated sample. This could imply that MALDI is better in identifying proteins from very 
complex samples but if the complexity is reduced, the instruments are not as different regarding 
identification efficiency. Notably, the amount of injected material from in-gel digests in the MALDI-
based analyses was only half of the amount used in the ESI-based analyses because of detector 
saturation when injecting the whole extract from in-gel digests as it was done in ESI-analyses. Of 
course, this could also be the reason for the lower increase in the number of identified proteins. 
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The combination of mascot search results from three instruments for each of the analytical strategies 
resulted in an increased number of identifications as well as sequence coverage for both approaches. 
110 proteins were identified by both approaches and, as expected, many of the proteins were 
identified only in the sample that underwent prefractionation by SDS-PAGE (571 proteins). One could 
assume that all of the proteins identified in the liquid digest should also be identified by the GeLC-MS 
approach because of decreased sample complexity due to prior prefractionation. However, there 
were 16 proteins present in the liquid digest that were not captured by the gel-based strategy (see 
Table 5.1). 
Table 5.1. Identified proteins in the supernatant of primary human hepatocytes by one dimensional LC-MS 
only. Given are the Swiss-Prot accession number (no.), the protein name, the molecular weight (MW) and the 
number of peptides assigned to each protein (pep.) 
accession no. protein name MW [kDa] pep. 
Q96M02 Uncharacterized protein C10orf90 77.9 1 
Q13505 Metaxin-1 51.5 1 
Q99969 Retinoic acid receptor responder protein 2 18.6 2 
P07737 Profilin-1  15.0 2 
P09382 Galectin-1   14.7 2 
P52758 Ribonuclease UK114 14.5 3 
P07148 fatty acid binding protein liver 14.0 5 
O60814 Histone H2-B 14.0 3 
P14174 Macrophage migration inhibitory factor 12.5 2 
P10599 Thioredoxin 11.7 1 
P20962 Parathymosin 11.5 2 
P62805 Histone H4   11.4 2 
P02655 Apolipoprotein C-II    11.3 2 
P04080 Cystatin-B 11.1 1 
P61604 10  heat shock protein, mitochondrial   10.9 1 
P02656 Apolipoprotein C-III 10.8 1 
 
Most of these proteins were in the low-molecular weight range between 10 and 19 kDa, while the 
tool to cut the gel-lanes reached from the top of the gel to about 20 kDa. Hence, these proteins could 
not be identified, just because they were not cut. The liquid digest did not suffer from this kind of 
restrictions, thus allowing the identification of small proteins down to the applied cut-off during 
ultrafiltration, in this case 10 kDa. The two proteins identified having a molecular weight above 20 
kDa, namely Metaxin-1 and an uncharacterized protein which gene lies on chromosome 10, orf 90, 
were identified by one peptide. A big advantage of the GeLC-MS approach is the increased sequence 
coverage, facilitating unambiguous identification of proteins. As an example, Complement 4-A was 
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reported for the liquid digest together with Complement 4-B, two genes for the same protein that 
have a distinct polymorphism and lie on different alleles in the human genome. However, in the gel-
based analysis, only Complement 4-B was reported, because the specific peptide distinguishing the 
two isoforms was identified leading to the exclusion of 4-A isoform as a possible candidate.  
Summarizing, the three different instruments or better the two different ionization methods are 
highly complementary in regard to protein identification as it was already shown previously [Bodnar 
et al., 2003]. Furthermore, the prefractionation step was very advantageous for the in-depth analysis 
of proteins in the conditioned medium of primary human hepatocytes. The almost 6-fold increase in 
identified proteins favours this prefractionation step for secretome analysis, although the fraction of 
secreted proteins is reduced. However, because the total number of identifications is that much 
higher, the total number of secreted proteins is also elevated. An important drawback of the 
prefractionation is the tremendous increase in analysis time. One sample is divided in at least 24 
samples, increasing the measurement time by a factor of about 12. For the MALDI analysis, this 
corresponds to an increase from 11 hours to almost 130 hours just regarding the measurement time, 
excluding increased time needed for sample preparation and post-processing of the acquired data. 
This could be reduced in future experiments by shortening the run-time of the SDS-PAGE just until 
the proteins are separated in the first third of the separation gel. This would prefractionate the 
sample but with a reduced number of fractions being a compromise between complexity- and 
analysis time reduction. In this strategy, the whole sample could be analyzed without losing low 
molecular-weight proteins as mentioned above. 
5.5 Donor-to-donor variance of identified proteins 
During preliminary experiments, the supernatants from monolayer cultures of primary human 
hepatocytes from three different donors were analyzed without prior immunodepletion. 
Supernatants were collected after 24h of cultivation and analyzed by LC-MALDI. 144 proteins were 
identified in the sample of donor 1. In the sample of donor 2, 72 proteins were identified and for 
donor 3, 74 proteins were identified. For all Identifications, the FDR was adjusted to 0% by not 
allowing any decoy hit during score threshold adjustment. The total number of proteins identified 
from these three samples was 163, and the distribution of the proteins among the samples is shown 
in Figure 5.2. 
Only 25 % (40) of proteins were identified in all three samples, which is much below the run-to-run 
reproducibility of the analytical workflow (60 %), thus indicating differences in sample composition 
due to the different donors. Interestingly, 37 % of identifications were only found in the sample of 
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donor 1 and it was assumed that this could be due to a higher amount of intracellular proteins leaked 
into the culture medium during cultivation. However, the percentage of intracellular proteins was 
found to be 55 %, which is exactly the same as for donor 2. 
 
Figure 5.2. Overlap in identified proteins in the secretome of PHH of three different donors after 24h in 
monolayer culture. Samples were concentrated by ultrafiltration, digested using trypsin and analyzed by LC-
MALDI. Overlaps are given as percentage of total identified proteins. 
For donor 3, the intracellular proteins accounted for only 28 % of total identifications. 69 % of the 
commonly identified proteins in all three donors were annotated as secreted and 50 % of the 
proteins overlapped in at least two donors indicating that there exists donor to donor variability in 
secreted proteins already at the qualitative level. This is in consistence with other studies where 
several donors were compared regarding general physiological and metabolic parameters [Mueller et 
al., 2011b]. 
5.6 Prediction of secreted proteins 
In this thesis, the secretome is defined as the whole range of proteins released by the hepatocytes 
into the culture medium by active secretion, either by classical or non-classical secretion pathways. 
To enter the well-described classical secretion pathway, proteins need a signal peptide that directs 
the translating ribosomes to the endoplasmic reticulum (ER). The nascent polypeptide chain is co-
translationally translocated into the lumen of the ER and proteins are secreted by exocytosis after 
traveling through the Golgi apparatus [van Vliet et al., 2003]. Alternatively, proteins can be secreted 
via non-classical secretion pathways circumventing the route through the ER and Golgi but these 
pathways are not yet fully understood [Nickel and Rabouille, 2009]. However, it exists an online tool 
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(SecretomeP) that was shown to predict secretion via non-classical pathways of candidate proteins 
quite accurately based on their amino acid sequence [Bendtsen et al., 2004]. The subcellular 
localization of identified proteins reported in the results section was based on the annotations in 
Uniprot. These annotations come mostly from the published literature and are manually reviewed, 
but proteins could also have different localizations that were not yet discovered. Hence, all identified 
proteins were examined for the presence of a signal peptide as reported in the Uniprot database 
using DAVID and if this feature was lacking, proteins were checked for possible secretion using 
SecretomeP to predict all possibly secreted proteins and also find proteins having a signal peptide 
not annotated in Uniprot. Meanwhile, this strategy is commonly applied when secretomes are 
analyzed [Skalnikova et al., 2011]. 
In the supernatant of the monolayer culture, a total of 126 proteins were identified. 75 % of these 
proteins possessed a signal peptide and another 11 % were predicted to be secreted by SecretomeP. 
In the sample of phase I of the bioreactor culture, 133 proteins were identified in total. 53 % 
featured a signal peptide while another 20 % were predicted to be non-classically secreted. Among 
the 250 proteins identified in the sample of the second phase of the bioreactor culture, 46 % 
contained a signal peptide and further 20 % were possibly non-classically secreted. In summary, 86 % 
(109 proteins) of proteins identified in monolayer culture, 73 % (98 proteins) of proteins during 
phase I and 66 % (165 proteins) of proteins identified in the sample of phase II of the bioreactor were 
found in the conditioned medium as a result of active secretion. 
Several studies analyzed the liver secretome using hepatocellular carcinoma cell lines [Zwickl et al., 
2005; Yamashita et al., 2007; Lewis et al., 2010], primary rat hepatocytes in sandwich culture [Farkas 
et al., 2005] or perfused rat liver [Zhang et al., 2010]. But so far, only one study analyzed the 
secretome of primary human hepatocytes (PHH) in monolayer culture [Slany et al., 2010]. In this 
study, the cytoplasmic and extracellular proteomes of PHH and two hepatocellular carcinoma cell 
lines (HepG2 and Hep3B) were analyzed by two-dimensional gel-electrophoresis and LC-MS. Secreted 
proteins were accepted based on the same criteria as in this thesis, namely the presence of a signal 
peptide or positive prediction by SecretomeP. The authors found 72 secreted proteins in the 
conditioned medium of a standard monolayer culture of human hepatocytes collected after 24h of 
serum-free cultivation. 46 of them were reported to be plasma proteins. As mentioned above, the 
number of possibly secreted proteins identified in monolayer culture in this work was almost 50 % 
higher (109), with 56 of them being known plasma proteins. Furthermore, among the proteins we 
identified in the secretome of PHH, there were 11 proteins that were claimed by Slany et al. to be 
expressed only in HepG2 cells. On the other hand, Slany and co-workers identified 19 proteins in the 
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secretome of PHH that were not found in this thesis. One of the proteins identified by Slany but not 
in this work was albumin, which could not been identified due to the preceeding immunodepletion. 
Another one was alpha-fetoprotein, a known marker for hepatic tumors that should only be 
expressed by fetal liver and liver tumors but not adult hepatocytes [Wu, 1990; Marrero and Lok, 
2004] and should not be present in cultures of primary hepatocytes derived of an adult liver. 13 of 
the 19 proteins were identified with only one peptide, thus indicating that these proteins were 
present in low abundance and may have been lost during immunodepletion which was not 
performed during sample preparation by Slany et al. However, most of the 11 proteins identified in 
this thesis and not found by Slany (i.e. 8) were identified with more than three peptides. Another 
reason for the differences could be the different instruments used for identification. Since Slany et al. 
used an LC-ESI-MS for identification of proteins the differences could be a result of the different 
ionization methods, especially for proteins detected with only few peptides. Nevertheless, the list of 
proteins found to be secreted by PHH in monolayer culture during this thesis is the most extended 
reported up to now, but further studies will surely lead to identification of additional secretory 
proteins of PHH especially because of the plethora of complementary proteomics techniques that 
can and will be used for secretome analysis in the future. 
 
5.7 Impact of cultivation technique on the secretome 
An interesting question is if the secretome of PHH in monolayer culture differs to the secretome 
when the cells are cultivated in a three-dimensional environment like the bioreactor used in this 
work. A first investigation was performed on the level of detectability. In the bioreactor, the secreted 
proteins have to pass the membranes surrounding the cell compartment of the bioreactor to be 
identified in the conditioned medium, while the monolayer culture does not suffer of such 
limitations since proteins are released directly into the conditioned medium covering the cells. 
Although the membranes in the bioreactor have a molecular weight cut-off of about 500 kDa 
[Zeilinger et al., 2004], it was questionable if proteins could diffuse through the membranes and 
subsequently be identified in the conditioned medium. Therefore, the identified proteins in each 
culture condition were ordered by size and the distribution between the different culture conditions 
and/or culture phases in the bioreactor was examined (see Fig. 5.2).   
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Figure 5.2. Size distribution (in kDa) of identified proteins in the secretome of PHH in monolayer culture (ML) 
and during phase I (days 4-6; BR p1) and phase II (days 7-10; BR p2) of a three-dimensional bioreactor culture. 
The percentage of identified proteins with a molecular weight above (a) and below (b) 80 kDa is shown. 
Indeed, more proteins with a molecular weight above 200 kDa were identified in the monolayer 
culture and the later phase of the bioreactor but not in the early phase of the three-dimensional 
culture (see Fig.5.2 a). This indicates that larger proteins need longer to diffuse out of the cell 
compartment but can, in principle, be detected. Smaller proteins were comparably distributed in the 
two culture conditions and the two phases of the bioreactor, except for the proteins between 80 kDa 
and 100 kDa, for which the percentage was lower in the second phase of the bioreactor. In 
conclusion, the presence of the membrane-barrier showed only minimal effects on the detectable 
proteins in regard to their protein size, but a delayed appearance of larger proteins in the 
conditioned medium of bioreactor cultures was observed.  
A further concern was the contamination of the secretome by intracellular proteins released into the 
bioreactor. Compared to the proteins identified in monolayer culture, the proportion of proteins 
known to be secreted in the samples from the bioreactor cultivation was reduced. During phase I of 
the bioreactor, the percentage of secreted proteins is about two-third the number of secreted 
proteins in monolayer culture, while in the second phase, the number of proteins known to be 
secreted is only one half of the proteins in standard monolayer culture. Most probably, this is due to 
the fact that the bioreactor is perfused in recirculation mode with fresh medium being added in low 
rates of about 0.5 ml per hour. This results, at first sight, in a complete replacement of medium in the 
bioreactor circuit (total volume is 12 ml) during one day of cultivation, comparable to the daily 
medium change in monolayer cultures. But, in fact, the medium in the bioreactor is rather 
continuously diluted with fresh medium. Thus, the intracellular proteins released from dying cells can 
accumulate in the system resulting in a reduced fraction of secreted proteins. Consequently, the 
percentage of intracellular proteins is increasing or, vice versa, the percentage of secreted proteins is 
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decreasing. The accumulation of intracellular proteins is confirmed by the biological processes found 
to be enriched in the bioreactor culture, both in phase I and phase II. Many processes taking place in 
intracellular compartments of the cell like “Amino acid metabolism” and “Carbohydrate 
metabolism”, “Vitamin metabolism”, “Fatty acid beta-oxidation” and “Tricarboxylic acid pathway” or 
“Protein folding” were enriched in the samples of the bioreactor culture but not in the monolayer 
culture. In summary, due to the increased fraction of intracellular proteins in the conditioned 
medium of PHH cultivated in the 3D-bioreactor, there is an increase in enriched intracellular 
processes like metabolic pathways from the cytosol (Glycolysis) or pathways that take place in 
intacellular organelles like the endoplasmic reticulum (protein folding) or mitochondria (TCA-cycle, 
beta oxidation). 
After discarding proteins not likely to be secreted based on a lacking signal peptide and non-
prediction by SecretomeP, the resulting protein lists were compared to identify differences in the 
secretome as a result of different cultivation conditions. It has already been shown by histological 
observations that hepatocytes cultivated in the bioreactor exhibit liver-morphology including 
structures resembling bile canaliculi [Gerlach et al., 2003a; Schmelzer et al., 2009]. To build up these 
tissue-like structures, the inoculated hepatocytes have to undergo well-regulated reorganization and 
regeneration processes which in vivo are accompanied by extensive cell communication 
[Zimmermann, 2004]. Several proteins involved in such processes were found in the bioreactor 
samples but not in the corresponding monolayer culture and are reported as follows. 
Thrombospondin-1, an adhesive glycoprotein involved in cell-to-cell and cell-to-matrix interactions 
was identified and it was shown to be upregulated in congenital fibrosis [El-Youssef et al., 1999]. 
Another protein, laminin γ, mediates attachment and migration but also organization of cells into 
tissues [Ishibashi et al., 2005], stimulates proliferation of epithelial cells [Virtanen et al., 2003] and 
was recently shown to be expressed in the basement membrane influencing cell polarity [Li et al., 
2011]. The junctional adhesion molecule A (F11 receptor) has claimed to play a role in early tight-
junction assembly according to gene ontology database based on protein homology. Furthermore, 
two proteins involved in angiogenesis were identified: Aminopeptidase N was found to be 
upregulated in tissues undergoing extensive angiogenesis like tumors and the corpus luteum and 
antagonists of this protein specifically inhibited angiogenesis [Pasqualini et al., 2000]. Complement 
C5 is a protein indirectly involved in angiogenisis by positive regulation of vascular endothelial 
growth factor (VEGF) production [Ambati et al., 2003; Nozaki et al., 2006]. VEGF not only stimulates 
blood-vessel formation but also proliferation and migration of endothelial cells [Patan, 2004; Evans 
et al., 2010; Skalnikova et al., 2011]. A role of VEGF during late phases of liver regeneration 
(resinusoidation) was also reported [LeCouter et al., 2003; Zimmermann, 2004]. Moreover, vanin-1 
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was identified in the bioreactor culture. Martin and co-workers showed that the mouse homologue 
of this protein is secreted and involved in tissue repair in the context of oxidative stress [Martin et 
al., 2001]. Very recently, a study showed the significant upregulation of interferon-gamma (INFγ) in 
rats following partial hepatectomy and thus indicating a function of this cytokine in liver 
regeneration [Batusic et al., 2011]. One protein involved in the INFγ-mediated signaling pathway that 
was found in the bioreactor was INFγ inducible protein 30. The expression of this protein is positively 
influenced by INFγ and a secreted isoform was postulated to play a role in intra- and interchain 
disulfide bonding [Luster et al., 1988] which could possibly play a role in reorganization of 
extracellular matrix during tissue reconstruction. Another protein found in the bioreactor that is 
induced by INFγ is metallothionein-2 [Kusari et al., 1987]. This protein was shown to interact with 
protein kinase D1 [Rao et al., 2003] which, in turn, stimulates angiogenisis and cell proliferation 
[Johannes et al., 1994; Storz and Toker, 2003; Ha et al., 2008]. Metallothioneins are also thought to 
be involved in the cells response to oxidative stress [Baird et al., 2006]. 
The aforementioned proteins take part in many processes required for liver remodeling like cell 
proliferation, cell differentiation, cell migration, angiogenesis, tight junction assembly and cell-to-cell 
or cell-to-matrix interactions. These findings serve as complementary confirmation of former 
histological studies indicating that the primary hepatocytes undergo tissue reconstruction in this 
hollow-fiber system. The proteins were not found in monolayer culture after 48h. However, almost 
all of these proteins were found in the sample that underwent prefractionation by SDS-PAGE. This 
sample was collected after 96h of cultivation in monolayer culture thus indicating that the cells start 
to produce these proteins in the later phase of cultivation. Indeed, these proteins were not found in 
phase I of the bioreactor but in phase II. Notably, the first day of phase II is corresponding to 96h of 
serum-free monolayer cultivation in respect of timepoint of cell isolation and seeding or inoculation 
into the bioreactor, respectively. The hepatocytes obviously try to reorganize in both cultures by 
expressing the required proteins but in standard monolayer culture, there is no possibility to build-up 
tissue-like structures and subsequently cells cannot survive for a longer period. In contrast, the cells 
in the bioreactor are able to reorganize and survive because the high-density three-dimensional 
culture in the bioreactor provides an optimal environment. Additionally to the proteins involved in 
cell proliferation, some proteins were found that are indicative of oxidative stress in the bioreactor 
culture. However, proteins that are involved in protection against oxidative stress have also a 
connection to liver regeneration [Beyer et al., 2008].  Furthermore, the presence of proteins being 
part of the oxidative stress response could be a result of the way of oxygenation in the bioreactor. 
Oxygen is directly introduced into the cell compartment through the gassing capillaries which is not 
really physiological but overcame the problem of limited oxygen supply in this bioreactor. Using a 
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modified gassing system as developed during this thesis [Mueller et al., 2011b] in which the medium 
is saturated with oxygen before the entrance into the bioreactor could lead to an oxygen supply 
closer to the situation found in vivo. From the difference in oxygen concentration in the medium 
before and after the bioreactor, the oxygen uptake rate of the cells can be determined which could 
furthermore serve as an online parameter for cell viability during cultivation. A strategy ideally 
mimicking the in vivo situation would be an oxygen transport system in the medium based on 
hemoglobin. Recently, such a technique was published using hemoglobin-based oxygen carriers in an 
hepatic hollow-fiber bioreactor [Chen and Palmer, 2010]. 
5.8 Effects of diclofenac on the secretome 
Diclofenac is a widely used non-steroidal anti-inflammatory drug (NSAID) and is a typical example for 
idiosyncratic drug toxicity causing liver injury, cholestasis as well as lipid accumulation disorders (i.e. 
steatosis) by inhibition of fatty acid oxidation [Banks et al., 1995; Baldwin et al., 1998]. There is 
evidence that both oxidative stress and mitochondrial dysfunction, alone or in combination play a 
role in liver injury during treatment with this NSAID [Galati et al., 2002; Masubuchi et al., 2002]. Also 
immune-mediated liver injury was reported as a result of allergic responses to protein adducts of 
drug-glucuronides formed during diclofenac detoxification in mice [Yang, 1996]. Furthermore, 
diclofenac induced apoptosis both in leukemia cells and in hepatoma cells [Franceschelli et al., 2011; 
Singh et al., 2011]. Although the incidence rate of diclofenac induced liver failure in clinics is very low, 
the wide use of this drug causes an impressive absolute number of cases worldwide but the toxic 
effect is exhibited only after chronic treatment [Walker, 1997; Boelsterli, 2003]. In vitro, only very 
high doses of diclofenac cause acute toxicity in human hepatocytes [Bort et al., 1999]. In this thesis, 
diclofenac was applied at two different concentrations plus an untreated control to bioreactor 
cultures of primary human hepatocytes. One lower concentration was applied (6.4 µM) 
corresponding to the maximal therapeutic concentration in human patients [Hinz et al., 2005]  while 
the second concentration (100µM) was more closer to the EC50 value of diclofenac but still in the 
subtoxic range [Bort et al., 1999]. The effects of diclofenac on the secretome were investigated 
during the later phase of the culture (days 7 to 10) and differences were detected by peptide hit 
counting. Although this technique is not as sensitive and robust in detecting differences in protein 
expression as isotopic labeling or spectrum counting, it provides approximates of protein abundance 
in compared samples [Pang et al., 2002; Gao et al., 2003; Gao et al., 2004; Liu et al., 2004]. Proteins 
exhibiting differences in peptide hits during analysis of the conditioned medium of the bioreactor 
cultures will in the following be referred to as being “regulated”. However, it has to be kept in mind 
that an altered abundance of a protein in the conditioned medium is not necessarily caused solely by 
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an altered gene expression. Other processes down-stream of transcription could be affected by the 
drug treatment and lead to altered amounts of a protein in the extracellular space. Post 
transcriptional regulation on the level of mRNA or altered protein degradation but also impacts on 
the secretion mechanism itself could result in observed differences upon treatment with diclofenac. 
Twelve proteins were found to have significant differences in peptide counts upon application of 
diclofenac compared to the control. Overall, only two proteins were down-regulated while ten 
proteins showed up-regulation. Furthermore, five proteins exhibited regulation already upon 
application of the lower, therapeutic concentration and except for one protein all of them were up-
regulated. One of the up-regulated proteins was -1-antitrypsin but this protein should have been 
removed by the immunodepletion column. Since the difference in peptide counts could be a result of 
insufficient depletion, this protein will not be discussed in detail but it cannot be excluded that this 
protein was up-regulated and exceeded the binding capacity of the antibody resin. Leucine-rich -2-
glycoprotein was up-regulated in the group treated with the lower concentration of diclofenac only 
but not in the group treated with the higher dose. It was recently identified as an inflammatory 
biomarker for autoimmune diseases [Serada et al., 2010]. Fibrinogen  chain and histidine-rich 
glycoprotein were up-regulated in both groups treated with diclofenac. The latter acts as a 
protective protein in autoimmune processes [Gorgani and Theofilopoulos, 2007] and the former 
protein, fibrinogen, has been found to be up-regulated in blood plasma during xenobiotic-induced 
cholestatic liver injury in mice [Luyendyk et al., 2011]. The higher abundance of these proteins upon 
diclofenac treatment indicates that already at a therapeutic concentration, diclofenac induces 
inflammatory immune responses and cholestatic processes. One protein was down-regulated in both 
treated groups, 4-hydroxyphenylpyruvate dioxygenase (Hpd), but for this protein, no direct link to 
diclofenac toxicity could be made. It is part of the tyrosine catabolic pathway and mice hepatocytes 
carrying a mutation in the gene encoding Hpd and the gene for the last enzyme in the tyrosine 
catabolic pathway (fumarylacetoacetate hydrolase) rapidly underwent apoptosis, but only when 
homogentisate (intermediate metabolite of tyrosine degradation) was administered [Nakamura et al., 
2007]. This probably indicates an anti-apoptotic function of this protein counteracting the pro-
apoptotic effect exhibited by diclofenac [Gomez-Lechon et al., 2003b]. Additionally, a recent study of 
our lab showed significant decrease in tyrosine uptake of PHH upon diclofenac treatment indicating 
that this metabolic pathway is somehow affected by this drug [Mueller et al., 2012]. 
The abundance of seven proteins was altered in the condidioned medium of the bioreactor treated 
with 100 µM diclofenac. One up-regulated protein was retinol-binding-protein 4. Actually being an 
important protein in vitamin A metabolism and transport, it was significantly up-regulated in plasma 
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of children with non-alcoholic fatty liver disease and therefore claimed to be a biomarker for 
intrahepatic lipid content [Romanowska et al., 2011]. This is indicative of accumulation of lipids in 
the cells due to diclofenac treatment which has been reported for colorectal carcinoma cells 
[Baldwin et al., 1998]. Additionally, two apolipoproteins were highly up-regulated, apolipoprotein A-I 
and apolipoprotein A-IV. Both proteins are involved in lipid transport and have been shown to 
promote efflux of excess cellular lipids [Remaley et al., 2001]. They could possibly provide 
elimination of accumulated lipids out of the cells. In addition, apolipoprotein A-IV possesses 
antioxidant activity by removal of free radicals [Wong et al., 2007]. Ceruloplasmin was also up-
regulated upon 100 µM diclofenac. Besides its function in copper- and iron transport, it is an 
effective antioxidant [Gutteridge, 1992; Patel et al., 2002]. NADPH dependent isocitrate 
dehydrogenase was down-regulated and a decrease in transcripts of this protein was demonstrated 
to accompany development of apoptosis in rat liver [Tsvetikova et al., 2010]. The differential 
expression of these proteins supports the apoptotic effect of diclofenac that was linked to the 
formation of reactive oxygen species [Gomez-Lechon et al., 2003a]. Another up-regulated protein, -
2-macroglobulin, has strong anti-inflammatory effects by binding of proinflammatory cytokines like 
tumor necrosis factor alpha and Interleukin-6 [Webb and Gonias, 1998] with the former being a 
known inductor of liver injury [Schwabe and Brenner, 2006]. The last protein up-regulated in the 
bioreactor treated with 100µM diclofenac was inter- -trypsin inhibitor heavy chain H2, which was 
demonstrated to also play a significant role in inflammation [Zhuo et al., 2004]. 
Taken together, all proteins that exhibited significant differences in peptide counts upon application 
of diclofenac could, directly or indirectly, be connected to mechanisms of toxicity known for this 
NSAID. Observed differences in secreted proteins were larger in the group treated with a higher 
concentration of diclofenac than in the group treated with a therapeutic concentration. More 
proteins showed significantly altered peptide counts according to a one way ANOVA test and the 
observed change in identified peptides was larger upon application of the higher concentration. This 
was confirmed statistically by PCA of the acquired data. The cluster of the group undergoing high-
dose treatment showed a higher separation from the control group than the cluster of cells exposed 
to the therapeutic concentration. Moreover, the respective groups were well separated and did not 
overlap within the 95 % confidence intervals. In both treated groups, regulated proteins were 
identified being indicative of or protective against rather sensitive pathways like immune-mediated 
inflammatory reactions. Immunological processes are thought to play an essential role in 
idiosyncratic toxicity of diclofenac [Yang, 1996; Bessone, 2010]. However, the occurrence of such 
events could be questioned because of the absence of cells of the immune system in the bioreactor. 
Even though the applied method for cell isolation results in a high purity of hepatocytes up to almost 
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100 %, it cannot be excluded that liver macrophages (stellate cells) found their way into the 
bioreactor. On the other hand, the altering in secretion of proteins related to immune-mediated 
inflammatory responses could be interpreted as an initial step for recruiting of immune cells which 
results in onset of inflammation in vivo. Moreover, proteins providing hints for ongoing cholestasis 
and apoptosis were identified already at a therapeutic concentration of diclofenac pinpointing the 
high sensitivity of the proteomic approach. When a higher concentration was applied, the 
differences in the secretome could be correlated to the occurrence of severe drug adverse reactions 
like lipid accumulation and apoptosis but also oxidative stress, all of them being known effects of 
diclofenac treatment. This work proved, for the first time, the proposed mechanisms of diclofenac 
induced hepatotoxicity based on proteomic analysis of secreted proteins. Several studies 
investigated the effect of diclofenac on the intracellular proteome of primary rat cardiomyocytes, on 
rat bile as well as human plasma, but none of the proteins found to be altered in this thesis were 
reported in these studies [Jones et al., 2003; Baek et al., 2010; van Erk et al., 2010]. Thus, the 
secreted proteins found to be affected by diclofenac display new findings worth further investigation 
to confirm and evaluate these new biomarker candidates for diclofenac induced hepatotoxicity.  
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6. Conclusion and outlook 
In the presented thesis, the secreted proteins of primary human hepatocytes in a 3D-bioreactor have 
been analyzed by proteomics. It was evident from the results that the use of FCS for cultivation has 
to be avoided if a proteomic analysis is aspired, particularly if the extracellular proteome is to be 
analyzed. The tissue-like behavior of cells cultivated in the bioreactor was confirmed which makes 
this device a suitable tool for the investigation of human specific hepatotoxicity during early drug 
testing. However, the high number of required cells for inoculation (2.5 x 107) and the high costs as 
well as the needed expertise to run this system restrict its use to few laboratories and make it 
unsuitable for high-throughput screenings. To overcome this problem, the bioreactor should be 
further down-scaled which is currently under development. Other three-dimensional cultivation 
techniques for in vitro drug testing should be considered ensuring tissue reconstruction and allowing 
the use in large-scale drug testing. A quite novel cultivation format applied to hepatocytes is the 
spheroid culture. These are spherical tissue-like structures which can be easily obtained by 
cultivation of cells in a hanging drop in a 96-well format. First experiments already proved the 
applicability of spheroids for in vitro drug testing using HepG2 cells [Mueller et al., 2011a] and also 
HepaRG cells using quite low cell numbers (2,000-10,000). The HepaRG cell line is derived from a 
human hepatocellular carcinoma and has recently gained much attention from the toxicological 
community because it shows metabolic activities comparable to primary hepatocytes and maintains 
these features for many weeks. This cell line could overcome the problem of donor-to-donor 
variability as well as limited availability of primary human hepatocytes and will be investigated and 
characterized for the use in toxicoproteomic research in the future.  
To the best of my knowledge, no other proteomic study investigated the effects of diclofenac on the 
secretome of primary human hepatocytes so far. Several proteins were found to exhibit altered 
abundances in the secretome upon diclofenac exposure and almost all proteins could be connected 
to the proposed mechanisms of toxicity. Of course, these findings have to be confirmed by additional 
experiments to select possible biomarker candidates for diclofenac-induced hepatotoxicity. The 
samples from 2D monolayer cultures treated with diclofenac generated during this thesis could 
unfortunately not be analyzed because of paucity of time but this should be made up to validate the 
findings obtained with the bioreactor. In order to discover predictive biomarkers that can be used as 
universal indicators of drug induced hepatotoxicity, other drugs will have to be administered and 
possible overlaps in changes of protein abundances have to be unveiled. However, it is not likely, but 
also not excluded, that one common biomarker for all drugs will be discovered. It is rather likely that 
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the different mechanisms of toxicity are represented by different (sets of) proteins that have to be 
monitored together to predict toxicity of a new drug. Furthermore, these proteins are likely to be 
present in very low amounts in plasma of patients during clinical surveillance which could be below 
the sensitivity of commonly used proteomic workflows. Therefore, a more sensitive quantification 
method like MRM should be applied. MRM is furthermore capable of absolute quantification as well 
as multiplexing thus allowing targeted quantification of several proteins at once which would 
increase the throughput. In any case, the preliminary examination of a new drug by discovery 
proteomics techniques like 2D-DIGE can be used for preclinical toxicity studies but also for 
classification of the drug´s mode of action. 
The application of proteomics techniques on toxicological research will for sure provide deeper 
insights into the mechanisms of drug toxicity in the future, especially if applied together with other 
fields of systems biology like genomics, transcriptomics and metabolomics. The cross-linking of such 
techniques in toxicology by means of computational methods is very promising to understand the 
general processes affected by treatment with a drug and to find new biomarkers that are indicative 
of adverse drug reactions. This will lead to improvements not only in early drug development but 
also clinical surveillance in the future. 
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Table I. Identified proteins in the conditioned medium of PHH in monolayer culture after 24h using LC-MALDI. 
Gene name (GN), Swiss-Prot Accesion number (Acc. no.), identified peptides (pep), sequence coverage (seq. 
cov.), signal peptide (SP),SecretomeP prediction status (SecP) 
No. Protein name Acc. no. MW [Da] pep seq. cov. SP SecP 
1 Complement C3  GN=C3 P01024 187,131.10 38 22.5% yes  
2 Apolipoprotein A-IV  GN=APOA4 P06727 45,381.30 19 43.2% yes  
3 Complement C4-A  GN=C4A P0C0L4 192,754.80 19 10.7% yes  
4 Fibronectin  GN=FN1 P02751 262,598.90 18 9.01% yes  
5 Apolipoprotein E  GN=APOE P02649 36,135.50 14 41.6% yes  
6 Complement factor B  GN=CFB P00751 85,515.20 13 15.6% yes  
7 Alpha-1-antichymotrypsin  GN=SERPINA3 P01011 47,634.90 13 28.1% yes  
8 Complement C1s subcomponent  GN=C1S P09871 76,666.20 12 17.9% yes  
9 Apolipoprotein A-I  GN=APOA1 P02647 30,760.50 12 35.6% yes  
10 Complement C1r subcomponent  GN=C1R P00736 80,101.60 10 16.9% yes  
11 Prothrombin  GN=F2 P00734 70,018.80 10 19.6% yes  
12 Protein AMBP  GN=AMBP P02760 38,981.50 10 35.2% yes  
13 Alpha-1-antitrypsin  GN=SERPINA1 P01009 46,719.90 9 24.6% yes  
14 Ceruloplasmin  GN=CP P00450 122,189.90 9 8.92% yes  
15 Apolipoprotein B-100  GN=APOB P04114 515,596.80 8 1.86% yes  
16 Hemopexin  GN=HPX P02790 51,658.50 8 16.5% yes  
17 Alpha-2-macroglobulin  GN=A2M P01023 163,271.90 8 6.51% yes  
18 Beta-2-glycoprotein 1  GN=APOH P02749 38,280.50 8 28.1% yes  
19 Serum amyloid A protein  GN=SAA1 P02735 13,514.50 7 54.9% yes  
20 Complement factor H  GN=CFH P08603 139,078.20 7 8.45% yes  
21 Vitronectin  GN=VTN P04004 54,288.10 7 16.1% yes  
22 Vitamin D-binding protein  GN=GC P02774 52,946.60 7 24.1% yes  
23 Zinc-alpha-2-glycoprotein  GN=AZGP1 P25311 34,240.60 7 22.8% yes  
24 Alcohol dehydrogenase 1B  GN=ADH1B P00325 39,836.30 6 16.8%  no 
25 Haptoglobin  GN=HP P00738 45,186.90 6 16.00% yes  
26 Hyaluronan-binding protein 2  GN=HABP2 Q14520 62,653.40 6 12.00% yes  
27 Fibrinogen gamma chain  GN=FGG P02679 51,495.30 6 14.8% yes  
28 Fibrinogen alpha chain  GN=FGA P02671 94,955.40 6 9.93% yes  
29 Plasminogen  GN=PLG P00747 90,549.40 5 9.38% yes  
30 Kininogen-1  GN=KNG1 P01042 71,939.60 5 7.61% yes  
31 Plasma protease C1 inhibitor  GN=SERPING1 P05155 55,137.50 5 9.8% yes  
32 Fibrinogen beta chain  GN=FGB P02675 55,910.60 5 11.4% yes  
33 Alpha-1-acid glycoprotein 1  GN=ORM1 P02763 23,494.10 5 19.9% yes  
34 Alpha-2-HS-glycoprotein  GN=AHSG P02765 39,305.40 5 15.8% yes  
35 Inter-alpha-trypsin inhibitor heavy chain H2  GN=ITIH2 P19823 106,447.50 5 5.81% yes  
36 Glutamate dehydrogenase 1, mitochondrial  GN=GLUD1 P00367 61,381.70 4 6.81%  no 
37 Neutrophil gelatinase-associated lipocalin  GN=LCN2 P80188 22,570.90 4 25.3% yes  
38 Complement C2  GN=C2 P06681 83,250.80 4 6.91% yes  
39 Clusterin  GN=CLU P10909 52,476.90 4 10.0% yes  
40 Insulin-like growth factor-binding protein 2  GN=IGFBP2 P18065 34,795.60 4 14.2% yes  
41 Pigment epithelium-derived factor  GN=SERPINF1 P36955 46,296.30 4 8.13% yes  
42 Beta-2-microglobulin  GN=B2M P61769 13,696.90 4 24.4% yes  
43 Serotransferrin  GN=TF P02787 77,046.30 4 7.74% yes  
44 Actin, cytoplasmic 1  GN=ACTB P60709 41,719.80 4 15.2%  no 
45 Calreticulin  GN=CALR P27797 48,124.90 4 11.00% yes  
46 Inter-alpha-trypsin inhibitor heavy chain H4  GN=ITIH4 Q14624 103,340.40 3 3.66% yes  
47 Glutathione S-transferase A1  GN=GSTA1 P08263 25,615.00 3 11.7%  no 
48 Alpha-2-antiplasmin  GN=SERPINF2 P08697 54,548.60 3 6.72% yes  
49 Complement component C8 gamma chain  GN=C8G P07360 22,259.30 3 16.8% yes  
50 Nucleobindin-1  GN=NUCB1 Q02818 53,861.60 3 9.11% yes  
51 Angiotensinogen  GN=AGT P01019 53,136.80 3 7.63% yes  
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52 Fructose-1,6-bisphosphatase 1  GN=FBP1 P09467 36,825.20 3 12.1%  0.515 
53 Retinol-binding protein 4  GN=RBP4 P02753 22,992.30 3 15.9% yes  
54 Apolipoprotein C-III  GN=APOC3 P02656 10,834.30 3 34.3% yes  
55 Plasminogen activator inhibitor 1  GN=SERPINE1 P05121 45,042.20 3 6.72% yes  
56 Histidine-rich glycoprotein  GN=HRG P04196 59,558.60 3 6.1% yes  
57 Insulin-like growth factor-binding protein complex acid labile subunit  GN=IGFALS P35858 66,020.60 3 6.12% yes  
58 Fibrinogen-like protein 1  GN=FGL1 Q08830 36,361.90 3 10.9% yes  
59 Histone H4  GN=HIST1H4A P62805 11,349.70 3 29.1%  no 
60 Transforming growth factor-beta-induced protein ig-h3  GN=TGFBI Q15582 74,664.90 3 5.71% yes  
61 Insulin-like growth factor-binding protein 4  GN=IGFBP4 P22692 27,915.70 2 9.3% yes  
62 Apolipoprotein C-II  GN=APOC2 P02655 11,266.10 2 19.8% yes  
63 Coagulation factor XII  GN=F12 P00748 67,772.60 2 3.9% yes  
64 Coagulation factor X  GN=F10 P00742 54,714.10 2 6.76% yes  
65 Metalloproteinase inhibitor 1  GN=TIMP1 P01033 23,153.10 2 11.1% yes  
66 Insulin-like growth factor-binding protein 1  GN=IGFBP1 P08833 27,884.90 2 11.6% yes  
67 Cytochrome b5  GN=CYB5A P00167 15,312.30 2 20.1%  0.567 
68 3-ketoacyl-CoA thiolase, mitochondrial  GN=ACAA2 P42765 41,906.20 2 6.55%  no 
69 Leucine-rich alpha-2-glycoprotein  GN=LRG1 P02750 38,161.70 2 5.76% yes  
70 Retinoic acid receptor responder protein 2  GN=RARRES2 Q99969 18,599.30 2 14.7% yes  
71 Inter-alpha-trypsin inhibitor heavy chain H3  GN=ITIH3 Q06033 99,832.90 2 2.81% yes  
72 Betaine--homocysteine S-methyltransferase 1  GN=BHMT Q93088 44,980.60 2 7.88%  no 
73 Protein disulfide-isomerase  GN=P4HB P07237 57,100.10 2 5.51% yes  
74 Polymeric immunoglobulin receptor  GN=PIGR P01833 83,265.40 2 2.36% yes  
75 Fructose-bisphosphate aldolase B  GN=ALDOB P05062 39,455.30 2 6.04%  no 
76 Galectin-3-binding protein  GN=LGALS3BP Q08380 65,314.10 2 3.93% yes  
77 HLA class I histocompatibility antigen, A-25 alpha chain  GN=HLA-A P18462 41,199.70 2 6.58% yes  
78 Liver carboxylesterase 1  GN=CES1 P23141 62,504.40 2 4.06% yes  
79 Chitinase-3-like protein 1  GN=CHI3L1 P36222 42,609.00 2 5.22% yes  
80 Agrin  GN=AGRN O00468 214,820.00 2 1.32% yes  
81 Cathepsin Z  GN=CTSZ Q9UBR2 33,850.20 2 7.26% yes  
82 Syndecan-1  GN=SDC1 P18827 32,443.40 1 5.48% yes  
83 Antithrombin-III  GN=SERPINC1 P01008 52,586.00 1 3.66% yes  
84 Cathepsin B  GN=CTSB P07858 37,803.20 1 5.01% yes  
85 Triosephosphate isomerase  GN=TPI1 P60174 26,651.10 1 5.22%  0.51 
86 Fatty acid-binding protein, liver  GN=FABP1 P07148 14,190.70 1 8.66%  no 
87 Inter-alpha-trypsin inhibitor heavy chain H1  GN=ITIH1 P19827 101,371.80 1 1.32% yes  
88 Cathepsin L1  GN=CTSL1 P07711 37,546.10 1 3.6% yes  
89 Ornithine carbamoyltransferase, mitochondrial  GN=OTC P00480 39,919.00 1 3.95%  no 
90 Alpha-1-acid glycoprotein 2  GN=ORM2 P19652 23,585.20 1 12.4% yes  
91 Proprotein convertase subtilisin/kexin type 9  GN=PCSK9 Q8NBP7 74,266.40 1 1.88% yes  
92 Serum amyloid A-4 protein  GN=SAA4 P35542 14,729.20 1 8.46% yes  
93 Cell adhesion molecule 1  GN=CADM1 Q9BY67 48,491.30 1 2.94% yes  
94 Malate dehydrogenase, cytoplasmic  GN=MDH1 P40925 36,408.90 1 3.59%  no 
95 Amyloid beta A4 protein  GN=APP P05067 86,923.30 1 1.69% yes  
96 Ezrin  GN=EZR P15311 69,396.60 1 1.71%  0.563 
97 Zinc finger imprinted 2  GN=ZIM2 Q9NZV7 61,145.50 1 2.28%  0.666 
98 Cystatin-C  GN=CST3 P01034 15,781.20 1 7.53% yes  
99 Alcohol dehydrogenase 1C  GN=ADH1C P00326 39,849.60 1 10.1%  no 
100 Carboxylesterase 2  GN=CES2 O00748 61,789.30 1 2.15% yes  
101 Angiopoietin-related protein 3  GN=ANGPTL3 Q9Y5C1 53,621.30 1 3.04% yes  
102 SPARC  GN=SPARC P09486 34,613.90 1 4.29% yes  
103 Histone H3.1  GN=HIST1H3A P68431 15,386.70 1 6.62%  0.681 
104 Histone H2A type 1-B/E  GN=HIST1H2AB P04908 14,118.00 1 6.92%  0.536 
105 Plasma serine protease inhibitor  GN=SERPINA5 P05154 45,684.80 1 2.46% yes  
106 Proactivator polypeptide  GN=PSAP P07602 58,094.00 1 2.1% yes  
107 Complement factor I  GN=CFI P05156 65,731.80 1 1.2% yes  
108 Rab GDP dissociation inhibitor alpha  GN=GDI1 P31150 50,566.10 1 4.25%  no 
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109 Malate dehydrogenase, mitochondrial  GN=MDH2 P40926 35,485.70 1 3.85%  0.644 
110 Protein disulfide-isomerase A4  GN=PDIA4 P13667 72,916.00 1 1.71% yes  
111 Nck-associated protein 1-like  GN=NCKAP1L P55160 128,140.30 1 0.71%  0.552 
112 Protein FAM83H  GN=FAM83H Q6ZRV2 127,105.90 1 0.594%  no 
113 Plasma kallikrein  GN=KLKB1 P03952 71,351.70 1 1.57% yes  
114 Apolipoprotein A-II  GN=APOA2 P02652 11,157.20 1 9.00% yes  
115 Alpha-actinin-4  GN=ACTN4 O43707 104,839.20 1 0.988%  no 
116 Osteopontin  GN=SPP1 P10451 35,404.60 1 5.41% yes  
117 Apolipoprotein C-I  GN=APOC1 P02654 9,314.30 1 10.8% yes  
118 S-adenosylmethionine synthase isoform type-1  GN=MAT1A Q00266 43,629.50 1 2.28%  no 
119 Leucine-rich repeat-containing protein 16B  GN=LRRC16B Q8ND23 150,214.80 1 0.583%  no 
120 4-aminobutyrate aminotransferase, mitochondrial  GN=ABAT P80404 56,422.80 1 2.8%  0.575 
121 Superoxide dismutase [Cu-Zn]  GN=SOD1 P00441 15,917.30 1 9.09%  0.648 
122 Mannan-binding lectin serine protease 2  GN=MASP2 O00187 75,685.40 1 1.17% yes  
123 Phosphatidylethanolamine-binding protein 1  GN=PEBP1 P30086 21,038.90 1 8.02%  0.672 
124 Angiopoietin-related protein 4  GN=ANGPTL4 Q9BY76 45,196.00 1 2.71% yes  
125 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial  GN=ECH1 Q13011 35,798.20 1 3.05%  0.696 
126 39S ribosomal protein L21, mitochondrial  GN=MRPL21 Q7Z2W9 22,797.10 1 3.9%  0.695 
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Table II. Identified proteins in the conditioned medium of PHH in bioreactor culture during phase I (day 4-6) 
using LC-MALDI. Gene name (GN), Swiss-Prot Accesion number (Acc. no.), identified peptides (Pep), sequence 
coverage (Seq. cov.), signal peptide (SP), SecretomeP prediction status (SecP) 
No. Protein name Acc. no. MW [Da] Pep Seq. cov. SP SecP 
1 Complement C3  GN=C3   P01024 187,131.10 22 15.9% yes  
2 Complement C4-A  GN=C4A   P0C0L4 192,754.80 17 9.98% yes  
3 Ceruloplasmin  GN=CP   P00450 122,189.90 14 16.1% yes  
4 Complement factor B  GN=CFB   P00751 85,515.20 13 19.6% yes  
5 Liver carboxylesterase 1  GN=CES1   P23141 62,504.40 13 25.7% yes  
6 Glutamate dehydrogenase 1, mitochondrial  GN=GLUD1   P00367 61,381.70 12 28.7%  no 
7 Alpha-1-antichymotrypsin  GN=SERPINA3   P01011 47,634.90 12 29.8% yes  
8 Complement factor H  GN=CFH   P08603 139,078.20 11 10.7% yes  
9 Alpha-2-macroglobulin  GN=A2M   P01023 163,271.90 10 8.34% yes  
10 Protein AMBP  GN=AMBP   P02760 38,981.50 9 30.4% yes  
11 Vitamin D-binding protein  GN=GC   P02774 52,946.60 9 24.1% yes  
12 Protein disulfide-isomerase A3  GN=PDIA3   P30101 56,766.60 9 19.6% yes  
13 Antithrombin-III  GN=SERPINC1   P01008 52,586.00 8 20.3% yes  
14 Hemopexin  GN=HPX   P02790 51,658.50 8 22.9% yes  
15 Catalase  GN=CAT   P04040 59,738.50 8 17.3%  no 
16 Alpha-1-acid glycoprotein 1  GN=ORM1   P02763 23,494.10 7 35.3% yes  
17 Alpha-1B-glycoprotein  GN=A1BG   P04217 54,235.30 7 17.2% yes  
18 Complement C1r subcomponent  GN=C1R   P00736 80,101.60 6 10.4% yes  
19 Apolipoprotein A-I  GN=APOA1   P02647 30,760.50 6 23.6% yes  
20 Beta-2-glycoprotein 1  GN=APOH   P02749 38,280.50 6 22.0% yes  
21 Fibronectin  GN=FN1   P02751 262,598.90 6 2.93% yes  
22 Glutathione S-transferase A2  GN=GSTA2   P09210 25,647.90 6 18.0%  no 
23 Complement C1s subcomponent  GN=C1S   P09871 76,666.20 6 9.45% yes  
24 Alcohol dehydrogenase [NADP+]  GN=AKR1A1   P14550 36,555.60 6 23.4%  no 
25 Insulin-like growth factor-binding protein complex acid labile subunit  GN=IGFALS   P35858 66,020.60 6 11.4% yes  
26 Malate dehydrogenase, mitochondrial  GN=MDH2   P40926 35,485.70 6 20.7%  0.644 
27 Triosephosphate isomerase  GN=TPI1   P60174 26,651.10 6 32.5%  0.51 
28 POTE ankyrin domain family member F  GN=POTEF   A5A3E0 121,429.10 5 5.67%  no 
29 Aspartate aminotransferase, mitochondrial  GN=GOT2   P00505 47,500.60 5 12.1%  0.505 
30 Superoxide dismutase [Mn], mitochondrial  GN=SOD2   P04179 24,704.60 5 20.3% yes  
31 Alpha-enolase  GN=ENO1   P06733 47,152.20 5 15.9%  0.536 
32 Fructose-1,6-bisphosphatase 1  GN=FBP1   P09467 36,825.20 5 19.2%  0.515 
33 Aspartate aminotransferase, cytoplasmic  GN=GOT1   P17174 46,230.10 5 11.9%  no 
34 Phosphatidylethanolamine-binding protein 1  GN=PEBP1   P30086 21,038.90 5 39.0%  0.672 
35 Pigment epithelium-derived factor  GN=SERPINF1   P36955 46,296.30 5 11.0% yes  
36 Aminoacylase-1  GN=ACY1   Q03154 45,866.30 5 11.3%  no 
37 Carboxylesterase 2  GN=CES2   O00748 61,789.30 4 8.59% yes  
38 Angiotensinogen  GN=AGT   P01019 53,136.80 4 10.7% yes  
39 Serotransferrin  GN=TF   P02787 77,046.30 4 7.16% yes  
40 Histidine-rich glycoprotein  GN=HRG   P04196 59,558.60 4 7.81% yes  
41 Fructose-bisphosphate aldolase B  GN=ALDOB   P05062 39,455.30 4 15.1%  no 
42 Plasminogen activator inhibitor 1  GN=SERPINE1   P05121 45,042.20 4 9.45% yes  
43 Plasma protease C1 inhibitor  GN=SERPING1   P05155 55,137.50 4 9.2% yes  
44 Complement factor I  GN=CFI   P05156 65,731.80 4 6.52% yes  
45 Fatty acid-binding protein, liver  GN=FABP1   P07148 14,190.70 4 33.9%  no 
46 Cathepsin B  GN=CTSB   P07858 37,803.20 4 15.6% yes  
47 Heat shock cognate 71 kDa protein  GN=HSPA8   P11142 70,881.80 4 8.51%  no 
48 Inter-alpha-trypsin inhibitor heavy chain H2  GN=ITIH2   P19823 106,447.50 4 4.76% yes  
49 Serine--pyruvate aminotransferase  GN=AGXT   P21549 42,993.40 4 12.2%  0.747 
50 Peptidyl-prolyl cis-trans isomerase B  GN=PPIB   P23284 23,725.20 4 19.0% yes  
51 Endoplasmic reticulum resident protein 29  GN=ERP29   P30040 28,976.90 4 18.0% yes  
52 Chitinase-3-like protein 1  GN=CHI3L1   P36222 42,609.00 4 16.2% yes  
53 L-lactate dehydrogenase A chain  GN=LDHA   P00338 36,671.20 3 8.13%  0.549 
54 Phosphoglycerate kinase 1  GN=PGK1   P00558 44,597.30 3 11.8%  no 
55 Apolipoprotein E  GN=APOE   P02649 36,135.50 3 11.0% yes  
56 Serum amyloid P-component  GN=APCS   P02743 25,369.70 3 12.6% yes  
57 Leucine-rich alpha-2-glycoprotein  GN=LRG1   P02750 38,161.70 3 8.07% yes  
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58 Retinol-binding protein 4  GN=RBP4   P02753 22,992.30 3 15.4% yes  
59 Glucose-6-phosphate isomerase  GN=GPI   P06744 63,130.40 3 6.63%  no 
60 Monocyte differentiation antigen CD14  GN=CD14   P08571 40,058.60 3 12.5% yes  
61 Thioredoxin  GN=TXN   P10599 11,719.30 3 32.4%  no 
62 Fumarylacetoacetase  GN=FAH   P16930 46,357.60 3 8.59%  0.582 
63 Glycine amidinotransferase, mitochondrial  GN=GATM   P50440 48,438.60 3 6.38%  0.699 
64 10 kDa heat shock protein, mitochondrial  GN=HSPE1   P61604 10,913.70 3 19.6%  0.57 
65 Beta-2-microglobulin  GN=B2M   P61769 13,696.90 3 21.8% yes  
66 Neutrophil gelatinase-associated lipocalin  GN=LCN2   P80188 22,570.90 3 21.7% yes  
67 4-aminobutyrate aminotransferase, mitochondrial  GN=ABAT   P80404 56,422.80 3 6.4%  0.575 
68 Inter-alpha-trypsin inhibitor heavy chain H3  GN=ITIH3   Q06033 99,832.90 3 3.71% yes  
69 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial  GN=ECH1   Q13011 35,798.20 3 12.2%  0.696 
70 Selenium-binding protein 1  GN=SELENBP1   Q13228 52,374.00 3 6.36%  no 
71 Thioredoxin domain-containing protein 5  GN=TXNDC5   Q8NBS9 47,611.10 3 9.49% yes  
72 Isocitrate dehydrogenase [NADP] cytoplasmic  GN=IDH1   O75874 46,642.50 2 5.31%  0.547 
73 Cytochrome b5  GN=CYB5A   P00167 15,312.30 2 20.1%  0.567 
74 Alcohol dehydrogenase 1C  GN=ADH1C   P00326 39,849.60 2 4.27%  no 
75 Retinal dehydrogenase 1  GN=ALDH1A1   P00352 54,844.80 2 4.59%  0.501 
76 Ornithine carbamoyltransferase, mitochondrial  GN=OTC   P00480 39,919.00 2 6.78%  no 
77 Prothrombin  GN=F2   P00734 70,018.80 2 3.54% yes  
78 Plasminogen  GN=PLG   P00747 90,549.40 2 3.58% yes  
79 Coagulation factor XII  GN=F12   P00748 67,772.60 2 4.39% yes  
80 Metalloproteinase inhibitor 1  GN=TIMP1   P01033 23,153.10 2 11.1% yes  
81 Kininogen-1  GN=KNG1   P01042 71,939.60 2 3.11% yes  
82 Polymeric immunoglobulin receptor  GN=PIGR   P01833 83,265.40 2 3.93% yes  
83 Argininosuccinate lyase  GN=ASL   P04424 51,641.00 2 6.68%  no 
84 Complement C2  GN=C2   P06681 83,250.80 2 2.66% yes  
85 Apolipoprotein A-IV  GN=APOA4   P06727 45,381.30 2 5.3% yes  
86 Beta-glucuronidase  GN=GUSB   P08236 74,714.70 2 2.61% yes  
87 Mannose-binding protein C  GN=MBL2   P11226 26,126.10 2 6.85% yes  
88 Delta-aminolevulinic acid dehydratase  GN=ALAD   P13716 36,277.30 2 6.06%  0.637 
89 Inter-alpha-trypsin inhibitor heavy chain H1  GN=ITIH1   P19827 101,371.80 2 3.29% yes  
90 Insulin-like growth factor-binding protein 4  GN=IGFBP4   P22692 27,915.70 2 11.2% yes  
91 Zinc-alpha-2-glycoprotein  GN=AZGP1   P25311 34,240.60 2 8.05% yes  
92 Moesin  GN=MSN   P26038 67,803.80 2 3.29%  0.53 
93 D-dopachrome decarboxylase  GN=DDT   P30046 12,694.20 2 19.5%  no 
94 4-hydroxyphenylpyruvate dioxygenase  GN=HPD   P32754 44,916.90 2 8.4%  0.517 
95 Phosphoglucomutase-1  GN=PGM1   P36871 61,433.00 2 4.27%  no 
96 Aldo-keto reductase family 1 member C2  GN=AKR1C2   P52895 36,717.90 2 8.36%  no 
97 Glutathione S-transferase omega-1  GN=GSTO1   P78417 27,549.20 2 9.96%  no 
98 Complement factor H-related protein 1  GN=CFHR1   Q03591 37,632.40 2 12.4% yes  
99 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial  GN=HIBCH   Q6NVY1 43,466.00 2 4.15%  0.549 
100 Gamma-glutamyl hydrolase  GN=GGH   Q92820 35,947.90 2 8.49% yes  
101 Ester hydrolase C11orf54  GN=C11orf54   Q9H0W9 35,099.70 2 6.67%  no 
102 Dimethylglycine dehydrogenase, mitochondrial  GN=DMGDH   Q9UI17 96,794.90 2 3.46% yes  
103 Alpha-actinin-4  GN=ACTN4   O43707 104,839.20 1 0.988%  no 
104 GDH/6PGL endoplasmic bifunctional protein  GN=H6PD   O95479 88,875.60 1 1.52% yes  
105 Glutathione reductase, mitochondrial  GN=GSR   P00390 56,239.40 1 2.3%  0.54 
106 Superoxide dismutase [Cu-Zn]  GN=SOD1   P00441 15,917.30 1 9.09%  0.648 
107 Purine nucleoside phosphorylase  GN=PNP   P00491 32,100.00 1 5.19%  0.509 
108 Complement component C9  GN=C9   P02748 63,156.80 1 2.15% yes  
109 Tissue alpha-L-fucosidase  GN=FUCA1   P04066 53,671.90 1 2.36% yes  
110 Proactivator polypeptide  GN=PSAP   P07602 58,094.00 1 2.1% yes  
111 Cathepsin L1  GN=CTSL1   P07711 37,546.10 1 3.6% yes  
112 Corticosteroid-binding globulin  GN=SERPINA6   P08185 45,124.10 1 3.21% yes  
113 Alpha-2-antiplasmin  GN=SERPINF2   P08697 54,548.60 1 1.83% yes  
114 60 kDa heat shock protein, mitochondrial  GN=HSPD1   P10809 61,037.70 1 3.14%  no 
115 Lysosome-associated membrane glycoprotein 2  GN=LAMP2   P13473 44,942.90 1 1.95% yes  
116 Phosphoglycerate mutase 1  GN=PGAM1   P18669 28,786.80 1 4.33%  no 
117 Alpha-1-acid glycoprotein 2  GN=ORM2   P19652 23,585.20 1 13.4% yes  
118 14-3-3 protein theta  GN=YWHAQ   P27348 27,747.40 1 3.67%  no 
119 Cystathionine gamma-lyase  GN=CTH   P32929 44,490.50 1 3.46%  0.526 
120 Serine hydroxymethyltransferase, cytosolic  GN=SHMT1   P34896 53,065.80 1 2.28%  no 
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121 Transaldolase  GN=TALDO1   P37837 37,523.70 1 3.56%  no 
122 Malate dehydrogenase, cytoplasmic  GN=MDH1   P40925 36,408.90 1 3.59%  no 
123 3-hydroxyanthranilate 3,4-dioxygenase  GN=HAAO   P46952 32,538.20 1 3.5%  no 
124 Ribonuclease UK114  GN=HRSP12   P52758 14,476.10 1 11.7%  0.714 
125 Calmodulin  GN=CALM1   P62158 16,820.00 1 11.4%  0.676 
126 Peptidyl-prolyl cis-trans isomerase A  GN=PPIA   P62937 17,994.90 1 8.48%  no 
127 Aldehyde oxidase  GN=AOX1   Q06278 147,902.70 1 0.822%  no 
128 Enoyl-CoA hydratase domain-containing protein 2, mitochondrial  GN=ECHDC2   Q86YB7 31,108.70 1 5.14% yes  
129 Betaine--homocysteine S-methyltransferase 1  GN=BHMT   Q93088 44,980.60 1 4.19%  no 
130 N-acetylmuramoyl-L-alanine amidase  GN=PGLYRP2   Q96PD5 62,199.90 1 2.6% yes  
131 Phospholysine phosphohistidine inorganic pyrophosphate phosphatase  GN=LHPP   Q9H008 29,147.40 1 4.44%  no 
132 Cathepsin Z  GN=CTSZ   Q9UBR2 33,850.20 1 3.3%  0.861 
133 Phosphoserine aminotransferase  GN=PSAT1   Q9Y617 40,405.30 1 2.43%  no 
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Table III. Identified proteins in the conditioned medium of PHH in bioreactor culture during phase II (day 7-10) 
using LC-MALDI. Gene name (GN), Swiss-Prot Accesion number (Acc. no.), identified peptides (Pep), sequence 
coverage (Seq. cov.), signal peptide (SP), SecretomeP prediction status (SecP) 
No. Protein name Acc. no. MW [Da] Pep Seq. cov. SP SecP 
1 Complement C3  GN=C3   P01024 187,131.10 33 24.4% yes  
2 Complement factor H  GN=CFH   P08603 139,078.20 19 19.3% yes  
3 Ceruloplasmin  GN=CP   P00450 122,189.90 15 17.5% yes  
4 Alpha-2-macroglobulin  GN=A2M   P01023 163,271.90 13 10.8% yes  
5 Alpha-1-antichymotrypsin  GN=SERPINA3   P01011 47,634.90 12 27.4% yes  
6 Protein AMBP  GN=AMBP   P02760 38,981.50 12 38.1% yes  
7 Complement C4-A  GN=C4A   P0C0L4 192,754.80 12 7.68% yes  
8 Alpha-actinin-4  GN=ACTN4   O43707 104,839.20 11 14.5%  no 
9 Complement factor B  GN=CFB   P00751 85,515.20 11 16.1% yes  
10 Vitamin D-binding protein  GN=GC   P02774 52,946.60 11 32.7% yes  
11 Moesin  GN=MSN   P26038 67,803.80 11 13.7%  0.53 
12 Apolipoprotein E  GN=APOE   P02649 36,135.50 10 27.8% yes  
13 Fibronectin  GN=FN1   P02751 262,598.90 9 4.15% yes  
14 Alpha-enolase  GN=ENO1   P06733 47,152.20 9 26.3%  0.536 
15 Aspartate aminotransferase, cytoplasmic  GN=GOT1   P17174 46,230.10 9 23.2%  no 
16 Liver carboxylesterase 1  GN=CES1   P23141 62,504.40 9 19.2% yes  
17 Triosephosphate isomerase  GN=TPI1   P60174 26,651.10 9 48.2%  0.51 
18 Aldo-keto reductase family 1 member C1  GN=AKR1C1   Q04828 36,771.10 9 28.2%  no 
19 Isocitrate dehydrogenase [NADP] cytoplasmic  GN=IDH1   O75874 46,642.50 8 18.1%  0.547 
20 Retinal dehydrogenase 1  GN=ALDH1A1   P00352 54,844.80 8 23.4%  0.501 
21 Hemopexin  GN=HPX   P02790 51,658.50 8 21.9% yes  
22 Heat shock cognate 71 kDa protein  GN=HSPA8   P11142 70,881.80 8 17.2%  no 
23 Actin, cytoplasmic 1  GN=ACTB   P60709 41,719.80 8 25.9%  no 
24 Aldo-keto reductase family 1 member B10  GN=AKR1B10   O60218 36,003.40 7 26.9%  no 
25 Alcohol dehydrogenase 1C  GN=ADH1C   P00326 39,849.60 7 18.4%  no 
26 Glutamate dehydrogenase 1, mitochondrial  GN=GLUD1   P00367 61,381.70 7 16.3%  no 
27 Alpha-1-acid glycoprotein 1  GN=ORM1   P02763 23,494.10 7 38.8% yes  
28 Complement C1s subcomponent  GN=C1S   P09871 76,666.20 7 12.6% yes  
29 Phosphatidylethanolamine-binding protein 1  GN=PEBP1   P30086 21,038.90 7 48.1%  0.672 
30 Protein disulfide-isomerase A3  GN=PDIA3   P30101 56,766.60 7 16.6% yes  
31 Aminoacylase-1  GN=ACY1   Q03154 45,866.30 7 18.9%  no 
32 Complement C1r subcomponent  GN=C1R   P00736 80,101.60 6 10.2% yes  
33 Fibrinogen gamma chain  GN=FGG   P02679 51,495.30 6 15.2% yes  
34 Beta-2-glycoprotein 1  GN=APOH   P02749 38,280.50 6 24.6% yes  
35 Catalase  GN=CAT   P04040 59,738.50 6 13.3%  no 
36 Superoxide dismutase [Mn], mitochondrial  GN=SOD2   P04179 24,704.60 6 30.2% yes  
37 Histidine-rich glycoprotein  GN=HRG   P04196 59,558.60 6 11.8% yes  
38 Glucose-6-phosphate isomerase  GN=GPI   P06744 63,130.40 6 12.2%  no 
39 Glutathione S-transferase A2  GN=GSTA2   P09210 25,647.90 6 18.0%  no 
40 Inter-alpha-trypsin inhibitor heavy chain H2  GN=ITIH2   P19823 106,447.50 6 5.6% yes  
41 1,4-alpha-glucan-branching enzyme  GN=GBE1   Q04446 80,444.90 6 9.26%  no 
42 Argininosuccinate synthase  GN=ASS1   P00966 46,513.30 5 9.95%  no 
43 Antithrombin-III  GN=SERPINC1   P01008 52,586.00 5 13.6% yes  
44 Kininogen-1  GN=KNG1   P01042 71,939.60 5 6.83% yes  
45 Apolipoprotein A-I  GN=APOA1   P02647 30,760.50 5 20.6% yes  
46 Fibrinogen alpha chain  GN=FGA   P02671 94,955.40 5 9.01% yes  
47 Fibrinogen beta chain  GN=FGB   P02675 55,910.60 5 10.8% yes  
48 Serotransferrin  GN=TF   P02787 77,046.30 5 9.03% yes  
49 Apolipoprotein B-100  GN=APOB   P04114 515,596.80 5 1.49% yes  
50 Fructose-bisphosphate aldolase B  GN=ALDOB   P05062 39,455.30 5 20.1%  no 
51 Fatty acid-binding protein, liver  GN=FABP1   P07148 14,190.70 5 41.7%  no 
52 Pigment epithelium-derived factor  GN=SERPINF1   P36955 46,296.30 5 13.4% yes  
53 L-lactate dehydrogenase A chain  GN=LDHA   P00338 36,671.20 4 11.7%  0.549 
54 Retinol-binding protein 4  GN=RBP4   P02753 22,992.30 4 20.9% yes  
55 Keratin, type II cytoskeletal 1  GN=KRT1   P04264 66,022.30 4 10.4%  no 
56 Plasma protease C1 inhibitor  GN=SERPING1   P05155 55,137.50 4 9.2% yes  
57 Complement factor I  GN=CFI   P05156 65,731.80 4 9.78% yes  
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58 Proactivator polypeptide  GN=PSAP   P07602 58,094.00 4 7.63% yes  
59 Cathepsin B  GN=CTSB   P07858 37,803.20 4 18.3% yes  
60 Heat shock 70 kDa protein 1A/1B  GN=HSPA1A   P08107 70,036.00 4 8.89%  no 
61 Monocyte differentiation antigen CD14  GN=CD14   P08571 40,058.60 4 14.9% yes  
62 Thioredoxin  GN=TXN   P10599 11,719.30 4 41.0%  no 
63 Alcohol dehydrogenase [NADP+]  GN=AKR1A1   P14550 36,555.60 4 16.3%  no 
64 Zinc-alpha-2-glycoprotein  GN=AZGP1   P25311 34,240.60 4 15.4% yes  
65 4-hydroxyphenylpyruvate dioxygenase  GN=HPD   P32754 44,916.90 4 10.4%  0.517 
66 Peptidyl-prolyl cis-trans isomerase A  GN=PPIA   P62937 17,994.90 4 24.2%  no 
67 14-3-3 protein zeta/delta  GN=YWHAZ   P63104 27,727.90 4 13.9%  no 
68 Peroxiredoxin-1  GN=PRDX1   Q06830 22,092.90 4 26.1%  0.528 
69 Phosphoglycerate kinase 1  GN=PGK1   P00558 44,597.30 3 12.0%  no 
70 Prothrombin  GN=F2   P00734 70,018.80 3 5.14% yes  
71 Plasminogen  GN=PLG   P00747 90,549.40 3 4.81% yes  
72 Metalloproteinase inhibitor 1  GN=TIMP1   P01033 23,153.10 3 20.3% yes  
73 Prelamin-A/C  GN=LMNA   P02545 74,122.60 3 4.82%  no 
74 Leucine-rich alpha-2-glycoprotein  GN=LRG1   P02750 38,161.70 3 8.93% yes  
75 Metallothionein-2  GN=MT2A   P02795 6,023.60 3 34.4%  0.856 
76 Alpha-1B-glycoprotein  GN=A1BG   P04217 54,235.30 3 5.45% yes  
77 Argininosuccinate lyase  GN=ASL   P04424 51,641.00 3 9.7%  no 
78 Keratin, type I cytoskeletal 18  GN=KRT18   P05783 48,041.00 3 7.44%  0.725 
79 Protein disulfide-isomerase  GN=P4HB   P07237 57,100.10 3 7.09% yes  
80 Cathepsin D  GN=CTSD   P07339 44,535.00 3 6.31% yes  
81 Fructose-1,6-bisphosphatase 1  GN=FBP1   P09467 36,825.20 3 10.7%  0.515 
82 Delta-aminolevulinic acid dehydratase  GN=ALAD   P13716 36,277.30 3 11.8%  0.637 
83 Nucleoside diphosphate kinase A  GN=NME1   P15531 17,130.70 3 25.7%  no 
84 Fumarylacetoacetase  GN=FAH   P16930 46,357.60 3 9.07%  0.582 
85 Serine--pyruvate aminotransferase  GN=AGXT   P21549 42,993.40 3 9.69%  0.747 
86 Insulin-like growth factor-binding protein 4  GN=IGFBP4   P22692 27,915.70 3 11.2% yes  
87 Calreticulin  GN=CALR   P27797 48,124.90 3 9.59% yes  
88 Transketolase  GN=TKT   P29401 67,861.40 3 8.51%  no 
89 Endoplasmic reticulum resident protein 29  GN=ERP29   P30040 28,976.90 3 11.1% yes  
90 Peroxiredoxin-6  GN=PRDX6   P30041 25,018.10 3 15.2%  no 
91 Serine hydroxymethyltransferase, cytosolic  GN=SHMT1   P34896 53,065.80 3 7.87%  no 
92 Chitinase-3-like protein 1  GN=CHI3L1   P36222 42,609.00 3 12.5% yes  
93 Rho GDP-dissociation inhibitor 1  GN=ARHGDIA   P52565 23,189.50 3 18.6%  no 
94 10 kDa heat shock protein, mitochondrial  GN=HSPE1   P61604 10,913.70 3 19.6%  0.57 
95 Beta-2-microglobulin  GN=B2M   P61769 13,696.90 3 21.8% yes  
96 Glutathione S-transferase omega-1  GN=GSTO1   P78417 27,549.20 3 13.3%  no 
97 Nucleobindin-1  GN=NUCB1   Q02818 53,861.60 3 9.54% yes  
98 Complement factor H-related protein 1  GN=CFHR1   Q03591 37,632.40 3 13.9% yes  
99 Inter-alpha-trypsin inhibitor heavy chain H3  GN=ITIH3   Q06033 99,832.90 3 4.38% yes  
100 Selenium-binding protein 1  GN=SELENBP1   Q13228 52,374.00 3 6.36%  no 
101 Spectrin alpha chain, brain  GN=SPTAN1   Q13813 284,524.70 3 1.74%  no 
102 Betaine--homocysteine S-methyltransferase 1  GN=BHMT   Q93088 44,980.60 3 10.1%  no 
103 Cathepsin Z  GN=CTSZ   Q9UBR2 33,850.20 3 12.2% yes  
104 Carboxylesterase 2  GN=CES2   O00748 61,789.30 2 3.4% yes  
105 Cytochrome b5  GN=CYB5A   P00167 15,312.30 2 25.4%  0.567 
106 Alcohol dehydrogenase 1B  GN=ADH1B   P00325 39,836.30 2 18.4%  no 
107 Superoxide dismutase [Cu-Zn]  GN=SOD1   P00441 15,917.30 2 13.6%  0.648 
108 Ornithine carbamoyltransferase, mitochondrial  GN=OTC   P00480 39,919.00 2 7.91%  no 
109 Aspartate aminotransferase, mitochondrial  GN=GOT2   P00505 47,500.60 2 5.12%  0.505 
110 Coagulation factor XII  GN=F12   P00748 67,772.60 2 4.39% yes  
111 Alpha-1-antitrypsin  GN=SERPINA1   P01009 46,719.90 2 5.26% yes  
112 Angiotensinogen  GN=AGT   P01019 53,136.80 2 4.54% yes  
113 Polymeric immunoglobulin receptor  GN=PIGR   P01833 83,265.40 2 2.75% yes  
114 Hemoglobin subunit delta  GN=HBD   P02042 16,037.10 2 12.9%  no 
115 Apolipoprotein C-III  GN=APOC3   P02656 10,834.30 2 27.3% yes  
116 Serum amyloid A protein  GN=SAA1   P02735 13,514.50 2 27.9% yes  
117 Heat shock protein beta-1  GN=HSPB1   P04792 22,764.60 2 12.7%  0.74 
118 Plasminogen activator inhibitor 1  GN=SERPINE1   P05121 45,042.20 2 4.23% yes  
119 Intercellular adhesion molecule 1  GN=ICAM1   P05362 57,806.50 2 4.32% yes  
120 Complement C2  GN=C2   P06681 83,250.80 2 3.19% yes  
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121 Apolipoprotein A-IV  GN=APOA4   P06727 45,381.30 2 5.3% yes  
122 Beta-hexosaminidase subunit alpha  GN=HEXA   P06865 60,686.00 2 4.16% yes  
123 Acyl-CoA-binding protein  GN=DBI   P07108 10,026.80 2 32.2%  0.553 
124 Profilin-1  GN=PFN1   P07737 15,036.30 2 16.4%  no 
125 Beta-glucuronidase  GN=GUSB   P08236 74,714.70 2 2.61% yes  
126 Alcohol dehydrogenase 4  GN=ADH4   P08319 40,204.80 2 5.53%  0.532 
127 Alpha-2-antiplasmin  GN=SERPINF2   P08697 54,548.60 2 4.07% yes  
128 Galectin-1  GN=LGALS1   P09382 14,697.80 2 16.3%  no 
129 Clusterin  GN=CLU   P10909 52,476.90 2 4.45% yes  
130 Alpha-actinin-1  GN=ACTN1   P12814 103,043.00 2 10.2%  no 
131 Xaa-Pro dipeptidase  GN=PEPD   P12955 54,529.70 2 5.27%  no 
132 Farnesyl pyrophosphate synthase  GN=FDPS   P14324 48,258.70 2 5.49% yes  
133 Aminopeptidase N  GN=ANPEP   P15144 109,524.40 2 1.76% yes  
134 Aldo-keto reductase family 1 member C4  GN=AKR1C4   P17516 37,049.40 2 13.0%  no 
135 Phosphoglycerate mutase 1  GN=PGAM1   P18669 28,786.80 2 11.4%  no 
136 Inter-alpha-trypsin inhibitor heavy chain H1  GN=ITIH1   P19827 101,371.80 2 2.74% yes  
137 Peptidyl-prolyl cis-trans isomerase B  GN=PPIB   P23284 23,725.20 2 8.8% yes  
138 D-dopachrome decarboxylase  GN=DDT   P30046 12,694.20 2 19.5%  no 
139 UMP-CMP kinase  GN=CMPK1   P30085 22,205.00 2 10.7%  0.604 
140 Transaldolase  GN=TALDO1   P37837 37,523.70 2 7.42%  no 
141 Malate dehydrogenase, cytoplasmic  GN=MDH1   P40925 36,408.90 2 5.99%  no 
142 Aldo-keto reductase family 1 member C3  GN=AKR1C3   P42330 36,836.10 2 25.7%  0.709 
143 3-hydroxyanthranilate 3,4-dioxygenase  GN=HAAO   P46952 32,538.20 2 5.94%  no 
144 NADP-dependent malic enzyme  GN=ME1   P48163 64,133.40 2 3.5%  no 
145 14-3-3 protein gamma  GN=YWHAG   P61981 28,285.10 2 13.8%  no 
146 Calmodulin  GN=CALM1   P62158 16,820.00 2 16.8%  0.676 
147 Histone H4  GN=HIST1H4A   P62805 11,349.70 2 17.5%  no 
148 Quinone oxidoreductase  GN=CRYZ   Q08257 35,189.30 2 7.6%  0.511 
149 Insulin-like growth factor-binding protein 7  GN=IGFBP7   Q16270 29,111.80 2 12.4% yes  
150 Thioredoxin domain-containing protein 5  GN=TXNDC5   Q8NBS9 47,611.10 2 7.41% yes  
151 Ester hydrolase C11orf54  GN=C11orf54   Q9H0W9 35,099.70 2 6.67%  no 
152 Omega-amidase NIT2  GN=NIT2   Q9NQR4 30,590.80 2 11.6%  0.663 
153 Ribosome-binding protein 1  GN=RRBP1   Q9P2E9 152,452.50 2 2.48%  no 
154 Phosphoserine aminotransferase  GN=PSAT1   Q9Y617 40,405.30 2 5.14%  no 
155 Membrane-associated progesterone receptor component 1  GN=PGRMC1   O00264 21,654.20 1 10.3%  no 
156 Agrin  GN=AGRN   O00468 214,820.00 1 0.7% yes  
157 Pirin  GN=PIR   O00625 32,095.70 1 4.48%   
158 Pantetheinase  GN=VNN1   O95497 56,994.30 1 2.92% yes  
159 Glutathione reductase, mitochondrial  GN=GSR   P00390 56,239.40 1 2.3%  0.54 
160 Carbonic anhydrase 2  GN=CA2   P00918 29,228.60 1 3.46%  no 
161 Complement C5  GN=C5   P01031 188,291.20 1 1.01% yes  
162 Insulin-like growth factor II  GN=IGF2   P01344 20,122.80 1 5.0% yes  
163 Apolipoprotein A-II  GN=APOA2   P02652 11,157.20 1 9.0% yes  
164 Serum amyloid P-component  GN=APCS   P02743 25,369.70 1 5.83% yes  
165 Complement component C9  GN=C9   P02748 63,156.80 1 2.15% yes  
166 Alpha-2-HS-glycoprotein  GN=AHSG   P02765 39,305.40 1 5.72% yes  
167 Transthyretin  GN=TTR   P02766 15,868.90 1 9.52% yes  
168 Ferritin light chain  GN=FTL   P02792 20,002.60 1 8.57%  no 
169 Vitronectin  GN=VTN   P04004 54,288.10 1 3.14% yes  
170 Tissue alpha-L-fucosidase  GN=FUCA1   P04066 53,671.90 1 2.36% yes  
171 Cystatin-B  GN=CSTB   P04080 11,121.30 1 12.2%  no 
172 Histone H2A type 1-B/E  GN=HIST1H2AB   P04908 14,118.00 1 6.92%  0.536 
173 Heparin cofactor 2  GN=SERPIND1   P05546 57,054.90 1 1.4% yes  
174 Complement component C8 gamma chain  GN=C8G   P07360 22,259.30 1 7.43% yes  
175 Beta-hexosaminidase subunit beta  GN=HEXB   P07686 63,095.30 1 1.98% yes  
176 Cathepsin L1  GN=CTSL1   P07711 37,546.10 1 3.6% yes  
177 Thrombospondin-1  GN=THBS1   P07996 129,363.70 1 1.03% yes  
178 Ribonuclease pancreatic  GN=RNASE1   P07998 17,625.80 1 4.49% yes  
179 Heme oxygenase 1  GN=HMOX1   P09601 32,801.10 1 5.56%  0.526 
180 Tissue factor pathway inhibitor  GN=TFPI   P10646 34,998.10 1 5.26% yes  
181 Laminin subunit gamma-1  GN=LAMC1   P11047 177,583.30 1 1.37% yes  
182 Gamma-interferon-inducible lysosomal thiol reductase  GN=IFI30   P13284 29,131.20 1 4.21% yes  
183 Lysosome-associated membrane glycoprotein 2  GN=LAMP2   P13473 44,942.90 1 1.95% yes  
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184 Translationally-controlled tumor protein  GN=TPT1   P13693 19,578.20 1 5.81%  0.581 
185 Plastin-2  GN=LCP1   P13796 70,273.20 1 1.44%  0.502 
186 CD59 glycoprotein  GN=CD59   P13987 14,159.20 1 9.38% yes  
187 Macrophage migration inhibitory factor  GN=MIF   P14174 12,458.50 1 7.83%  0.776 
188 Arylsulfatase A  GN=ARSA   P15289 53,571.20 1 2.76% yes  
189 Ezrin  GN=EZR   P15311 69,396.60 1 6.31%  0.563 
190 Ribosyldihydronicotinamide dehydrogenase [quinone]  GN=NQO2   P16083 25,900.80 1 7.79%  no 
191 Insulin-like growth factor-binding protein 2  GN=IGFBP2   P18065 34,795.60 1 7.08% yes  
192 Vinculin  GN=VCL   P18206 123,783.20 1 0.882%  no 
193 Syndecan-1  GN=SDC1   P18827 32,443.40 1 5.48% yes  
194 Alpha-1-acid glycoprotein 2  GN=ORM2   P19652 23,585.20 1 17.4% yes  
195 Nucleoside diphosphate kinase B  GN=NME2   P22392 17,280.20 1 25.7%  no 
196 Heterogeneous nuclear ribonucleoproteins A2/B1  GN=HNRNPA2B1   P22626 37,412.30 1 3.4%  no 
197 Cofilin-1  GN=CFL1   P23528 18,485.10 1 8.43%  0.628 
198 Cathepsin S  GN=CTSS   P25774 37,477.60 1 2.42% yes  
199 Peptidyl-prolyl cis-trans isomerase FKBP2  GN=FKBP2   P26885 15,631.60 1 8.45% yes  
200 14-3-3 protein theta  GN=YWHAQ   P27348 27,747.40 1 13.9%  no 
201 Flavin reductase  GN=BLVRB   P30043 22,100.70 1 7.28%  0.834 
202 Leukocyte elastase inhibitor  GN=SERPINB1   P30740 42,725.80 1 2.37%  0.516 
203 14-3-3 protein beta/alpha  GN=YWHAB   P31946 28,065.10 1 13.8%  no 
204 Cystathionine gamma-lyase  GN=CTH   P32929 44,490.50 1 3.46%  0.526 
205 Ribonuclease 4  GN=RNASE4   P34096 16,822.40 1 8.84% yes  
206 Serpin B6  GN=SERPINB6   P35237 42,604.80 1 3.99%  no 
207 Radixin  GN=RDX   P35241 68,547.50 1 8.06%  no 
208 Phosphoglucomutase-1  GN=PGM1   P36871 61,433.00 1 2.67%  no 
209 
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial  GN=DLST   P36957 48,737.20 1 2.43%  0.634 
210 Malate dehydrogenase, mitochondrial  GN=MDH2   P40926 35,485.70 1 3.55%  0.644 
211 Nicotinamide phosphoribosyltransferase  GN=NAMPT   P43490 55,504.50 1 1.43%  no 
212 Proteasome subunit beta type-2  GN=PSMB2   P49721 22,819.50 1 7.46%  no 
213 Rab GDP dissociation inhibitor beta  GN=GDI2   P50395 50,647.50 1 4.27%  no 
214 Aldo-keto reductase family 1 member C2  GN=AKR1C2   P52895 36,717.90 1 22.6%  no 
215 Nck-associated protein 1-like  GN=NCKAP1L   P55160 128,140.30 1 0.71%  0.552 
216 Galectin-4  GN=LGALS4   P56470 35,923.30 1 4.33%  no 
217 Actin-related protein 2/3 complex subunit 4  GN=ARPC4   P59998 19,649.40 1 4.76%  0.646 
218 Proteasome subunit alpha type-6  GN=PSMA6   P60900 27,381.50 1 4.07%  no 
219 Epididymal secretory protein E1  GN=NPC2   P61916 16,552.00 1 10.6% yes  
220 14-3-3 protein epsilon  GN=YWHAE   P62258 29,157.00 1 8.24%  no 
221 Nuclease-sensitive element-binding protein 1  GN=YBX1   P67809 35,905.70 1 3.7%  0.733 
222 Hemoglobin subunit alpha  GN=HBA1   P69905 15,239.60 1 10.6%  no 
223 Neutrophil gelatinase-associated lipocalin  GN=LCN2   P80188 22,570.90 1 7.58% yes  
224 Spectrin beta chain, brain 1  GN=SPTBN1   Q01082 274,595.40 1 0.338%  no 
225 14-3-3 protein eta  GN=YWHAH   Q04917 28,201.60 1 8.13%  no 
226 Aldehyde oxidase  GN=AOX1   Q06278 147,902.70 1 0.822%  no 
227 Bile salt sulfotransferase  GN=SULT2A1   Q06520 33,763.30 1 3.51%  0.538 
228 Galectin-3-binding protein  GN=LGALS3BP   Q08380 65,314.10 1 2.74% yes  
229 Fibrinogen-like protein 1  GN=FGL1   Q08830 36,361.90 1 3.53% yes  
230 Nicotinate-nucleotide pyrophosphorylase [carboxylating]  GN=QPRT   Q15274 30,827.30 1 4.04% yes  
231 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial  GN=HADH   Q16836 34,276.10 1 2.87%  no 
232 Coiled-coil domain-containing protein 96  GN=CCDC96   Q2M329 62,693.30 1 2.88%  0.622 
233 Beta-lactamase-like protein 2  GN=LACTB2   Q53H82 32,788.70 1 3.12%  no 
234 RUN domain-containing protein 3A  GN=RUNDC3A   Q59EK9 49,730.60 1 1.57%  no 
235 Protein Smaug homolog 2  GN=SAMD4B   Q5PRF9 75,466.60 1 2.16%  no 
236 Enoyl-CoA hydratase domain-containing protein 2, mitochondrial  GN=ECHDC2   Q86YB7 31,108.70 1 5.14% yes  
237 Uncharacterized protein KIAA0528  GN=KIAA0528   Q86YS7 110,430.70 1 0.7%  no 
238 Hornerin  GN=HRNR   Q86YZ3 282,354.70 1 0.667%  no 
239 Serine protease HTRA1  GN=HTRA1   Q92743 51,269.30 1 2.5% yes  
240 Protein DJ-1  GN=PARK7   Q99497 19,873.10 1 6.88%  no 
241 Retinoic acid receptor responder protein 2  GN=RARRES2   Q99969 18,599.30 1 7.36% yes  
242 Phospholysine phosphohistidine inorganic pyrophosphate phosphatase  GN=LHPP   Q9H008 29,147.40 1 4.44%  no 
243 SH3 domain-binding glutamic acid-rich-like protein 3  GN=SH3BGRL3   Q9H299 10,419.80 1 16.1%  0.768 
244 Interferon kappa  GN=IFNK   Q9P0W0 25,201.40 1 4.83% yes  
245 Peroxisomal sarcosine oxidase  GN=PIPOX   Q9P0Z9 44,049.10 1 3.59%  0.534 
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246 Beta-ureidopropionase  GN=UPB1   Q9UBR1 43,148.10 1 4.69%  0.539 
247 Protein canopy homolog 2  GN=CNPY2   Q9Y2B0 20,634.50 1 5.49% yes  
248 Heme-binding protein 2  GN=HEBP2   Q9Y5Z4 22,857.70 1 7.32%  0.793 
249 Junctional adhesion molecule A  GN=F11R   Q9Y624 32,565.10 1 3.68% yes  
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Table IV. Identified proteins in the conditioned medium of PHH in monolayer culture after 96h. Shown are 
proteins identified after merging the mascot search results of analyses on three different LC-MS systems (LC-
MALDI, LC-ESI ion trap and LC-ESI QTOF). Gene name (GN), Swiss-Prot Accesion number (Acc. no.), identified 
peptides (Pep), sequence coverage (Seq. cov.) 
No. Protein name Acc. no. MW [Da] pep seq. cov.  
1 Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 P01024 187,131.10 43 28.30% 
2 Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=1 P0C0L4 192,776.80 17 11.00% 
3 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 P60709 41,719.80 14 34.10% 
4 Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 P02649 36,135.50 14 45.40% 
5 Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2 P00751 85,515.20 12 16.40% 
6 Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 P02774 52,946.60 12 28.10% 
7 Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 P02760 38,981.50 12 39.20% 
8 Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 P02751 262,598.90 12 7.00% 
9 Complement C1s subcomponent OS=Homo sapiens GN=C1S PE=1 SV=1 P09871 76,666.20 12 17.60% 
10 Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 P06727 45,381.30 10 27.00% 
11 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 P10909 52,476.90 10 25.60% 
12 Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 P00450 122,189.90 10 10.50% 
13 Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 P02647 30,760.50 10 36.30% 
14 Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 P01011 47,634.90 9 22.90% 
15 Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 P01009 46,719.90 9 21.80% 
16 Plasminogen activator inhibitor 1 OS=Homo sapiens GN=SERPINE1 PE=1 SV=1 P05121 45,042.20 7 15.20% 
17 Alcohol dehydrogenase 1B OS=Homo sapiens GN=ADH1B PE=1 SV=2 P00325 39,836.30 7 21.30% 
18 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 P01023 163,271.90 7 6.92% 
19 Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1 SV=3 P02749 38,280.50 7 20.00% 
20 Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 P08603 139,078.20 7 6.66% 
21 Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 P06733 47,152.20 6 16.40% 
22 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 P04004 54,288.10 6 13.20% 
23 Glutamate dehydrogenase 1, mitochondrial OS=Homo sapiens GN=GLUD1 PE=1 SV=2 P00367 61,381.70 5 10.60% 
24 Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 P04114 515,596.80 5 1.34% 
25 Insulin-like growth factor-binding protein 2 OS=Homo sapiens GN=IGFBP2 PE=1 SV=2 P18065 34,795.60 5 22.20% 
26 Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 P00738 45,186.90 5 14.50% 
27 Complement C1r subcomponent OS=Homo sapiens GN=C1R PE=1 SV=2 P00736 80,101.60 5 8.65% 
28 Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 P00734 70,018.80 5 12.70% 
29 Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 P01042 71,939.60 5 7.30% 
30 Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 P02765 39,305.40 5 16.90% 
31 Fructose-bisphosphate aldolase B OS=Homo sapiens GN=ALDOB PE=1 SV=2 P05062 39,455.30 5 20.30% 
32 Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3 P49327 273,409.10 5 2.35% 
33 Fatty acid-binding protein, liver OS=Homo sapiens GN=FABP1 PE=1 SV=1 P07148 14,190.70 5 37.80% 
34 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=2 P60174 26,651.10 5 24.90% 
35 Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2 P19823 106,447.50 5 5.50% 
36 Aspartate aminotransferase, cytoplasmic OS=Homo sapiens GN=GOT1 PE=1 SV=3 P17174 46,230.10 5 14.00% 
37 Pigment epithelium-derived factor OS=Homo sapiens GN=SERPINF1 PE=1 SV=4 P36955 46,296.30 4 9.81% 
38 Phosphatidylethanolamine-binding protein 1 OS=Homo sapiens GN=PEBP1 PE=1 SV=3 P30086 21,038.90 4 26.70% 
39 Hyaluronan-binding protein 2 OS=Homo sapiens GN=HABP2 PE=1 SV=1 Q14520 62,653.40 4 8.39% 
40 Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 P11142 70,881.80 4 8.36% 
41 Retinol-binding protein 4 OS=Homo sapiens GN=RBP4 PE=1 SV=3 P02753 22,992.30 4 15.90% 
42 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 P04406 36,035.30 4 17.00% 
43 Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 Q06830 22,092.90 4 19.10% 
44 Liver carboxylesterase 1 OS=Homo sapiens GN=CES1 PE=1 SV=2 P23141 62,504.40 4 8.47% 
45 Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 P04075 39,402.60 3 9.34% 
46 L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 P00338 36,671.20 3 9.64% 
47 Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4 Q14624 103,340.40 3 4.19% 
48 Alcohol dehydrogenase 4 OS=Homo sapiens GN=ADH4 PE=1 SV=5 P08319 40,204.80 3 8.16% 
49 Keratin, type II cytoskeletal 8 OS=Homo sapiens GN=KRT8 PE=1 SV=7 P05787 53,688.20 3 6.21% 
50 Keratin, type I cytoskeletal 18 OS=Homo sapiens GN=KRT18 PE=1 SV=2 P05783 48,041.00 3 6.74% 
51 Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 PE=1 SV=3 P08697 54,548.60 3 6.72% 
52 Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 P07339 44,535.00 3 9.95% 
53 Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 P07900 84,645.20 3 4.78% 
54 Cathepsin B OS=Homo sapiens GN=CTSB PE=1 SV=3 P07858 37,803.20 3 12.10% 
55 Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 P02763 23,494.10 3 8.96% 
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56 Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 P01019 53,136.80 3 6.39% 
57 UTP--glucose-1-phosphate uridylyltransferase OS=Homo sapiens GN=UGP2 PE=1 SV=5 Q16851 56,924.00 3 6.30% 
58 Monocyte differentiation antigen CD14 OS=Homo sapiens GN=CD14 PE=1 SV=2 P08571 40,058.60 3 9.60% 
59 Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 P05155 55,137.50 3 7.40% 
60 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 P02671 94,955.40 3 4.85% 
61 Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGK1 PE=1 SV=3 P00558 44,597.30 3 10.10% 
62 Histone H2B type 1-K OS=Homo sapiens GN=HIST1H2BK PE=1 SV=3 O60814 13,872.60 3 21.40% 
63 Protein disulfide-isomerase OS=Homo sapiens GN=P4HB PE=1 SV=3 P07237 57,100.10 3 7.28% 
64 Ribonuclease UK114 OS=Homo sapiens GN=HRSP12 PE=1 SV=1 P52758 14,476.10 3 27.00% 
65 Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 Q08380 65,314.10 3 5.81% 
66 Superoxide dismutase [Cu-Zn] OS=Homo sapiens GN=SOD1 PE=1 SV=2 P00441 15,917.30 3 24.70% 
67 Glutathione S-transferase A1 OS=Homo sapiens GN=GSTA1 PE=1 SV=3 P08263 25,615.00 2 8.56% 
68 Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 P02675 55,910.60 2 4.89% 
69 Insulin-like growth factor-binding protein 4 OS=Homo sapiens GN=IGFBP4 PE=1 SV=2 P22692 27,915.70 2 10.50% 
70 Neutrophil gelatinase-associated lipocalin OS=Homo sapiens GN=LCN2 PE=1 SV=2 P80188 22,570.90 2 16.20% 
71 Insulin-like growth factor-binding protein 1 OS=Homo sapiens GN=IGFBP1 PE=1 SV=1 P08833 27,884.90 2 11.60% 
72 Macrophage migration inhibitory factor OS=Homo sapiens GN=MIF PE=1 SV=4 P14174 12,458.50 2 17.40% 
73 Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 P29401 67,861.40 2 4.33% 
74 Aminoacylase-1 OS=Homo sapiens GN=ACY1 PE=1 SV=1 Q03154 45,866.30 2 6.37% 
75 Trypsin precursor - Sus scrofa P00761 24,391.30 2 7.79% 
76 1,4-alpha-glucan-branching enzyme OS=Homo sapiens GN=GBE1 PE=1 SV=2 Q04446 80,444.90 2 3.85% 
77 Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 P68104 50,123.20 2 4.33% 
78 Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 P61769 13,696.90 2 13.40% 
79 Aldo-keto reductase family 1 member C2 OS=Homo sapiens GN=AKR1C2 PE=1 SV=3 P52895 36,717.90 2 5.57% 
80 Nicotinate-nucleotide pyrophosphorylase [carboxylating] OS=Homo sapiens GN=QPRT PE=1 SV=3 Q15274 30,827.30 2 6.40% 
81 Phosphoglucomutase-1 OS=Homo sapiens GN=PGM1 PE=1 SV=3 P36871 61,433.00 2 4.80% 
82 Parathymosin OS=Homo sapiens GN=PTMS PE=1 SV=2 P20962 11,511.60 2 22.50% 
83 Fructose-1,6-bisphosphatase 1 OS=Homo sapiens GN=FBP1 PE=1 SV=5 P09467 36,825.20 2 7.99% 
84 60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 P10809 61,037.70 2 3.66% 
85 Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 P02750 38,161.70 2 5.76% 
86 Retinoic acid receptor responder protein 2 OS=Homo sapiens GN=RARRES2 PE=1 SV=1 Q99969 18,599.30 2 14.70% 
87 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 P09382 14,697.80 2 16.30% 
88 Betaine--homocysteine S-methyltransferase 1 OS=Homo sapiens GN=BHMT PE=1 SV=2 Q93088 44,980.60 2 6.16% 
89 HLA class I histocompatibility antigen, A-32 alpha chain OS=Homo sapiens GN=HLA-A PE=2 SV=2 P10314 41,029.90 2 10.10% 
90 Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2 P04792 22,764.60 2 13.20% 
91 Plasma serine protease inhibitor OS=Homo sapiens GN=SERPINA5 PE=1 SV=2 P05154 45,684.80 2 5.67% 
92 Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 P02679 51,495.30 2 4.64% 
93 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 P62805 11,349.70 2 19.40% 
94 Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 P07737 15,036.30 2 20.00% 
95 Apolipoprotein C-II OS=Homo sapiens GN=APOC2 PE=1 SV=1 P02655 11,266.10 2 17.80% 
96 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 P63104 27,727.90 2 8.98% 
97 Glutathione S-transferase omega-1 OS=Homo sapiens GN=GSTO1 PE=1 SV=2 P78417 27,549.20 2 9.96% 
98 Carboxypeptidase N subunit 2 OS=Homo sapiens GN=CPN2 PE=1 SV=2 P22792 60,598.80 2 3.30% 
99 Insulin-like growth factor-binding protein complex acid labile subunit OS=Homo sapiens GN=IGFALS PE=1 SV=1 P35858 66,020.60 2 4.63% 
100 Malate dehydrogenase, cytoplasmic OS=Homo sapiens GN=MDH1 PE=1 SV=4 P40925 36,408.90 2 8.68% 
101 Apolipoprotein C-III OS=Homo sapiens GN=APOC3 PE=1 SV=1 P02656 10,834.30 1 16.20% 
102 Calreticulin OS=Homo sapiens GN=CALR PE=1 SV=1 P27797 48,124.90 1 3.12% 
103 Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 P02790 51,658.50 1 2.38% 
104 Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 P02766 15,868.90 1 8.84% 
105 Superoxide dismutase [Mn], mitochondrial OS=Homo sapiens GN=SOD2 PE=1 SV=2 P04179 24,704.60 1 6.31% 
106 Nucleoside diphosphate kinase A OS=Homo sapiens GN=NME1 PE=1 SV=1 P15531 17,130.70 1 7.89% 
107 10 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPE1 PE=1 SV=2 P61604 10,913.70 1 13.70% 
108 Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 P68363 50,133.70 1 3.33% 
109 Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 P04080 11,121.30 1 12.20% 
110 14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 P31946 28,065.10 1 5.69% 
111 Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 P14625 92,453.70 1 1.37% 
112 Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 P30041 25,018.10 1 5.36% 
113 Alpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 SV=2 O43707 104,839.20 1 1.32% 
114 THUMP domain-containing protein 1 OS=Homo sapiens GN=THUMPD1 PE=1 SV=2 Q9NXG2 39,297.50 1 2.27% 
115 Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4 P01833 83,265.40 1 2.09% 
116 Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 P10599 11,719.30 1 8.57% 
117 Uncharacterized protein C10orf90 OS=Homo sapiens GN=C10orf90 PE=2 SV=2 Q96M02 77,893.30 1 1.00% 
118 Complement factor I OS=Homo sapiens GN=CFI PE=1 SV=2 P05156 65,731.80 1 3.26% 
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119 Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 P02787 77,046.30 1 2.01% 
120 Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 A8MT79 34,240.60 1 3.36% 
121 Proprotein convertase subtilisin/kexin type 9 OS=Homo sapiens GN=PCSK9 PE=1 SV=3 Q8NBP7 74,266.40 1 1.45% 
122 Acyl-coenzyme A thioesterase 2, mitochondrial OS=Homo sapiens GN=ACOT2 PE=1 SV=6 P49753 53,201.40 1 2.28% 
123 Proline-rich acidic protein 1 OS=Homo sapiens GN=PRAP1 PE=2 SV=2 Q96NZ9 17,189.20 1 5.96% 
124 Metaxin-1 OS=Homo sapiens GN=MTX1 PE=1 SV=2 Q13505 51,460.00 1 1.29% 
125 Thioredoxin-dependent peroxide reductase, mitochondrial OS=Homo sapiens GN=PRDX3 PE=1 SV=3 P30048 27,674.70 1 4.30% 
126 Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1 P04196 59,558.60 1 1.71% 
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Table V. Identified proteins in the conditioned medium of PHH in monolayer culture after 96h after 
prefractionation by SDS-PAGE. Shown are proteins identified after merging the mascot search results of 
analyses on three different LC-MS systems (LC-MALDI, LC-ESI ion trap and LC-ESI QTOF) with 24 gel bands each. 
Gene name (GN), Swiss-Prot Accesion number (Acc. no.), identified peptides (Pep), sequence coverage (Seq. 
cov.) 
No. Protein name Acc. no. MW [Da] pep seq. cov.  
1 Apolipoprotein B-100  GN=APOB   P04114 515,596.80 189 46.00% 
2 Complement C3  GN=C3   P01024 187,131.10 127 81.20% 
3 Fatty acid synthase  GN=FASN   P49327 273,409.10 91 47.60% 
4 Complement C4-B  GN=C4B   P0C0L5 192,776.80 81 58.30% 
5 Fibronectin  GN=FN1   P02751 262,598.90 68 38.00% 
6 Alpha-2-macroglobulin  GN=A2M   P01023 163,271.90 63 58.40% 
7 Filamin-B  GN=FLNB   O75369 278,140.80 56 30.00% 
8 Complement factor H  GN=CFH   P08603 139,078.20 55 54.70% 
9 Carbamoyl-phosphate synthase [ammonia], mitochondrial  GN=CPS1   P31327 164,924.70 53 43.90% 
10 Ceruloplasmin  GN=CP   P00450 122,189.90 51 55.50% 
11 Alpha-actinin-4  GN=ACTN4   O43707 104,839.20 42 54.90% 
12 Inter-alpha-trypsin inhibitor heavy chain H2  GN=ITIH2   P19823 106,447.50 40 43.10% 
13 Complement factor B  GN=CFB   P00751 85,515.20 35 46.60% 
14 Inter-alpha-trypsin inhibitor heavy chain H4  GN=ITIH4   Q14624 103,340.40 34 44.30% 
15 Apolipoprotein A-I  GN=APOA1   P02647 30,760.50 33 86.50% 
16 Alpha-1-antitrypsin  GN=SERPINA1   P01009 46,719.90 33 69.10% 
17 Complement C1s subcomponent  GN=C1S   P09871 76,666.20 33 55.10% 
18 Heat shock protein HSP 90-alpha  GN=HSP90AA1   P07900 84,645.20 31 42.50% 
19 Vitamin D-binding protein  GN=GC   P02774 52,946.60 31 63.30% 
20 Moesin  GN=MSN   P26038 67,803.80 30 49.20% 
21 Apolipoprotein A-IV  GN=APOA4   P06727 45,381.30 30 71.00% 
22 Thrombospondin-1  GN=THBS1   P07996 129,363.70 30 35.10% 
23 Serotransferrin  GN=TF   P02787 77,046.30 30 55.00% 
24 Elongation factor 2  GN=EEF2   P13639 95,322.10 29 39.20% 
25 Alpha-enolase  GN=ENO1   P06733 47,152.20 29 71.40% 
26 Liver carboxylesterase 1  GN=CES1   P23141 62,504.40 29 57.10% 
27 Fibrinogen beta chain  GN=FGB   P02675 55,910.60 28 67.40% 
28 Apolipoprotein E  GN=APOE   P02649 36,135.50 28 80.40% 
29 Inter-alpha-trypsin inhibitor heavy chain H3  GN=ITIH3   Q06033 99,832.90 28 37.30% 
30 Complement C1r subcomponent  GN=C1R   P00736 80,101.60 27 45.80% 
31 Prothrombin  GN=F2   P00734 70,018.80 27 52.70% 
32 Aldehyde oxidase  GN=AOX1   Q06278 147,902.70 27 21.50% 
33 Kininogen-1  GN=KNG1   P01042 71,939.60 26 35.90% 
34 Complement C5  GN=C5   P01031 188,291.20 26 18.60% 
35 L-lactate dehydrogenase A chain  GN=LDHA   P00338 36,671.20 26 83.10% 
36 Aspartate aminotransferase, cytoplasmic  GN=GOT1   P17174 46,230.10 26 73.10% 
37 Retinal dehydrogenase 1  GN=ALDH1A1   P00352 54,844.80 25 57.70% 
38 Glucose-6-phosphate isomerase  GN=GPI   P06744 63,130.40 25 46.10% 
39 Keratin, type II cytoskeletal 8  GN=KRT8   P05787 53,688.20 25 44.70% 
40 Alpha-1-antichymotrypsin  GN=SERPINA3   P01011 47,634.90 24 57.20% 
41 10-formyltetrahydrofolate dehydrogenase  GN=ALDH1L1   O75891 98,812.20 24 32.00% 
42 Actin, cytoplasmic 1  GN=ACTB   P60709 41,719.80 23 68.30% 
43 Haptoglobin  GN=HP   P00738 45,186.90 23 55.90% 
44 Glutamate dehydrogenase 1, mitochondrial  GN=GLUD1   P00367 61,381.70 23 44.60% 
45 Plasminogen activator inhibitor 1  GN=SERPINE1   P05121 45,042.20 23 63.40% 
46 Alcohol dehydrogenase 1B  GN=ADH1B   P00325 39,836.30 22 72.30% 
47 Pigment epithelium-derived factor  GN=SERPINF1   P36955 46,296.30 22 59.10% 
48 Fibrinogen gamma chain  GN=FGG   P02679 51,495.30 22 60.70% 
49 Isocitrate dehydrogenase [NADP] cytoplasmic  GN=IDH1   O75874 46,642.50 22 63.30% 
50 Inter-alpha-trypsin inhibitor heavy chain H1  GN=ITIH1   P19827 101,371.80 22 32.70% 
51 UTP--glucose-1-phosphate uridylyltransferase  GN=UGP2   Q16851 56,924.00 22 49.00% 
52 Complement C2  GN=C2   P06681 83,250.80 22 32.20% 
53 Aldo-keto reductase family 1 member B10  GN=AKR1B10   O60218 36,003.40 21 78.80% 
54 Clusterin  GN=CLU   P10909 52,476.90 21 43.40% 
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55 Agrin  GN=AGRN   O00468 214,820.00 21 13.20% 
56 Aldo-keto reductase family 1 member C1  GN=AKR1C1   Q04828 36,771.10 21 71.20% 
57 Protein disulfide-isomerase  GN=P4HB   P07237 57,100.10 21 44.90% 
58 Transforming growth factor-beta-induced protein ig-h3  GN=TGFBI   Q15582 74,664.90 21 41.40% 
59 Rab GDP dissociation inhibitor beta  GN=GDI2   P50395 50,647.50 21 60.20% 
60 Phosphoglycerate kinase 1  GN=PGK1   P00558 44,597.30 20 57.60% 
61 Aminoacylase-1  GN=ACY1   Q03154 45,866.30 20 63.50% 
62 Fibrinogen alpha chain  GN=FGA   P02671 94,955.40 20 30.30% 
63 Plasminogen  GN=PLG   P00747 90,549.40 20 30.00% 
64 Plasma protease C1 inhibitor  GN=SERPING1   P05155 55,137.50 20 38.00% 
65 Keratin, type I cytoskeletal 18  GN=KRT18   P05783 48,041.00 20 50.70% 
66 Plasma kallikrein  GN=KLKB1   P03952 71,351.70 20 32.10% 
67 Transketolase  GN=TKT   P29401 67,861.40 19 39.80% 
68 Fructose-bisphosphate aldolase B  GN=ALDOB   P05062 39,455.30 19 76.60% 
69 Prostaglandin reductase 1  GN=PTGR1   Q14914 35,852.50 19 63.50% 
70 Triosephosphate isomerase  GN=TPI1   P60174 26,651.10 19 86.70% 
71 Fructose-bisphosphate aldolase A  GN=ALDOA   P04075 39,402.60 19 71.40% 
72 14-3-3 protein zeta/delta  GN=YWHAZ   P63104 27,727.90 19 62.90% 
73 Peroxiredoxin-6  GN=PRDX6   P30041 25,018.10 19 79.90% 
74 Heat shock cognate 71 kDa protein  GN=HSPA8   P11142 70,881.80 19 40.90% 
75 Protein AMBP  GN=AMBP   P02760 38,981.50 19 56.50% 
76 4-hydroxyphenylpyruvate dioxygenase  GN=HPD   P32754 44,916.90 19 62.30% 
77 1,4-alpha-glucan-branching enzyme  GN=GBE1   Q04446 80,444.90 19 29.60% 
78 Antithrombin-III  GN=SERPINC1   P01008 52,586.00 18 45.30% 
79 Phosphoglucomutase-1  GN=PGM1   P36871 61,433.00 18 38.60% 
80 Argininosuccinate synthase  GN=ASS1   P00966 46,513.30 18 43.20% 
81 Hemopexin  GN=HPX   P02790 51,658.50 18 43.70% 
82 Complement factor I  GN=CFI   P05156 65,731.80 18 37.60% 
83 Plastin-3  GN=PLS3   P13797 70,795.90 18 33.80% 
84 60 kDa heat shock protein, mitochondrial  GN=HSPD1   P10809 61,037.70 18 43.60% 
85 Polymeric immunoglobulin receptor  GN=PIGR   P01833 83,265.40 18 26.70% 
86 Histidine-rich glycoprotein  GN=HRG   P04196 59,558.60 18 39.40% 
87 Proteasome subunit alpha type-1  GN=PSMA1   P25786 29,538.00 17 65.40% 
88 Alpha-actinin-1  GN=ACTN1   P12814 103,043.00 17 47.50% 
89 Tubulin beta chain  GN=TUBB   P07437 49,652.60 17 54.70% 
90 Alcohol dehydrogenase [NADP+]  GN=AKR1A1   P14550 36,555.60 17 51.40% 
91 Fructose-1,6-bisphosphatase 1  GN=FBP1   P09467 36,825.20 17 53.30% 
92 Plasma serine protease inhibitor  GN=SERPINA5   P05154 45,684.80 17 49.50% 
93 Phosphoglycerate mutase 1  GN=PGAM1   P18669 28,786.80 17 77.60% 
94 Amyloid beta A4 protein  GN=APP   P05067 86,923.30 16 23.40% 
95 Peroxiredoxin-1  GN=PRDX1   Q06830 22,092.90 16 78.90% 
96 Argininosuccinate lyase  GN=ASL   P04424 51,641.00 16 40.30% 
97 Glyceraldehyde-3-phosphate dehydrogenase  GN=GAPDH   P04406 36,035.30 16 56.10% 
98 Heat shock protein beta-1  GN=HSPB1   P04792 22,764.60 16 68.80% 
99 Vinculin  GN=VCL   P18206 123,783.20 16 19.30% 
100 Protein disulfide-isomerase A3  GN=PDIA3   P30101 56,766.60 16 39.20% 
101 Hyaluronan-binding protein 2  GN=HABP2   Q14520 62,653.40 16 29.80% 
102 Nucleobindin-1  GN=NUCB1   Q02818 53,861.60 16 39.50% 
103 Betaine--homocysteine S-methyltransferase 1  GN=BHMT   Q93088 44,980.60 16 56.90% 
104 3-ketoacyl-CoA thiolase, mitochondrial  GN=ACAA2   P42765 41,906.20 16 58.40% 
105 Heparin cofactor 2  GN=SERPIND1   P05546 57,054.90 16 38.70% 
106 Malate dehydrogenase, mitochondrial  GN=MDH2   P40926 35,485.70 16 59.50% 
107 Proteasome activator complex subunit 1  GN=PSME1   Q06323 28,705.80 16 65.10% 
108 Cytoplasmic aconitate hydratase  GN=ACO1   P21399 98,383.00 16 23.80% 
109 Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing)  GN=DAK   Q3LXA3 58,930.10 16 42.30% 
110 Serine hydroxymethyltransferase, cytosolic  GN=SHMT1   P34896 53,065.80 16 39.10% 
111 Glycogen debranching enzyme  GN=AGL   P35573 174,749.60 16 13.10% 
112 Superoxide dismutase [Mn], mitochondrial  GN=SOD2   P04179 24,704.60 15 68.00% 
113 Transgelin-2  GN=TAGLN2   P37802 22,373.90 15 79.40% 
114 Carbonyl reductase [NADPH] 1  GN=CBR1   P16152 30,356.80 15 70.40% 
115 Catalase  GN=CAT   P04040 59,738.50 15 35.30% 
116 Insulin-like growth factor-binding protein 2  GN=IGFBP2   P18065 34,795.60 15 53.50% 
117 Selenium-binding protein 1  GN=SELENBP1   Q13228 52,374.00 15 34.70% 
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118 Zinc-alpha-2-glycoprotein  GN=AZGP1   P25311 34,240.60 15 54.00% 
119 Phosphatidylethanolamine-binding protein 1  GN=PEBP1   P30086 21,038.90 15 86.60% 
120 Cathepsin D  GN=CTSD   P07339 44,535.00 15 43.90% 
121 Neutrophil gelatinase-associated lipocalin  GN=LCN2   P80188 22,570.90 15 66.70% 
122 Glutathione S-transferase omega-1  GN=GSTO1   P78417 27,549.20 15 49.40% 
123 Galectin-3-binding protein  GN=LGALS3BP   Q08380 65,314.10 15 27.20% 
124 Nicotinamide phosphoribosyltransferase  GN=NAMPT   P43490 55,504.50 14 43.80% 
125 Serine--pyruvate aminotransferase  GN=AGXT   P21549 42,993.40 14 48.50% 
126 Aspartate aminotransferase, mitochondrial  GN=GOT2   P00505 47,500.60 14 35.80% 
127 Peptidyl-prolyl cis-trans isomerase B  GN=PPIB   P23284 23,725.20 14 57.40% 
128 Tubulin alpha-1B chain  GN=TUBA1B   P68363 50,133.70 14 42.40% 
129 Glutathione S-transferase A2  GN=GSTA2   P09210 25,647.90 14 48.60% 
130 14-3-3 protein epsilon  GN=YWHAE   P62258 29,157.00 14 69.40% 
131 Complement component C8 beta chain  GN=C8B   P07358 67,028.90 14 27.90% 
132 Annexin A2  GN=ANXA2   P07355 38,588.10 14 45.40% 
133 Heat shock protein HSP 90-beta  GN=HSP90AB1   P08238 83,249.30 14 39.40% 
134 Monocyte differentiation antigen CD14  GN=CD14   P08571 40,058.60 14 48.50% 
135 Glycine amidinotransferase, mitochondrial  GN=GATM   P50440 48,438.60 14 45.40% 
136 Keratin, type II cytoskeletal 1  GN=KRT1   P04264 66,022.30 14 32.80% 
137 Retinol-binding protein 4  GN=RBP4   P02753 22,992.30 14 77.10% 
138 Chitinase-3-like protein 1  GN=CHI3L1   P36222 42,609.00 14 43.60% 
139 Arginase-1  GN=ARG1   P05089 34,718.00 14 55.30% 
140 Endoplasmin  GN=HSP90B1   P14625 92,453.70 13 21.20% 
141 Alcohol dehydrogenase 4  GN=ADH4   P08319 40,204.80 13 48.90% 
142 6-phosphogluconate dehydrogenase, decarboxylating  GN=PGD   P52209 53,123.90 13 40.60% 
143 Purine nucleoside phosphorylase  GN=PNP   P00491 32,100.00 13 60.20% 
144 Protein DJ-1  GN=PARK7   Q99497 19,873.10 13 81.00% 
145 Complement component C8 gamma chain  GN=C8G   P07360 22,259.30 13 82.70% 
146 Malate dehydrogenase, cytoplasmic  GN=MDH1   P40925 36,408.90 13 50.00% 
147 Lipopolysaccharide-binding protein  GN=LBP   P18428 53,368.00 13 28.50% 
148 Fumarate hydratase, mitochondrial  GN=FH   P07954 54,619.80 13 37.30% 
149 Calreticulin  GN=CALR   P27797 48,124.90 13 33.10% 
150 Insulin-like growth factor-binding protein 1  GN=IGFBP1   P08833 27,884.90 13 47.50% 
151 Tropomyosin alpha-4 chain  GN=TPM4   P67936 28,504.40 13 41.10% 
152 Cathepsin B  GN=CTSB   P07858 37,803.20 12 43.10% 
153 Chloride intracellular channel protein 1  GN=CLIC1   O00299 26,905.30 12 59.30% 
154 Angiotensinogen  GN=AGT   P01019 53,136.80 12 34.60% 
155 Omega-amidase NIT2  GN=NIT2   Q9NQR4 30,590.80 12 59.80% 
156 Vitronectin  GN=VTN   P04004 54,288.10 12 33.30% 
157 Cytosolic non-specific dipeptidase  GN=CNDP2   Q96KP4 52,861.70 12 27.60% 
158 Proteasome subunit beta type-8  GN=PSMB8   P28062 30,336.80 12 43.80% 
159 Insulin-like growth factor-binding protein complex acid labile subunit  GN=IGFALS   P35858 66,020.60 12 26.00% 
160 Fibrinogen-like protein 1  GN=FGL1   Q08830 36,361.90 12 51.90% 
161 14-3-3 protein gamma  GN=YWHAG   P61981 28,285.10 12 63.60% 
162 Aminopeptidase N  GN=ANPEP   P15144 109,524.40 12 16.20% 
163 Nicotinamide N-methyltransferase  GN=NNMT   P40261 29,557.00 12 65.50% 
164 Glycogen phosphorylase, liver form  GN=PYGL   P06737 97,134.40 12 16.60% 
165 3-hydroxyanthranilate 3,4-dioxygenase  GN=HAAO   P46952 32,538.20 12 61.50% 
166 Laminin subunit gamma-1  GN=LAMC1   P11047 177,583.30 12 10.20% 
167 Proteasome activator complex subunit 2  GN=PSME2   Q9UL46 27,384.20 12 62.30% 
168 Alpha-1-acid glycoprotein 1  GN=ORM1   P02763 23,494.10 12 53.20% 
169 L-xylulose reductase  GN=DCXR   Q7Z4W1 25,894.20 12 69.30% 
170 Beta-2-glycoprotein 1  GN=APOH   P02749 38,280.50 12 46.70% 
171 Carbonic anhydrase 2  GN=CA2   P00918 29,228.60 12 61.90% 
172 Bile salt sulfotransferase  GN=SULT2A1   Q06520 33,763.30 12 46.30% 
173 Cytosol aminopeptidase  GN=LAP3   P28838 56,149.70 11 22.00% 
174 Lambda-crystallin homolog  GN=CRYL1   Q9Y2S2 35,401.30 11 40.80% 
175 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial  GN=ECH1   Q13011 35,798.20 11 47.60% 
176 Sorbitol dehydrogenase  GN=SORD   Q00796 38,306.60 11 38.10% 
177 Proteasome subunit alpha type-4  GN=PSMA4   P25789 29,466.80 11 54.80% 
178 Alpha-2-antiplasmin  GN=SERPINF2   P08697 54,548.60 11 30.10% 
179 Ornithine carbamoyltransferase, mitochondrial  GN=OTC   P00480 39,919.00 11 42.70% 
180 Vimentin  GN=VIM   P08670 53,634.60 11 25.50% 
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181 Gamma-glutamyl hydrolase  GN=GGH   Q92820 35,947.90 11 43.10% 
182 Leukocyte elastase inhibitor  GN=SERPINB1   P30740 42,725.80 11 35.10% 
183 Nidogen-1  GN=NID1   P14543 136,357.60 11 9.94% 
184 Insulin-like growth factor-binding protein 7  GN=IGFBP7   Q16270 29,111.80 11 44.70% 
185 Spectrin alpha chain, brain  GN=SPTAN1   Q13813 284,524.70 11 6.80% 
186 Fumarylacetoacetase  GN=FAH   P16930 46,357.60 11 38.40% 
187 Proteasome subunit alpha type-7  GN=PSMA7   O14818 27,869.10 11 55.20% 
188 Proteasome subunit alpha type-6  GN=PSMA6   P60900 27,381.50 11 45.90% 
189 Transaldolase  GN=TALDO1   P37837 37,523.70 11 35.00% 
190 78 kDa glucose-regulated protein  GN=HSPA5   P11021 72,316.70 11 25.70% 
191 Low-density lipoprotein receptor  GN=LDLR   P01130 95,356.70 11 15.00% 
192 Basement membrane-specific heparan sulfate proteoglycan core protein  GN=HSPG2   P98160 468,792.60 10 3.17% 
193 Farnesyl pyrophosphate synthase  GN=FDPS   P14324 48,258.70 10 33.90% 
194 Carboxypeptidase N subunit 2  GN=CPN2   P22792 60,598.80 10 29.50% 
195 Elongation factor 1-alpha 1  GN=EEF1A1   P68104 50,123.20 10 32.50% 
196 Galectin-4  GN=LGALS4   P56470 35,923.30 10 38.40% 
197 Angiopoietin-related protein 3  GN=ANGPTL3   Q9Y5C1 53,621.30 10 21.30% 
198 Kallistatin  GN=SERPINA4   P29622 48,526.00 10 30.20% 
199 6-phosphogluconolactonase  GN=PGLS   O95336 27,529.50 10 57.80% 
200 Protein disulfide-isomerase A4  GN=PDIA4   P13667 72,916.00 10 18.60% 
201 UMP-CMP kinase  GN=CMPK1   P30085 22,205.00 10 54.10% 
202 Endoplasmic reticulum resident protein 29  GN=ERP29   P30040 28,976.90 10 45.60% 
203 4-aminobutyrate aminotransferase, mitochondrial  GN=ABAT   P80404 56,422.80 10 26.60% 
204 Alpha-1B-glycoprotein  GN=A1BG   P04217 54,235.30 10 36.60% 
205 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial  GN=HADH   Q16836 34,276.10 10 45.50% 
206 Alpha-2-HS-glycoprotein  GN=AHSG   P02765 39,305.40 10 29.20% 
207 Leucine-rich alpha-2-glycoprotein  GN=LRG1   P02750 38,161.70 10 33.40% 
208 Transthyretin  GN=TTR   P02766 15,868.90 10 73.50% 
209 Proprotein convertase subtilisin/kexin type 9  GN=PCSK9   Q8NBP7 74,266.40 10 20.80% 
210 Aflatoxin B1 aldehyde reductase member 3  GN=AKR7A3   O95154 37,188.80 10 43.20% 
211 Acetyl-CoA acetyltransferase, cytosolic  GN=ACAT2   Q9BWD1 41,332.40 9 40.30% 
212 Intercellular adhesion molecule 1  GN=ICAM1   P05362 57,806.50 9 20.30% 
213 Pyruvate kinase isozymes M1/M2  GN=PKM2   P14618 57,919.50 9 21.30% 
214 Quinone oxidoreductase  GN=CRYZ   Q08257 35,189.30 9 41.00% 
215 Adenylate kinase 2, mitochondrial  GN=AK2   P54819 26,461.00 9 46.90% 
216 Thymidine phosphorylase  GN=TYMP   P19971 49,937.80 9 30.10% 
217 SPARC  GN=SPARC   P09486 34,613.90 9 27.40% 
218 Glyoxalase domain-containing protein 4  GN=GLOD4   Q9HC38 34,776.10 9 37.40% 
219 Coagulation factor XII  GN=F12   P00748 67,772.60 9 16.10% 
220 Homogentisate 1,2-dioxygenase  GN=HGD   Q93099 49,946.70 9 33.00% 
221 Keratin, type I cytoskeletal 9  GN=KRT9   P35527 62,047.80 9 19.70% 
222 Keratin, type I cytoskeletal 10  GN=KRT10   P13645 58,810.80 9 16.80% 
223 Carboxymethylenebutenolidase homolog  GN=CMBL   Q96DG6 28,030.60 9 40.40% 
224 Glutathione S-transferase Mu 1  GN=GSTM1   P09488 25,695.70 9 44.00% 
225 Actin-related protein 2/3 complex subunit 2  GN=ARPC2   O15144 34,315.70 9 33.30% 
226 Dihydropteridine reductase  GN=QDPR   P09417 25,771.50 9 52.00% 
227 Receptor-type tyrosine-protein phosphatase F  GN=PTPRF   P10586 212,860.00 9 5.77% 
228 Filamin-A  GN=FLNA   P21333 280,711.40 9 6.31% 
229 Aldo-keto reductase family 1 member C3  GN=AKR1C3   P42330 36,836.10 9 68.10% 
230 UDP-glucose 6-dehydrogenase  GN=UGDH   O60701 55,007.30 9 25.50% 
231 Ferritin heavy chain  GN=FTH1   P02794 21,208.20 9 51.40% 
232 Ferritin light chain  GN=FTL   P02792 20,002.60 9 54.30% 
233 Serum amyloid P-component  GN=APCS   P02743 25,369.70 9 35.90% 
234 Matrix metalloproteinase-9  GN=MMP9   P14780 78,441.70 9 16.10% 
235 Glutathione S-transferase theta-1  GN=GSTT1   P30711 27,317.90 9 37.90% 
236 Spectrin beta chain, brain 1  GN=SPTBN1   Q01082 274,595.40 9 6.09% 
237 Lactoylglutathione lyase  GN=GLO1   Q04760 20,760.80 9 47.30% 
238 Proteasome subunit beta type-1  GN=PSMB1   P20618 26,472.50 8 41.90% 
239 Vesicular integral-membrane protein VIP36  GN=LMAN2   Q12907 40,211.50 8 31.20% 
240 Eukaryotic initiation factor 4A-I  GN=EIF4A1   P60842 46,137.30 8 24.90% 
241 Beta-Ala-His dipeptidase  GN=CNDP1   Q96KN2 56,689.30 8 21.30% 
242 Cullin-associated NEDD8-dissociated protein 1  GN=CAND1   Q86VP6 136,363.10 8 9.76% 
243 Proteasome subunit alpha type-3  GN=PSMA3   P25788 28,415.70 8 28.20% 
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244 Proteasome subunit alpha type-2  GN=PSMA2   P25787 25,880.90 8 46.20% 
245 Superoxide dismutase [Cu-Zn]  GN=SOD1   P00441 15,917.30 8 68.20% 
246 Insulin-like growth factor-binding protein 4  GN=IGFBP4   P22692 27,915.70 8 41.10% 
247 14-3-3 protein eta  GN=YWHAH   Q04917 28,201.60 8 56.50% 
248 Delta-aminolevulinic acid dehydratase  GN=ALAD   P13716 36,277.30 8 31.50% 
249 Proteasome subunit beta type-5  GN=PSMB5   P28074 28,463.00 8 30.80% 
250 Translationally-controlled tumor protein  GN=TPT1   P13693 19,578.20 8 67.40% 
251 Complement component C6  GN=C6   P13671 104,768.20 8 11.60% 
252 Glyoxylate reductase/hydroxypyruvate reductase  GN=GRHPR   Q9UBQ7 35,651.10 8 33.50% 
253 Dipeptidyl peptidase 4  GN=DPP4   P27487 88,263.00 8 11.40% 
254 Thioredoxin-dependent peroxide reductase, mitochondrial  GN=PRDX3   P30048 27,674.70 8 43.00% 
255 Flavin reductase  GN=BLVRB   P30043 22,100.70 8 63.60% 
256 Beta-hexosaminidase subunit beta  GN=HEXB   P07686 63,095.30 8 18.90% 
257 Peroxiredoxin-2  GN=PRDX2   P32119 21,874.40 8 40.40% 
258 Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic  GN=GPD1   P21695 37,549.60 8 31.20% 
259 Apoptosis regulator BAX  GN=BAX   Q07812 21,167.20 8 54.70% 
260 14-3-3 protein theta  GN=YWHAQ   P27348 27,747.40 8 51.80% 
261 Heterogeneous nuclear ribonucleoproteins A2/B1  GN=HNRNPA2B1   P22626 37,412.30 8 26.60% 
262 F-actin-capping protein subunit beta  GN=CAPZB   P47756 31,333.60 8 32.10% 
263 Adenylate kinase isoenzyme 1  GN=AK1   P00568 21,617.10 7 40.20% 
264 ATP-citrate synthase  GN=ACLY   P53396 120,824.80 7 9.08% 
265 Inorganic pyrophosphatase  GN=PPA1   Q15181 32,642.60 7 35.30% 
266 Transmembrane protein 132A  GN=TMEM132A   Q24JP5 110,089.40 7 9.19% 
267 Phosphoserine aminotransferase  GN=PSAT1   Q9Y617 40,405.30 7 19.70% 
268 Cathepsin S  GN=CTSS   P25774 37,477.60 7 24.80% 
269 3,2-trans-enoyl-CoA isomerase, mitochondrial  GN=DCI   P42126 32,798.50 7 32.10% 
270 HLA class I histocompatibility antigen, A-25 alpha chain  GN=HLA-A   P18462 41,199.70 7 29.00% 
271 Metalloproteinase inhibitor 1  GN=TIMP1   P01033 23,153.10 7 53.10% 
272 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  GN=PLOD1   Q02809 83,534.50 7 13.10% 
273 Hepatocyte growth factor-like protein  GN=MST1   P26927 80,299.80 7 14.50% 
274 Protein disulfide-isomerase A6  GN=PDIA6   Q15084 48,104.30 7 20.00% 
275 Proteasome subunit alpha type-5  GN=PSMA5   P28066 26,393.30 7 47.70% 
276 Maleylacetoacetate isomerase  GN=GSTZ1   O43708 24,195.00 7 32.40% 
277 GTP:AMP phosphotransferase, mitochondrial  GN=AK3   Q9UIJ7 25,548.30 7 36.60% 
278 3-mercaptopyruvate sulfurtransferase  GN=MPST   P25325 33,160.80 7 32.00% 
279 Complement component C8 alpha chain  GN=C8A   P07357 65,145.80 7 12.80% 
280 Adenylyl cyclase-associated protein 1  GN=CAP1   Q01518 51,883.60 7 22.10% 
281 Calcineurin-like phosphoesterase domain-containing protein 1  GN=CPPED1   Q9BRF8 35,530.60 7 25.80% 
282 Alcohol dehydrogenase 6  GN=ADH6   P28332 39,070.80 7 23.10% 
283 Tropomyosin alpha-1 chain  GN=TPM1   P09493 32,692.00 7 32.40% 
284 Histamine N-methyltransferase  GN=HNMT   P50135 33,278.60 7 30.80% 
285 Alcohol dehydrogenase 1C  GN=ADH1C   P00326 39,849.60 7 57.10% 
286 Abhydrolase domain-containing protein 14B  GN=ABHD14B   Q96IU4 22,328.00 7 42.90% 
287 Elongation factor 1-gamma  GN=EEF1G   P26641 50,101.40 7 23.10% 
288 Talin-1  GN=TLN1   Q9Y490 269,747.10 7 4.25% 
289 Peroxiredoxin-4  GN=PRDX4   Q13162 30,523.10 7 44.60% 
290 Ester hydrolase C11orf54  GN=C11orf54   Q9H0W9 35,099.70 7 34.30% 
291 N-acetylmuramoyl-L-alanine amidase  GN=PGLYRP2   Q96PD5 62,199.90 7 21.00% 
292 Nicotinate-nucleotide pyrophosphorylase [carboxylating]  GN=QPRT   Q15274 30,827.30 7 27.30% 
293 Enoyl-CoA hydratase, mitochondrial  GN=ECHS1   P30084 31,370.20 7 35.20% 
294 14-3-3 protein beta/alpha  GN=YWHAB   P31946 28,065.10 7 61.80% 
295 Glucosidase 2 subunit beta  GN=PRKCSH   P14314 59,407.70 7 16.30% 
296 Importin subunit beta-1  GN=KPNB1   Q14974 97,153.30 6 9.59% 
297 Eukaryotic translation initiation factor 5A-1  GN=EIF5A   P63241 16,814.70 6 47.40% 
298 Guanine deaminase  GN=GDA   Q9Y2T3 50,985.90 6 18.10% 
299 Alpha-mannosidase 2  GN=MAN2A1   Q16706 131,127.70 6 6.64% 
300 Chloride intracellular channel protein 4  GN=CLIC4   Q9Y696 28,755.60 6 33.20% 
301 Phospholysine phosphohistidine inorganic pyrophosphate phosphatase  GN=LHPP   Q9H008 29,147.40 6 37.40% 
302 Nucleoside diphosphate kinase A  GN=NME1   P15531 17,130.70 6 53.30% 
303 BH3-interacting domain death agonist  GN=BID   P55957 21,977.30 6 47.70% 
304 Sulfotransferase 1A1  GN=SULT1A1   P50225 34,147.90 6 25.40% 
305 C-reactive protein  GN=CRP   P02741 25,021.00 6 23.20% 
306 ATP synthase subunit beta, mitochondrial  GN=ATP5B   P06576 56,542.50 6 16.40% 
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307 Proactivator polypeptide  GN=PSAP   P07602 58,094.00 6 14.30% 
308 Keratin, type II cytoskeletal 2 epidermal  GN=KRT2   P35908 65,415.90 6 19.60% 
309 Ubiquitin-like modifier-activating enzyme 1  GN=UBA1   P22314 117,832.30 6 10.40% 
310 Isopentenyl-diphosphate Delta-isomerase 1  GN=IDI1   Q13907 26,302.30 6 26.40% 
311 Prelamin-A/C  GN=LMNA   P02545 74,122.60 6 12.50% 
312 Proteasome subunit beta type-7  GN=PSMB7   Q99436 29,947.90 6 36.10% 
313 Coagulation factor X  GN=F10   P00742 54,714.10 6 15.60% 
314 Proteasome subunit beta type-4  GN=PSMB4   P28070 29,187.00 6 31.80% 
315 Proteasome subunit beta type-9  GN=PSMB9   P28065 23,246.40 6 33.80% 
316 Hydroxymethylglutaryl-CoA synthase, cytoplasmic  GN=HMGCS1   Q01581 57,277.00 6 16.00% 
317 Adenosylhomocysteinase  GN=AHCY   P23526 47,699.10 6 18.10% 
318 Interleukin-18  GN=IL18   Q14116 22,309.40 6 38.30% 
319 14-3-3 protein sigma  GN=SFN   P31947 27,756.80 6 49.20% 
320 3-hydroxyisobutyrate dehydrogenase, mitochondrial  GN=HIBADH   P31937 35,312.00 6 25.90% 
321 Hepatocyte growth factor receptor  GN=MET   P08581 155,525.40 6 5.11% 
322 60S acidic ribosomal protein P0  GN=RPLP0   P05388 34,256.30 6 32.50% 
323 Spondin-2  GN=SPON2   Q9BUD6 35,828.40 6 17.80% 
324 Alpha-1-acid glycoprotein 2  GN=ORM2   P19652 23,585.20 6 52.20% 
325 Protein-L-isoaspartate(D-aspartate) O-methyltransferase  GN=PCMT1   P22061 24,618.80 6 35.20% 
326 Heme-binding protein 1  GN=HEBP1   Q9NRV9 21,079.40 6 49.20% 
327 Serum paraoxonase/arylesterase 1  GN=PON1   P27169 39,714.40 6 24.50% 
328 Aldehyde dehydrogenase, mitochondrial  GN=ALDH2   P05091 56,363.40 6 17.80% 
329 Alcohol dehydrogenase class-3  GN=ADH5   P11766 39,705.80 6 22.20% 
330 Collagen alpha-1(XVIII) chain  GN=COL18A1   P39060 178,169.70 6 4.45% 
331 Ezrin  GN=EZR   P15311 69,396.60 6 20.00% 
332 Complement component C9  GN=C9   P02748 63,156.80 6 11.60% 
333 Guanidinoacetate N-methyltransferase  GN=GAMT   Q14353 26,300.60 6 39.80% 
334 Ketohexokinase  GN=KHK   P50053 32,712.10 6 22.10% 
335 Actin-related protein 2  GN=ACTR2   P61160 44,743.70 6 19.00% 
336 Peroxidasin homolog  GN=PXDN   Q92626 165,257.70 6 6.56% 
337 Alanyl-tRNA synthetase, cytoplasmic  GN=AARS   P49588 106,795.20 6 7.44% 
338 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA  GN=MAN1A1   P33908 72,953.70 6 10.70% 
339 Hepatocellular carcinoma-associated protein TD26  GN=UNQ599/PRO1185   Q6UXH0 22,087.40 6 29.80% 
340 Acidic leucine-rich nuclear phosphoprotein 32 family member A  GN=ANP32A   P39687 28,568.10 6 20.50% 
341 Coagulation factor XIII B chain  GN=F13B   P05160 75,493.70 5 12.00% 
342 Dipeptidyl peptidase 3  GN=DPP3   Q9NY33 82,573.60 5 8.96% 
343 Glutathione synthetase  GN=GSS   P48637 52,367.90 5 12.40% 
344 Beta-1,4-galactosyltransferase 1  GN=B4GALT1   P15291 43,903.00 5 19.30% 
345 Glypican-1  GN=GPC1   P35052 61,663.30 5 12.70% 
346 Guanine nucleotide-binding protein subunit beta-2-like 1  GN=GNB2L1   P63244 35,058.90 5 16.10% 
347 Ribonuclease inhibitor  GN=RNH1   P13489 49,956.40 5 13.70% 
348 Proteoglycan 4  GN=PRG4   Q92954 151,062.20 5 4.27% 
349 Protein Z-dependent protease inhibitor  GN=SERPINA10   Q9UK55 50,690.70 5 15.10% 
350 Leukotriene A-4 hydrolase  GN=LTA4H   P09960 69,269.10 5 11.10% 
351 Regucalcin  GN=RGN   Q15493 33,234.90 5 21.70% 
352 SPRY domain-containing protein 4  GN=SPRYD4   Q8WW59 23,110.10 5 24.60% 
353 60S ribosomal protein L10a  GN=RPL10A   P62906 24,814.00 5 24.00% 
354 Adenine phosphoribosyltransferase  GN=APRT   P07741 19,590.50 5 36.10% 
355 C-1-tetrahydrofolate synthase, cytoplasmic  GN=MTHFD1   P11586 101,543.50 5 6.84% 
356 Epoxide hydrolase 1  GN=EPHX1   P07099 52,933.10 5 16.50% 
357 Serpin A11  GN=SERPINA11   Q86U17 46,973.10 5 15.40% 
358 Insulin-like growth factor-binding protein 3  GN=IGFBP3   P17936 31,656.10 5 22.70% 
359 Mannan-binding lectin serine protease 2  GN=MASP2   O00187 75,685.40 5 6.85% 
360 Proteasome subunit beta type-2  GN=PSMB2   P49721 22,819.50 5 32.30% 
361 Proteasome subunit beta type-3  GN=PSMB3   P49720 22,931.60 5 34.10% 
362 S-phase kinase-associated protein 1  GN=SKP1   P63208 18,640.30 5 30.70% 
363 V-type proton ATPase subunit S1  GN=ATP6AP1   Q15904 52,009.20 5 16.60% 
364 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1  GN=DDAH1   O94760 31,103.70 5 27.40% 
365 Cathepsin Z  GN=CTSZ   Q9UBR2 33,850.20 5 21.80% 
366 Lysosomal protective protein  GN=CTSA   P10619 54,449.60 5 11.90% 
367 Serum amyloid A-4 protein  GN=SAA4   P35542 14,729.20 5 40.80% 
368 ES1 protein homolog, mitochondrial  GN=C21orf33   P30042 28,151.60 5 26.50% 
369 Acetyl-CoA acetyltransferase, mitochondrial  GN=ACAT1   P24752 45,181.80 5 15.90% 
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370 Ubiquitin-conjugating enzyme E2 K  GN=UBE2K   P61086 22,389.10 5 34.50% 
371 Actin-related protein 2/3 complex subunit 3  GN=ARPC3   O15145 20,529.80 5 30.90% 
372 Heat shock 70 kDa protein 4  GN=HSPA4   P34932 94,313.90 5 8.21% 
373 Fibroblast growth factor 21  GN=FGF21   Q9NSA1 22,282.60 5 40.70% 
374 Acyl-coenzyme A thioesterase 2, mitochondrial  GN=ACOT2   P49753 53,201.40 5 16.10% 
375 Interferon-induced guanylate-binding protein 1  GN=GBP1   P32455 67,914.50 5 7.77% 
376 Rho GDP-dissociation inhibitor 1  GN=ARHGDIA   P52565 23,189.50 5 25.50% 
377 Corticosteroid-binding globulin  GN=SERPINA6   P08185 45,124.10 5 13.60% 
378 S-methyl-5'-thioadenosine phosphorylase  GN=MTAP   Q13126 31,218.30 5 30.40% 
379 Heat shock 70 kDa protein 1A/1B  GN=HSPA1A   P08107 70,036.00 5 14.20% 
380 Growth/differentiation factor 15  GN=GDF15   Q99988 34,122.80 5 17.20% 
381 Neutral alpha-glucosidase AB  GN=GANAB   Q14697 106,857.90 5 7.42% 
382 Putative L-aspartate dehydrogenase  GN=ASPDH   A6ND91 29,927.80 5 30.70% 
383 Eukaryotic translation initiation factor 6  GN=EIF6   P56537 26,580.20 5 37.10% 
384 Coagulation factor V  GN=F5   P12259 251,692.50 5 2.88% 
385 Annexin A5  GN=ANXA5   P08758 35,920.60 4 15.60% 
386 40S ribosomal protein S3  GN=RPS3   P23396 26,670.50 4 23.00% 
387 4-trimethylaminobutyraldehyde dehydrogenase  GN=ALDH9A1   P49189 53,784.00 4 8.91% 
388 Glutathione reductase, mitochondrial  GN=GSR   P00390 56,239.40 4 14.80% 
389 S-formylglutathione hydrolase  GN=ESD   P10768 31,445.60 4 26.60% 
390 Fructose-bisphosphate aldolase C  GN=ALDOC   P09972 39,438.20 4 27.70% 
391 NADP-dependent malic enzyme  GN=ME1   P48163 64,133.40 4 9.97% 
392 Translin  GN=TSN   Q15631 26,165.40 4 20.20% 
393 Heme-binding protein 2  GN=HEBP2   Q9Y5Z4 22,857.70 4 23.40% 
394 Prostaglandin E synthase 3  GN=PTGES3   Q15185 18,679.90 4 21.90% 
395 Acylamino-acid-releasing enzyme  GN=APEH   P13798 81,206.00 4 5.74% 
396 Hornerin  GN=HRNR   Q86YZ3 282,354.70 4 2.49% 
397 Cystathionine gamma-lyase  GN=CTH   P32929 44,490.50 4 15.60% 
398 Threonyl-tRNA synthetase, cytoplasmic  GN=TARS   P26639 83,419.80 4 7.19% 
399 Protocadherin Fat 1  GN=FAT1   Q14517 506,250.70 4 1.46% 
400 Ubiquitin carboxyl-terminal hydrolase isozyme L3  GN=UCHL3   P15374 26,164.80 4 25.70% 
401 Annexin A4  GN=ANXA4   P09525 35,866.30 4 16.90% 
402 Transitional endoplasmic reticulum ATPase  GN=VCP   P55072 89,306.80 4 7.44% 
403 Actin-related protein 3  GN=ACTR3   P61158 47,353.80 4 14.60% 
404 Dual specificity protein phosphatase 3  GN=DUSP3   P51452 20,460.80 4 29.20% 
405 Tissue factor pathway inhibitor  GN=TFPI   P10646 34,998.10 4 15.50% 
406 Proteasome subunit beta type-6  GN=PSMB6   P28072 25,339.90 4 15.10% 
407 Prolow-density lipoprotein receptor-related protein 1  GN=LRP1   Q07954 504,573.80 4 1.14% 
408 Beta-ureidopropionase  GN=UPB1   Q9UBR1 43,148.10 4 18.80% 
409 Attractin  GN=ATRN   O75882 158,518.30 4 3.43% 
410 Syndecan-4  GN=SDC4   P31431 21,624.10 4 24.70% 
411 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial  GN=HIBCH   Q6NVY1 43,466.00 4 9.84% 
412 Ribosyldihydronicotinamide dehydrogenase [quinone]  GN=NQO2   P16083 25,900.80 4 17.30% 
413 GTP-binding nuclear protein Ran  GN=RAN   P62826 24,405.10 4 19.90% 
414 Isochorismatase domain-containing protein 1  GN=ISOC1   Q96CN7 32,218.70 4 19.80% 
415 F-actin-capping protein subunit alpha-1  GN=CAPZA1   P52907 32,905.10 4 20.30% 
416 Aldo-keto reductase family 1 member C4  GN=AKR1C4   P17516 37,049.40 4 36.80% 
417 Actin-related protein 2/3 complex subunit 1B  GN=ARPC1B   O15143 40,931.80 4 15.30% 
418 SEC14-like protein 2  GN=SEC14L2   O76054 46,128.40 4 15.90% 
419 Carboxypeptidase B2  GN=CPB2   Q96IY4 48,406.70 4 12.80% 
420 UDP-glucose:glycoprotein glucosyltransferase 1  GN=UGGT1   Q9NYU2 177,176.90 4 3.28% 
421 Biotinidase  GN=BTD   P43251 61,115.40 4 10.50% 
422 Mannose-binding protein C  GN=MBL2   P11226 26,126.10 4 17.30% 
423 Tripeptidyl-peptidase 2  GN=TPP2   P29144 138,334.90 4 4.88% 
424 Monoglyceride lipase  GN=MGLL   Q99685 33,243.70 4 18.50% 
425 Renin receptor  GN=ATP6AP2   O75787 38,991.10 4 12.30% 
426 Beta-lactamase-like protein 2  GN=LACTB2   Q53H82 32,788.70 4 16.00% 
427 Catechol O-methyltransferase  GN=COMT   P21964 30,019.60 4 24.40% 
428 Sepiapterin reductase  GN=SPR   P35270 28,031.50 4 26.80% 
429 WD repeat-containing protein 1  GN=WDR1   O75083 66,175.20 4 6.44% 
430 Thioredoxin domain-containing protein 5  GN=TXNDC5   Q8NBS9 47,611.10 4 11.80% 
431 Villin-1  GN=VIL1   P09327 92,677.20 4 6.17% 
432 Platelet-activating factor acetylhydrolase IB subunit beta  GN=PAFAH1B2   P68402 25,551.50 4 18.80% 
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433 Valacyclovir hydrolase  GN=BPHL   Q86WA6 32,525.40 3 14.80% 
434 Tryptophanyl-tRNA synthetase, cytoplasmic  GN=WARS   P23381 53,149.60 3 11.70% 
435 Gamma-glutamylcyclotransferase  GN=GGCT   O75223 20,990.00 3 18.10% 
436 Dihydrolipoyl dehydrogenase, mitochondrial  GN=DLD   P09622 54,159.40 3 8.45% 
437 Bone morphogenetic protein 1  GN=BMP1   P13497 111,231.20 3 4.26% 
438 GDH/6PGL endoplasmic bifunctional protein  GN=H6PD   O95479 88,875.60 3 5.44% 
439 Microsomal triglyceride transfer protein large subunit  GN=MTTP   P55157 99,337.10 3 4.25% 
440 Apolipoprotein L1  GN=APOL1   O14791 43,957.30 3 8.54% 
441 Staphylococcal nuclease domain-containing protein 1  GN=SND1   Q7KZF4 101,980.50 3 4.29% 
442 Kynureninase  GN=KYNU   Q16719 52,335.30 3 9.25% 
443 Haloacid dehalogenase-like hydrolase domain-containing protein 1  GN=HDHD1   Q08623 25,232.00 3 21.90% 
444 Adapter molecule crk  GN=CRK   P46108 33,812.80 3 13.20% 
445 Fumarylacetoacetate hydrolase domain-containing protein 1  GN=FAHD1   Q6P587 24,825.40 3 12.90% 
446 Proline-rich acidic protein 1  GN=PRAP1   Q96NZ9 17,189.20 3 17.90% 
447 Procollagen C-endopeptidase enhancer 1  GN=PCOLCE   Q15113 47,954.50 3 8.69% 
448 Polyubiquitin-B  GN=UBB   P0CG47 25,744.80 3 16.60% 
449 Tubulin beta-2C chain  GN=TUBB2C   P68371 49,812.70 3 51.20% 
450 Glutathione S-transferase P  GN=GSTP1   P09211 23,338.70 3 22.40% 
451 Proliferation-associated protein 2G4  GN=PA2G4   Q9UQ80 43,768.70 3 9.90% 
452 Glycyl-tRNA synthetase  GN=GARS   P41250 83,149.60 3 6.36% 
453 2,4-dienoyl-CoA reductase, mitochondrial  GN=DECR1   Q16698 36,050.90 3 14.30% 
454 Laminin subunit alpha-5  GN=LAMA5   O15230 399,707.10 3 1.11% 
455 Protein NipSnap homolog 3A  GN=NIPSNAP3A   Q9UFN0 28,448.90 3 12.10% 
456 Acyl-protein thioesterase 2  GN=LYPLA2   O95372 24,719.20 3 10.40% 
457 C4b-binding protein alpha chain  GN=C4BPA   P04003 67,015.00 3 4.19% 
458 Vitamin K-dependent protein S  GN=PROS1   P07225 75,105.40 3 5.03% 
459 Leucine-rich repeat transmembrane protein FLRT3  GN=FLRT3   Q9NZU0 72,988.90 3 5.55% 
460 Calsyntenin-1  GN=CLSTN1   O94985 109,773.60 3 3.57% 
461 26S proteasome non-ATPase regulatory subunit 1  GN=PSMD1   Q99460 105,821.20 3 3.36% 
462 Metalloproteinase inhibitor 2  GN=TIMP2   P16035 24,381.90 3 22.70% 
463 Enoyl-CoA hydratase domain-containing protein 2, mitochondrial  GN=ECHDC2   Q86YB7 31,108.70 3 15.80% 
464 Radixin  GN=RDX   P35241 68,547.50 3 15.10% 
465 Peptidyl-prolyl cis-trans isomerase FKBP3  GN=FKBP3   Q00688 25,159.40 3 16.50% 
466 Heterogeneous nuclear ribonucleoprotein A1  GN=HNRNPA1   P09651 38,729.00 3 14.50% 
467 Dystroglycan  GN=DAG1   Q14118 97,424.20 3 5.81% 
468 Glycogen phosphorylase, brain form  GN=PYGB   P11216 96,680.30 3 8.07% 
469 60S ribosomal protein L12  GN=RPL12   P30050 17,801.10 3 26.70% 
470 Phenazine biosynthesis-like domain-containing protein  GN=PBLD   P30039 31,767.80 3 12.50% 
471 Asialoglycoprotein receptor 1  GN=ASGR1   P07306 33,167.40 3 10.30% 
472 Ras-related protein Rab-1A  GN=RAB1A   P62820 22,660.40 3 19.00% 
473 Formimidoyltransferase-cyclodeaminase  GN=FTCD   O95954 58,909.00 3 10.40% 
474 Epididymal secretory protein E1  GN=NPC2   P61916 16,552.00 3 31.80% 
475 Inositol monophosphatase 1  GN=IMPA1   P29218 30,170.50 3 17.00% 
476 Lysosomal alpha-glucosidase  GN=GAA   P10253 105,306.40 3 3.78% 
477 Apolipoprotein A-I-binding protein  GN=APOA1BP   Q8NCW5 31,657.40 3 13.20% 
478 Pyridoxine-5'-phosphate oxidase  GN=PNPO   Q9NVS9 29,970.20 3 18.40% 
479 Out at first protein homolog  GN=OAF   Q86UD1 30,670.40 3 20.10% 
480 Nucleophosmin  GN=NPM1   P06748 32,557.40 3 18.00% 
481 Gamma-interferon-inducible lysosomal thiol reductase  GN=IFI30   P13284 29,131.20 3 11.90% 
482 S-adenosylmethionine synthase isoform type-1  GN=MAT1A   Q00266 43,629.50 3 9.87% 
483 Poliovirus receptor  GN=PVR   P15151 45,283.50 3 11.30% 
484 Cysteine and glycine-rich protein 1  GN=CSRP1   P21291 20,549.10 3 21.80% 
485 Phosphatidylinositol transfer protein beta isoform  GN=PITPNB   P48739 31,522.30 3 17.30% 
486 26S proteasome non-ATPase regulatory subunit 2  GN=PSMD2   Q13200 100,184.20 3 5.07% 
487 Endoplasmic reticulum aminopeptidase 1  GN=ERAP1   Q9NZ08 107,219.90 3 4.14% 
488 Cell adhesion molecule 1  GN=CADM1   Q9BY67 48,491.30 3 10.90% 
489 Sulfhydryl oxidase 1  GN=QSOX1   O00391 82,560.70 3 5.76% 
490 Aldo-keto reductase family 1 member C2  GN=AKR1C2   P52895 36,717.90 3 63.20% 
491 Serum amyloid A protein  GN=SAA1   P02735 13,514.50 3 35.20% 
492 3'(2'),5'-bisphosphate nucleotidase 1  GN=BPNT1   O95861 33,374.70 3 10.70% 
493 ADP-sugar pyrophosphatase  GN=NUDT5   Q9UKK9 24,309.80 3 24.70% 
494 DNA-(apurinic or apyrimidinic site) lyase  GN=APEX1   P27695 35,537.70 3 15.40% 
495 Phosphoserine phosphatase  GN=PSPH   P78330 24,990.10 3 16.90% 
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496 Proline synthase co-transcribed bacterial homolog protein  GN=PROSC   O94903 30,325.80 3 12.70% 
497 Complement factor H-related protein 1  GN=CFHR1   Q03591 37,632.40 3 24.50% 
498 Ubiquitin-fold modifier-conjugating enzyme 1  GN=UFC1   Q9Y3C8 19,441.00 3 16.20% 
499 Tripeptidyl-peptidase 1  GN=TPP1   O14773 61,229.60 3 10.50% 
500 26S proteasome non-ATPase regulatory subunit 13  GN=PSMD13   Q9UNM6 42,927.90 3 10.60% 
501 Hepatocyte growth factor activator  GN=HGFAC   Q04756 70,663.50 3 5.19% 
502 Cathepsin H  GN=CTSH   P09668 37,375.80 2 3.28% 
503 Biliverdin reductase A  GN=BLVRA   P53004 33,411.00 2 9.46% 
504 Thyroxine-binding globulin  GN=SERPINA7   P05543 46,307.60 2 5.78% 
505 Cell surface glycoprotein MUC18  GN=MCAM   P43121 71,588.50 2 4.80% 
506 Putative hydrolase RBBP9  GN=RBBP9   O75884 20,982.00 2 11.30% 
507 Pantetheinase  GN=VNN1   O95497 56,994.30 2 4.68% 
508 Haloacid dehalogenase-like hydrolase domain-containing protein 3  GN=HDHD3   Q9BSH5 27,982.10 2 15.10% 
509 Apolipoprotein M  GN=APOM   O95445 21,235.90 2 11.20% 
510 F-box only protein 2  GN=FBXO2   Q9UK22 33,308.70 2 9.12% 
511 Diablo homolog, mitochondrial  GN=DIABLO   Q9NR28 27,112.70 2 8.79% 
512 Nicotinate phosphoribosyltransferase  GN=NAPRT1   Q6XQN6 57,560.50 2 6.13% 
513 Lysophospholipase-like protein 1  GN=LYPLAL1   Q5VWZ2 26,299.00 2 15.20% 
514 Inhibin beta E chain  GN=INHBE   P58166 38,543.60 2 5.71% 
515 Protein CREG1  GN=CREG1   O75629 24,057.00 2 14.10% 
516 Macrophage-capping protein  GN=CAPG   P40121 38,480.80 2 7.47% 
517 Elongation factor 1-beta  GN=EEF1B2   P24534 24,746.20 2 12.40% 
518 Coatomer subunit alpha  GN=COPA   P53621 138,331.30 2 2.86% 
519 Echinoderm microtubule-associated protein-like 4  GN=EML4   Q9HC35 108,899.50 2 2.55% 
520 Acidic leucine-rich nuclear phosphoprotein 32 family member B  GN=ANP32B   Q92688 28,770.60 2 23.50% 
521 Junctional adhesion molecule A  GN=F11R   Q9Y624 32,565.10 2 6.35% 
522 Dipeptidyl peptidase 1  GN=CTSC   P53634 51,836.30 2 4.54% 
523 Hydroxymethylglutaryl-CoA synthase, mitochondrial  GN=HMGCS2   P54868 56,619.00 2 6.50% 
524 Amyloid-like protein 2  GN=APLP2   Q06481 86,937.00 2 3.93% 
525 40S ribosomal protein S5  GN=RPS5   P46782 22,859.00 2 10.30% 
526 Ras-related protein Rab-7a  GN=RAB7A   P51149 23,472.00 2 11.60% 
527 Hypoxanthine-guanine phosphoribosyltransferase  GN=HPRT1   P00492 24,562.20 2 9.17% 
528 Citrate lyase subunit beta-like protein, mitochondrial  GN=CLYBL   Q8N0X4 37,342.70 2 6.18% 
529 26S proteasome non-ATPase regulatory subunit 8  GN=PSMD8   P48556 39,595.90 2 4.86% 
530 Vitamin K-dependent protein C  GN=PROC   P04070 52,053.10 2 5.86% 
531 Beta-hexosaminidase subunit alpha  GN=HEXA   P06865 60,686.00 2 5.67% 
532 Tetratricopeptide repeat protein 38  GN=TTC38   Q5R3I4 52,770.40 2 4.26% 
533 Scavenger receptor cysteine-rich type 1 protein M130  GN=CD163   Q86VB7 125,429.40 2 1.73% 
534 Myosin-binding protein C, cardiac-type  GN=MYBPC3   Q14896 140,588.50 2 1.26% 
535 Phosphoacetylglucosamine mutase  GN=PGM3   O95394 59,834.40 2 4.24% 
536 Proteasome subunit beta type-10  GN=PSMB10   P40306 28,918.00 2 11.00% 
537 Calpain small subunit 1  GN=CAPNS1   P04632 28,298.60 2 13.40% 
538 Cathepsin L1  GN=CTSL1   P07711 37,546.10 2 10.50% 
539 Xanthine dehydrogenase/oxidase  GN=XDH   P47989 146,408.10 2 2.78% 
540 Hydroxymethylglutaryl-CoA lyase, mitochondrial  GN=HMGCL   P35914 34,342.30 2 11.10% 
541 Phospholipid transfer protein  GN=PLTP   P55058 54,723.10 2 5.88% 
542 Carboxypeptidase N catalytic chain  GN=CPN1   P15169 52,268.30 2 5.02% 
543 Serine/threonine-protein phosphatase 2A activator  GN=PPP2R4   Q15257 40,649.70 2 6.42% 
544 Vacuolar protein sorting-associated protein 35  GN=VPS35   Q96QK1 91,692.00 2 3.02% 
545 UPF0568 protein C14orf166  GN=C14orf166   Q9Y224 28,051.30 2 13.90% 
546 Semaphorin-4B  GN=SEMA4B   Q9NPR2 92,176.00 2 2.76% 
547 Beta-2-microglobulin  GN=B2M   P61769 13,696.90 2 26.90% 
548 Complement C1r subcomponent-like protein  GN=C1RL   Q9NZP8 53,479.50 2 8.83% 
549 Complement factor D  GN=CFD   P00746 27,014.40 2 15.00% 
550 Coagulation factor IX  GN=F9   P00740 51,759.60 2 4.34% 
551 Dihydropyrimidinase  GN=DPYS   Q14117 56,611.90 2 6.17% 
552 Afamin  GN=AFM   P43652 69,052.10 2 4.51% 
553 Glutathione S-transferase A1  GN=GSTA1   P08263 25,615.00 2 48.60% 
554 Myosin-9  GN=MYH9   P35579 226,519.50 2 1.12% 
555 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial  GN=SDHA   P31040 72,673.70 2 3.77% 
556 HLA class I histocompatibility antigen, A-69 alpha chain  GN=HLA-A   P10316 40,958.20 2 25.80% 
557 Clathrin heavy chain 1  GN=CLTC   Q00610 191,600.90 2 1.25% 
558 Carboxypeptidase M  GN=CPM   P14384 50,497.20 2 7.67% 
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559 Stress-induced-phosphoprotein 1  GN=STIP1   P31948 62,624.10 2 4.60% 
560 Alcohol dehydrogenase 1A  GN=ADH1A   P07327 39,840.70 2 49.60% 
561 Cystathionine beta-synthase  GN=CBS   P35520 60,569.30 2 3.45% 
562 Isoamyl acetate-hydrolyzing esterase 1 homolog  GN=IAH1   Q2TAA2 27,581.70 2 10.90% 
563 Ubiquitin thioesterase OTUB1  GN=OTUB1   Q96FW1 31,266.60 2 12.50% 
564 Importin-5  GN=IPO5   O00410 123,614.20 2 2.10% 
565 Serine protease HTRA1  GN=HTRA1   Q92743 51,269.30 2 6.67% 
566 Carboxylesterase 2  GN=CES2   O00748 61,789.30 2 3.40% 
567 Phosphoglucomutase-2  GN=PGM2   Q96G03 68,267.70 2 4.08% 
568 Aminopeptidase B  GN=RNPEP   Q9H4A4 72,579.40 2 3.69% 
569 Ribonuclease pancreatic  GN=RNASE1   P07998 17,625.80 2 17.90% 
570 Ephrin-A1  GN=EFNA1   P20827 23,769.20 2 13.20% 
571 Propionyl-CoA carboxylase alpha chain, mitochondrial  GN=PCCA   P05165 80,041.20 2 3.16% 
572 Angiopoietin-related protein 4  GN=ANGPTL4   Q9BY76 45,196.00 2 5.67% 
573 Thioredoxin reductase 1, cytoplasmic  GN=TXNRD1   Q16881 70,888.90 2 4.93% 
574 Elongation factor 1-delta  GN=EEF1D   P29692 31,103.90 2 12.80% 
575 Polypeptide N-acetylgalactosaminyltransferase 2  GN=GALNT2   Q10471 64,715.10 2 3.68% 
576 26S proteasome non-ATPase regulatory subunit 14  GN=PSMD14   O00487 34,558.60 2 8.71% 
577 Mammalian ependymin-related protein 1  GN=EPDR1   Q9UM22 25,419.50 2 8.48% 
578 Gelsolin  GN=GSN   P06396 85,679.80 2 2.94% 
579 Bile acid-CoA:amino acid N-acyltransferase  GN=BAAT   Q14032 46,282.00 2 6.94% 
580 Ras-related protein Rab-11A  GN=RAB11A   P62491 24,375.90 2 11.10% 
581 Ephrin-B1  GN=EFNB1   P98172 37,989.40 2 8.38% 
582 Hsc70-interacting protein  GN=ST13   P50502 41,314.40 2 5.15% 
583 Quinone oxidoreductase PIG3  GN=TP53I3   Q53FA7 35,519.30 2 10.80% 
584 Very low-density lipoprotein receptor  GN=VLDLR   P98155 96,080.00 2 2.63% 
585 Receptor-type tyrosine-protein phosphatase kappa  GN=PTPRK   Q15262 162,085.20 2 2.71% 
586 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2  GN=DDAH2   O95865 29,626.30 2 11.20% 
587 Phosphopantothenate--cysteine ligase  GN=PPCS   Q9HAB8 33,988.00 2 5.47% 
588 Histone H2A type 1-B/E  GN=HIST1H2AB   P04908 14,118.00 2 21.50% 
589 Acyl-protein thioesterase 1  GN=LYPLA1   O75608 24,652.20 2 11.70% 
590 Apoptosis-inducing factor 1, mitochondrial  GN=AIFM1   O95831 66,883.50 2 3.75% 
591 Leucine-rich repeat-containing protein 59  GN=LRRC59   Q96AG4 34,913.40 2 7.49% 
592 Complement factor H-related protein 2  GN=CFHR2   P36980 30,632.60 2 20.70% 
593 Ribosome-binding protein 1  GN=RRBP1   Q9P2E9 152,452.50 2 2.20% 
594 26S proteasome non-ATPase regulatory subunit 3  GN=PSMD3   O43242 60,961.60 2 4.31% 
595 Glutathione S-transferase Mu 3  GN=GSTM3   P21266 26,543.10 2 15.60% 
596 Ubiquitin carboxyl-terminal hydrolase 5  GN=USP5   P45974 95,770.10 2 3.26% 
597 Protein CYR61  GN=CYR61   O00622 42,008.00 2 7.09% 
598 Lysosome-associated membrane glycoprotein 2  GN=LAMP2   P13473 44,942.90 2 4.88% 
599 Deoxyribonucleoside 5'-monophosphate N-glycosidase  GN=RCL   O43598 19,090.30 2 19.50% 
600 Rab GDP dissociation inhibitor alpha  GN=GDI1   P31150 50,566.10 1 22.10% 
601 Na(+)/H(+) exchange regulatory cofactor NHE-RF1  GN=SLC9A3R1   O14745 38,850.30 1 7.26% 
602 Interleukin-1 receptor antagonist protein  GN=IL1RN   P18510 20,037.40 1 10.70% 
603 Actin, alpha cardiac muscle 1  GN=ACTC1   P68032 42,002.10 1 31.80% 
604 Tubulin beta-2A chain  GN=TUBB2A   Q13885 49,889.10 1 46.50% 
605 Tubulin alpha-1A chain  GN=TUBA1A   Q71U36 50,117.70 1 39.20% 
606 L-lactate dehydrogenase B chain  GN=LDHB   P07195 36,620.60 1 9.88% 
607 Legumain  GN=LGMN   Q99538 49,393.00 1 3.93% 
608 HLA class I histocompatibility antigen, A-3 alpha chain  GN=HLA-A   P04439 40,822.60 1 17.80% 
609 DCN1-like protein 1  GN=DCUN1D1   Q96GG9 30,107.90 1 6.56% 
610 Interferon-induced guanylate-binding protein 2  GN=GBP2   P32456 67,193.10 1 3.89% 
611 Betaine--homocysteine S-methyltransferase 2  GN=BHMT2   Q9H2M3 40,336.40 1 13.50% 
612 Calsyntenin-3  GN=CLSTN3   Q9BQT9 106,080.20 1 1.78% 
613 Arylsulfatase A  GN=ARSA   P15289 53,571.20 1 3.35% 
614 Putative tropomyosin alpha-3 chain-like protein  PE=5  A6NL28 26,252.00 1 14.30% 
615 Ganglioside GM2 activator  GN=GM2A   P17900 20,821.20 1 5.18% 
616 Multiple inositol polyphosphate phosphatase 1  GN=MINPP1   Q9UNW1 55,034.90 1 2.26% 
617 Vasorin  GN=VASN   Q6EMK4 71,696.10 1 2.38% 
618 N-acetylglucosamine-1-phosphotransferase subunit gamma  GN=GNPTG   Q9UJJ9 33,956.00 1 6.56% 
619 Keratin, type II cytoskeletal 6B  GN=KRT6B   P04259 60,050.60 1 12.10% 
620 Trypsin-1  GN=PRSS1   P07477 26,540.00 1 8.10% 
621 Alpha-soluble NSF attachment protein  GN=NAPA   P54920 33,216.10 1 3.73% 
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622 Disintegrin and metalloproteinase domain-containing protein 9  GN=ADAM9   Q13443 90,538.10 1 2.20% 
623 Enoyl-CoA hydratase domain-containing protein 1  GN=ECHDC1   Q9NTX5 33,681.30 1 4.23% 
624 Ras-related protein Rab-10  GN=RAB10   P61026 22,524.10 1 11.00% 
625 Arginyl-tRNA synthetase, cytoplasmic  GN=RARS   P54136 75,364.00 1 1.97% 
626 Xylulose kinase  GN=XYLB   O75191 58,364.00 1 2.61% 
627 Xaa-Pro dipeptidase  GN=PEPD   P12955 54,529.70 1 2.03% 
628 Ras-related protein Rap-1b-like protein    A6NIZ1 20,906.90 1 6.52% 
629 Heat shock protein 75 kDa, mitochondrial  GN=TRAP1   Q12931 80,094.90 1 3.41% 
630 3-ketoacyl-CoA thiolase, peroxisomal  GN=ACAA1   P09110 44,274.10 1 3.07% 
631 Mu-crystallin homolog  GN=CRYM   Q14894 33,757.10 1 4.78% 
632 Aldose reductase  GN=AKR1B1   P15121 35,835.90 1 6.65% 
633 Phenylalanine-4-hydroxylase  GN=PAH   P00439 51,846.40 1 1.99% 
634 Eukaryotic initiation factor 4A-II  GN=EIF4A2   Q14240 46,385.60 1 18.70% 
635 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial  GN=NDUFV2   P19404 27,373.80 1 5.22% 
636 Complement component 1 Q subcomponent-binding protein, mitochondrial  GN=C1QBP   Q07021 31,344.60 1 4.96% 
637 Glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 1  GN=GFPT1   Q06210 78,789.70 1 2.29% 
638 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial  GN=IDH3A   P50213 39,574.50 1 2.73% 
639 Follistatin-related protein 1  GN=FSTL1   Q12841 34,967.30 1 3.25% 
640 Calcium-regulated heat stable protein 1  GN=CARHSP1   Q9Y2V2 15,873.60 1 10.90% 
641 D-3-phosphoglycerate dehydrogenase  GN=PHGDH   O43175 56,632.60 1 1.50% 
642 Nuclear pore complex protein Nup153  GN=NUP153   P49790 153,921.20 1 0.61% 
643 Coatomer subunit epsilon  GN=COPE   O14579 34,464.90 1 6.49% 
644 Cadherin-1  GN=CDH1   P12830 97,439.60 1 2.04% 
645 Plastin-1  GN=PLS1   Q14651 70,239.20 1 8.59% 
646 Beta-galactoside alpha-2,6-sialyltransferase 1  GN=ST6GAL1   P15907 46,588.20 1 5.67% 
647 THUMP domain-containing protein 1  GN=THUMPD1   Q9NXG2 39,297.50 1 2.27% 
648 Heterogeneous nuclear ribonucleoprotein D0  GN=HNRNPD   Q14103 38,416.50 1 3.94% 
649 F-actin-capping protein subunit alpha-2  GN=CAPZA2   P47755 32,931.20 1 8.74% 
650 Tropomyosin alpha-3 chain  GN=TPM3   P06753 32,802.20 1 23.60% 
651 Glutamate--cysteine ligase regulatory subunit  GN=GCLM   P48507 30,709.30 1 4.74% 
652 Putative gamma-glutamyltranspeptidase 3  GN=GGT3P PE=5  A6NGU5 61,484.00 1 2.29% 
653 Cadherin-2  GN=CDH2   P19022 99,793.80 1 1.55% 
654 Uncharacterized protein C21orf96  GN=C21orf96   Q9H7H1 14,655.50 1 10.10% 
655 Thiosulfate sulfurtransferase  GN=TST   Q16762 33,410.80 1 6.06% 
656 Aflatoxin B1 aldehyde reductase member 2  GN=AKR7A2   O43488 39,571.00 1 6.13% 
657 T-complex protein 1 subunit alpha  GN=TCP1   P17987 60,327.20 1 2.16% 
658 Nck-associated protein 1-like  GN=NCKAP1L   P55160 128,140.30 1 0.71% 
659 Coatomer subunit gamma-2  GN=COPG2   Q9UBF2 97,606.50 1 1.38% 
660 Adenosine kinase  GN=ADK   P55263 40,528.60 1 4.42% 
661 Beta-glucuronidase  GN=GUSB   P08236 74,714.70 1 1.38% 
662 Serpin B6  GN=SERPINB6   P35237 42,604.80 1 3.99% 
663 Calpain-15  GN=SOLH   O75808 117,293.90 1 0.55% 
664 Complement C1q subcomponent subunit C  GN=C1QC   P02747 25,756.00 1 5.31% 
665 Bleomycin hydrolase  GN=BLMH   Q13867 52,544.50 1 2.42% 
666 Bifunctional purine biosynthesis protein PURH  GN=ATIC   P31939 64,598.50 1 1.18% 
667 T-complex protein 1 subunit theta  GN=CCT8   P50990 59,603.00 1 2.19% 
668 Dual specificity protein kinase TTK  GN=TTK   P33981 97,057.20 1 0.70% 
669 Importin-7  GN=IPO7   O95373 119,501.50 1 1.45% 
670 Myomesin-1  GN=MYOM1   P52179 187,608.50 1 0.53% 
671 GDP-L-fucose synthase  GN=TSTA3   Q13630 35,874.60 1 3.43% 
672 Hydroxyacylglutathione hydrolase, mitochondrial  GN=HAGH   Q16775 33,787.50 1 5.19% 
673 Glutathione S-transferase kappa 1  GN=GSTK1   Q9Y2Q3 25,480.10 1 6.19% 
674 Osteoclast-stimulating factor 1  GN=OSTF1   Q92882 23,769.70 1 5.61% 
675 CASP8-associated protein 2  GN=CASP8AP2   Q9UKL3 222,641.80 1 0.45% 
676 Tissue factor pathway inhibitor 2  GN=TFPI2   P48307 26,916.90 1 3.40% 
677 Sialate O-acetylesterase  GN=SIAE   Q9HAT2 58,297.30 1 2.87% 
678 Beta-mannosidase  GN=MANBA   O00462 100,878.70 1 1.48% 
679 Endothelial cell-specific molecule 1  GN=ESM1   Q9NQ30 20,076.30 1 6.52% 
680 Enolase-phosphatase E1  GN=ENOPH1   Q9UHY7 28,914.40 1 4.60% 
681 Integral membrane protein 2B  GN=ITM2B   Q9Y287 30,321.10 1 3.76% 
 
